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CHAPTER 1 
INTRODUCTION 
 “Amyotrophic Lateral Sclerosis (ALS) is one of the most common neuromuscular 
diseases worldwide, and people of all races and ethnic backgrounds are affected” (NINDS, 
2013).   ALS is a rapidly progressive neuromuscular disease characterized by degeneration of 
the upper motor neurons (UMN) in the cortex, and lower motor neurons (LMN) in the 
brainstem and spinal cord (Francis, Bach, & Delisa, 1999; Giordana, 2011; Kiernan et al.; 
Kumar, Aslinia, Yale, & Mazza, 2011).  Increased muscle tone and spasticity are a result of 
deterioration of UMN tracts.  Muscle flaccidity, atrophy and fascicule are due to deterioration 
of LMN tracts (Baumann et al., 2010; Giordana, 2011; Kiernan et al.; Misulis & Head, 2007; 
Yorkston, Miller, & Strand, 1995).  Disease presentation, both onset and progression, is 
unique to each individual.  Functional decline is independent of age of onset or initial clinical 
presentation (Kawai et al., 2003; Yorkston et al., 1995).  The average life span after diagnosis 
is approximately two to five years (Bradley et al., 2001; Giordana, 2011).   
Progressive deterioration in speech, swallowing and respiratory function has been well 
documented (Hillel, 1999; Kawai et al., 2003; Kuhnlein et al., 2008; Ruoppolo et al., 2013; 
Sathyaprabha, Pradhan, Nalini, Thennarasu, & Raju, 2010; Tjaden & Turner, 2000).  A 
decline in speech function often precedes changes in swallowing (Ball, Willis, Beukelman, & 
Pattee, 2001; Devine, 2013).  Furthermore repeated assessments of swallowing function to 
determine the severity of dysphagia, disordered swallowing ability, and to reduce the risk of 
aspiration are vital.  Aspiration, the passage of food, liquid or saliva into the lungs, may result 
in pneumonia (Hadjikoutis & Wiles, 2001; Scannapieco, 2014; Smith Hammond, 2008).  
Respiratory failure in ALS, is frequently the result of bronchopneumonia, a lung infection of 
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fungal, viral or bacterial (including aspiration) origin (Corcia et al., 2008).  Mortality in ALS 
is most commonly a result of respiratory failure (Czaplinski, Yen, & Appel, 2006; Fitting, 
Paillex, Hirt, Aebischer, & Schluep, 1999; Hardiman, 2011b; Kiernan et al.; Mathus-Vliegen, 
Louwerse, Merkus, Tytgat, & Vianney de Jong, 1994; Morgan et al., 2005; Similowski et al., 
2000; Vender, Mauger, Walsh, Alam, & Simmons, 2007).  In a study by Corcia et al. (2008), 
post-mortem autopsy found that pneumonia was the cause of death in approximately 75% of 
individuals with ALS.   
Compensatory strategies and diet modification are often recommended to address 
issues of dysphagia in individuals with ALS.  Recommendations are generally reactive, based 
on an individual’s complaints. Experienced Speech-Language Pathologists attempt to predict 
the likely progression of dysphagia based on clinical assessment of components of the 
articulatory, respiratory and swallowing systems.  Although a relationship between 
deglutition, articulatory, and respiratory functions is known to exist, very little research has 
been conducted to attempt to identify measures that are predictive of decline in swallowing 
function in ALS.  There is an absence of foundational evidence on which to base any 
predictive measures regarding the severity of dysphagia.  The purpose of this study is to 
determine if the severity of dysphagia, as determine by Penetration Aspiration Scale (PAS) 
ratings (Rosenbek, Robbins, Roecker, Coyle, & Wood, 1996) and pharyngeal residue scale 
ratings (Kelly, Macfarlane, Ghufoor, Drinnan, & Lew-Gor, 2008) in individuals with ALS, 
can be predicted through performance on diadochokinesis (DDK) and force vital capacity 
(FVC) measures.  Additional aims of this study include the investigation of potential 
predictive relationships between dysphagia ratings and other commonly utilized measures in 
the evaluation and treatment of ALS including duration of disease, type of onset (axial, 
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bulbar, mixed), current Amyotrophic Lateral Sclerosis Function Rating Score – Revised 
(ALS-FRS-R) score (Cedarbaum et al., 1999), body mass index, and the Dysphagia Handicap 
Index (DHI) patient-reported outcomes based dysphagia tool (Silbergleit, Schultz, Jacobson, 
Beardsley, & Johnson, 2012). 
Based on existing literature describing the process of normal swallowing and the 
known deficits attributed to ALS, the following is hypothesized: 1) There will be  significant 
negative correlations between rate of production of diadochokinetic tasks with PAS ratings, 
pharyngeal residue ratings, and number of swallows per bolus; 2)  There will be significant 
negative correlations between FVC performance with PAS ratings, pharyngeal residue ratings 
and, number of swallows per bolus; and 3) There will be significant positive correlations 
between DHI total score and PAS rating, pharyngeal residue ratings, and number of swallows 
per bolus.  
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CHAPTER 2 
REVIEW OF LITERATURE 
 The existence of a degenerative process resulting in muscle weakness and spasticity 
including changes in speech, swallowing and respiratory function has been documented since 
the early 1800’s.  Charles Bell was credited as the first Neurologist to describe cases of ALS 
(Rowland, 2001) while Aran, Duchenne and Cruveilher contributed to early understanding of 
the syndrome (Gubbay, 1985; Wijesekera, 2009). In 1869, Dr. Jean Martin-Charcot was the 
first to provide a complete description of symptoms and neurogenic impairments associated 
with motor neuron involvement, and in 1874 he established Amyotrophic Lateral Sclerosis 
(ALS) as a unique disease (Rowland, 2001). During the 19th century, multiple physicians 
conducted research to investigate the etiologies of various disorders with similar muscle 
involvement that would be classified as Motor Neuron Disease (MND) (Mitsumoto, Chad, & 
Pioro, 1998; Rowland, 2001)  
Motor Neuron Physiology 
 In order to understand MND, it is important to examine the motor system and function 
of motor neurons.  Motor neurons are composed of three regions, UMN, LMN and bulbar 
region of the brainstem (Kiernan et al.; Wijesekera, 2009).  Together these three regions are 
responsible for relaying impulses necessary for voluntary motor activity from the motor 
cortex in the cerebrum through descending motor pathways to the desired muscles.  The 
motor cortex is composed of the premotor cortex, the supplemental motor cortex and the 
primary motor cortex (Mitsumoto et al., 1998).  The premotor cortex is involved in processing 
and planning the initiation of movement and the supplemental motor cortex is responsible for 
programming complex muscle sequences (Mitsumoto et al., 1998).  Finally, the primary 
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motor cortex is responsible for initiation and strength of muscle contractions (Carrow, Rivera, 
Mauldin, & Shamblin, 1974; Mitsumoto et al., 1998; Teismann, 2011). 
According to Mitsumoto et al. (1998), upper motor neurons originate in one of the 
areas of the motor cortex and relay neural impulses to LMNs through the pyramidal tract.  
The pyramidal tract controls volitional movement and is composed of the corticobulbar and 
corticospinal tracts.  Corticobulbar tract fibers synapse with cranial nerves in the brainstem 
and are responsible for voluntary control of muscles involved in speech and swallowing 
including the larynx, pharynx, palate, face and jaw (Kiernan et al.).  Corticospinal tract fibers 
synapse with LMN in the spine and govern voluntary fine muscle movements of the 
extremities. Impairments to the corticobulbar and corticospinal tracts are characterized by 
muscle spasticity.  
Motor Neuron Diseases 
Motor Neuron Disease (MND) is a category of progressive neurogenic disorders 
characterized by degeneration in one, two or all three regions of the motor pathway.  The 
category of MND is composed of six disorders whose etiologies are either hereditary, 
sporadic or both (Mitsumoto et al., 1998).  Amyotrophic Lateral Sclerosis is largely sporadic, 
but approximately 10% of documented cases are hereditary in nature (Haverkamp, 1995; 
Kiernan et al.; Wijesekera, 2009).  ALS is defined by degeneration in both UMN and LMN 
tracts with impairments in axial and bulbar functions (Chen, 2005; Kiernan et al.).  Mitsumoto 
et al. (1998) summarized the motor system impairments for each of the MNDs. Primary 
lateral sclerosis (PLS) is a sporadic disease characterized by UMN impairments of the face 
and extremities.  Adult onset Progressive Bulbar Palsy (PBP) is a sporadic disease, defined by 
initial degeneration of LMNs at the brainstem level affecting speech, swallowing and 
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mastication.  Progressive Muscular Atrophy (PMA) is a sporadic disease, described by 
degeneration of LMNs resulting in progressive axial weakness and atrophy without UMN 
degeneration.   It is highly likely that PLS, PBP and PMA will eventually become ALS 
(Carrow et al., 1974).  There is a chance, however, that each of those diseases will remain a 
pure disease process without transformation to ALS.   The other two diseases included in the 
MND category are pure diseases.  Spinal muscular atrophy (SMA) is a hereditary autosomal 
recessive disorder resulting in lower motor neuron impairments with axial weakness.  Lastly, 
pseudobulbar palsy is a sporadic disorder with deterioration of UMN impairment affecting 
speech and swallowing function without LMN involvement or degeneration.    
Diagnostic Testing 
Diagnosis of MNDs require a thorough assessment utilizing several diagnostic tools.  
Often confirmation of ALS is generally a diagnosis of exclusion.  There are many disorders 
that may result in motor neuron impairment.  The most common differential diagnoses 
include stroke, brain or spinal cancer, and spinal stenosis (Mitsumoto et al., 1998).  The most 
important diagnostic tool is clinical presentation and a thorough history and physical 
examination.  Supportive information is necessary from additional testing including 
neuroimaging of the head and spine to assess for potential cerebral infarcts, tumor and nerve 
impingement in the spinal column; electromyography (EMG) to evaluate nerve conduction of 
UMNs and LMNs; blood tests to evaluate creatine phosphokinase (CPK) levels, an enzyme 
found in the heart, brain and skeletal muscle that is secreted into the blood when muscle stress 
or damage occurs; and on rare occasion a muscle biopsy is completed (Brooks, 1994; 
Mitsumoto et al., 1998).  A diagnosis of ALS may take up to fifteen months from initial 
symptom onset (Hardiman, 2011b).  
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EMG assessments are crucial to diagnose ALS and other MNDs.  The requirements 
for World Federation of  Neurology Criteria for the Diagnosis of ALS  include 1) presence of 
LMN degeneration in one or more of the four regions (bulbar, cervical, thoracic, 
lumbrosacral); 2) presence of UMN degeneration in one or more of the four regions; and 3) 
determined progression of symptoms and spreading of impairment across regions.  The 
diagnosis is further classified as definite, probable, possible, or suspected ALS based upon the 
EMG findings. Definite ALS is defined through clinical presence of both UMN and LMN 
signs in the bulbar region and two or more spinal regions, or the presence of UMN and LMN 
in three spinal regions.  Probable ALS is defined clinically with UMN and LMN in at least 
two regions, but the regions may be different.  Possible ALS is defined as UMN and LMN 
present in only one region, or UMN signs present in two regions without signs of LMN 
involvement.  Primary lateral sclerosis and progressive bulbar palsy are a few of the disorders 
that fall in this category.  Suspected ALS is defined as presence of only LMN involvement in 
two or more regions (Brooks, 1994; de Carvalho et al., 2008). 
Amyotrophic Lateral Sclerosis 
Amyotrophic Lateral Sclerosis is a complicated disease that remains difficult to 
diagnose due to the variation of symptoms at onset and varied rate of progression (Hardiman, 
2011a).  Approximately 70% of the individuals diagnosed with ALS present with axial 
involvement, while 25% experience initial changes in bulbar function, speech or swallowing 
function (Hardiman, 2011a; Kuhnlein et al., 2008).  A small percentage initially experience a 
combination of bulbar and axial impairment (Kiernan et al.; Paris et al., 2013; Teismann, 
2011; Yorkston et al., 1995).  Less than five percent of all patients with ALS experience 
respiratory impairments as the initial symptom (Hardiman, 2011a; Lo Coco et al., 2006; 
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Similowski et al., 2000; Vender et al., 2007).  Disease progression eventually affects all 
extremities, speech production, respiration and swallowing function (Hillel, 1999; Kawai et 
al., 2003; Kuhnlein et al., 2008; Ruoppolo et al., 2013; Sathyaprabha et al., 2010; Tjaden & 
Turner, 2000).  The disease course and rate of decline varies from individual to individual.  
When presenting symptoms are bulbar in nature, a rapid rate of decline with reduced length of 
survival is likely.  
ALS – Early Speech and Swallowing Signs  
Subtle changes in speech production usually precede changes in swallowing function 
(Haverkamp, 1995; Kuhnlein et al., 2008).  Speech changes are largely due to lingual 
weakness resulting in imprecise movement generally when tired and then becoming more 
consistent throughout the day (Dworkin, Aronson, & Mulder, 1980; Weismer, Yunusova, & 
Westbury, 2003).  Hypernasality also becomes apparent due to palatal weakness (Kuhnlein et 
al., 2008).  As oral muscle strength declines, people with ALS will experience a decrease in 
rate of speech and vowel production will become centralized (Hillel, 1999; Turner & Tjaden, 
2000).  Throat clearing and coughing with liquids is generally the first reported sign of 
swallowing difficulty (Strand, Miller, Yorkston, & Hillel, 1996).  Swallowing impairments 
generally occur with liquids first due to the increased transit speed of liquids which requires 
more precise and timely coordination of oral pharyngeal muscle movements for airway 
protection and bolus propulsion.  Oral preparation of food is affected by lingual weakness and 
masseter weakness (Chen, 2005).  As muscle strength declines, meal time increases due to 
inefficient mastication and bolus propulsion resulting in residue in the oral cavity and the 
pharynx requiring additional dry swallows to clear the oral-pharyngeal region. 
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Respiratory Function in ALS 
The pulmonary system is a complex system involving structures, muscles and nerves 
originating in the brainstem and traveling inferiorly to the diaphragm and abdominal muscles 
(Similowski et al., 2000).  Impairment in diaphragm movement and the phrenic nerve has 
been implicated in the decline of pulmonary function and presence of dyspnea, shortness of 
breath.  There is a strong correlation between patients with reported dyspnea and increased 
respiratory rate, discoordinated abdominal movement with respiration, and decreased lung 
vital capacity (Similowski et al., 2000).  Dyspnea is quite common in the middle to late stages 
of the disease process (Lo Coco et al., 2006).   
Respiratory compromise in ALS is due to a combination of denervation of upper and 
lower motor neurons resulting in impairment of all three muscle groups of respiration, 
inhalation, exhalation and the upper airway including the palate and larynx, (Lyall, 
Donaldson, Polkey, Leigh, & Moxham, 2001).  Patients with the bulbar type of ALS have a 
higher likelihood of respiratory involvement in comparison to ALS patients with strictly limb 
involvement.  A study by Lyall et al. (2001) revealed that respiratory involvement in bulbar 
ALS was correlated specifically with lower maximum expiratory pressures, lower maximum 
inspiratory pressures, and increased rate of respiratory decline.  Respiratory decline is often 
accompanied by a slow generalized decline in overall strength (Magnus et al., 2002; Schmidt 
et al., 2006; Similowski et al., 2000).  Frequent assessment of pulmonary function is a critical 
determinant in predicting the rate of progression and length of survival in ALS (Lechtzin, 
Rothstein, Clawson, Diette, & Wiener, 2002; Lechtzin, Shade, Clawson, & Wiener, 2006; 
Schmidt et al., 2006).   
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Pulmonary function measurements are conducted through invasive and non-invasive 
methods.  Invasive measurements are more accurate and able to detect changes in muscle 
function, however, they also require internal placement of balloon catheters in the mid-
esophagus or at the level of the diaphragm.  Non-invasive measurements involve either a 
mouth piece or a nasal catheter.  There are several volitional non-invasive methods to assess 
respiratory function.  Some of these non-invasive assessments have high sensitivity and 
specificity similar to that of invasive measures (Lechtzin, Wiener, Shade, Clawson, & Diette, 
2002).  All volitional measurements of respiratory function are vulnerable, to some degree, to 
submaximal effort and poor lip seal (Fitting, 2006; Hadjikoutis & Wiles, 2001; Héritier, 
Rahm, Pasche, & Fitting, 1994; Lechtzin, Rothstein, et al., 2002; Lyall et al., 2001).  The 
most common methods of respiratory assessment include forced vital capacity (FVC), 
maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP).  Of these 
assessments, the most researched and commonly used method is forced vital capacity (FVC) 
in the upright position (Schmidt et al., 2006).   
Longitudinal research has established the importance of continued assessment of FVC 
throughout ALS disease progression (Hadjikoutis & Wiles, 2001; Vender et al., 2007).  
Assessment of respiratory function in patients with ALS through measurement of FVC has 
been conducted as a standard of assessment for many years (Lechtzin, Rothstein, et al., 2002).  
An average decline in FVC of approximately 3.5% per month is common in ALS (Lechtzin, 
Wiener, et al., 2002).  To measure FVC, a subject is asked to take a deep breath and exhale as 
quickly and forcefully as possible for as long as possible through a mouthpiece.  Normative 
data has been established for age, height, weight and gender. Measurements are generally 
reported in liters and as a percentage of predicted value (Lo Coco et al., 2006).  FVC has been 
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highly correlated with scores obtained on the Norris ALS Scale of thirty-four parameters of 
function (Lechtzin, Rothstein, et al., 2002; Lechtzin, Wiener, et al., 2002).  The forced vital 
capacity measure is able to identify changes in respiratory function with 53% sensitivity and 
89% specificity (Lechtzin, Rothstein, et al., 2002; Lyall et al., 2001).   
Predictive Ability of Respiratory Measures 
Respiratory measures are currently used to predict the likelihood of mortality once 
respiratory function falls below a certain degree of impairment in individuals with ALS.  A 
study by Morgan et al (2005) reported that in the ALS population,  the FVC measure was 
58% sensitive for predicting mortality in six months when the measurement was below 50% 
of the predicted value; however, when FVC was greater than 50% of the predicted value the 
measure was 96% specific.  Respiratory assessment through FVC is effective in documenting 
profound respiratory involvement.  Upright FVC has a 70% predictive value for ALS survival 
at one year when scores were within normal range (Schmidt et al., 2006).   
Normal Swallowing  
Normal swallowing function is dependent on coordinated, precise controlled 
movements of the articulators (Groher, 1992).  The movements and timing of swallowing 
function has been studied in normal healthy adults throughout adulthood (Butler et al., 2010; 
Ding, Logemann, Larson, & Rademaker, 2003).  The oral pharyngeal muscles involved in 
executing swallowing movements send and receive sensory and motor impulses through 
cranial nerves V, VII, IX, X and XII which synapse in the bulbar region of the brainstem with 
UMNs (Groher & Crary, 2010).  Impulses are then routed though different regions of the 
cerebrum and cerebellum.   
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Cerebral Involvement in Swallowing 
Swallowing function was once thought to be a “reflex”.  Recent research describes the 
act of swallowing as a “complex but stereotyped motor sequence” (Jean, 2001. p 929).  A 
brain stem driven operation (Martin, Goodyear, Gati, & Menon, 2001; Martin et al., 2004; 
Yorkston et al., 1995) controlled by a central pattern generator in the medulla oblongata that 
produces sequential and rhythmic patterns for swallowing (Jean, 2001).  Further research 
provided conflicting information identifying five major components involved in neural 
control of swallowing including sensory and motor features of the cranial nerves, cerebral and 
midbrain connections with the brainstem, bilateral swallowing centers within the brainstem, 
and the muscles and organs that are controlled by the other components (Robbins et al., 
2008). 
A study by Martin et al (2001) examined regions of cerebral activation using 
functional magnetic resonance imaging (fMRI) during various types of swallows including: 
naïve saliva swallow, voluntary saliva swallow and water bolus swallow.  Common areas of 
activation for all types of swallows included the bilateral premotor, primary motor and 
association motor cortices, as well as the insula and primary somatosensory cortices 
bilaterally.  Activation of these cortical areas was significant because it contradicted the 
previous belief that swallowing function was managed solely by the brainstem.  Volitional 
swallows resulted in activation of the anterior cingulate gyrus where as naïve secretion 
management swallows did not activate the cingulate region.  Activation of the sensory cortex 
was likely due to the need to integrate information regarding mastication, lingual position, 
secretion accumulation and sensory feedback from the oropharynx.  The motor cortex 
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controlled bolus manipulation and propulsion.  The insula was implicated in mediation of 
motor and sensory impulses to various cortical areas to govern functioning of the oropharynx, 
esophagus and gastrointestinal tract.  Anterior cingulate cortex activation was thought to be 
due to attention and premotor processing crucial in initiating a volitional swallow.    
Structures and Phases of Swallowing 
The swallowing mechanism is very complex.  It contains many structures and muscles 
responsible for bolus deformation, cohesion, and propulsion as well as airway protection.  
Swallowing function is typically divided into three main regions, the oral cavity, pharynx 
(nasopharynx and hypopharynx) and esophagus.  These three regions contain four phases of 
swallowing, the oral preparatory phase, the oral phase, the pharyngeal phase and the 
esophageal phase (Dodds, 1990).  
The oral preparatory phase is responsible for grinding and pulverizing solid foods as 
well as the creation of a cohesive bolus, of all material placed in the oral cavity, to prepare it 
for ingestion. During this phase, saliva is introduced to aid in pre-digestion, improved bolus 
cohesion and transit through the rest of the swallowing phases. The main structures involved 
in this phase of swallowing include the lips, teeth, tongue, velum and muscles of the lower 
face and jaw.  Labial movements are important to remove food from a utensil, cup or straw 
and create a seal to prevent drooling or anterior leakage of the bolus.  Appropriate tone of the 
facial muscles prevents pocketing of food in the buccal cavities.  Mastication is composed of 
coordinated movements of the lips, mandible, tongue and cheeks (Kikutani et al., 2009). 
Mastication and swallowing pattern in healthy individuals varies from that of people with 
swallow impairments in that healthy individuals thoroughly chew an entire bolus prior to 
swallowing.  Healthy individual also tend to swallow fewer times to ingest a bolus (Stachler 
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et al., 1994).   Food that requires additional deformation may be moved anteriorly, depending 
on sensory feedback, to be further broken down (Hiiemae & Palmer, 1999). Tongue 
movements are crucial in the oral preparatory, oral and pharyngeal phases of swallowing. 
During the oral preparatory phase, the tongue is responsible for movement of food laterally 
for mastication by the molars, and to collect food on the surface of the tongue to prepare 
boluses for transit into the pharynx (Hiiemae & Palmer, 1999; Wilson, 2007).  Oral 
preparation duration varies greatly depending on the texture and density of the bolus (Stachler 
et al., 1994).  Oral preparation for liquids is very short, where as preparatory needs for solid 
foods is much more extensive (Hiiemae & Palmer, 1999; Stachler et al., 1994).   
Once food has been appropriately masticated, the bolus is collected on the lingual 
surface and the oral phase is initiated and carried out (Groher & Crary, 2010).  The primary 
objective of the oral phase is movement of bolus material into the pharynx.  Several events 
occur in sequence to provide coordinated and efficient bolus transportation.  The tongue tip 
and lateral borders elevate to contact the alveolar ridge and hard palate respectively to contain 
the bolus on the center of the tongue and form a groove extending the length of the tongue.  
Timely sequential movements  and appropriate strength from elevation of the tip, blade and 
finally the dorsal segment of the tongue propel food and liquid from the anterior two-thirds of 
the oral cavity posteriorly to the base of the tongue, which is responsible for bolus propulsion 
through the pharynx (Robbins, Levine, Wood, Roecker, & Luschei, 1995; Wilson, 2007; 
Yoshida et al., 2006).  Simultaneously, the soft palate elevates and lateral and posterior walls 
of the nasopharynx contract to protect against nasopharyngeal regurgitation (Dodds, 1990).   
As the bolus enters the oral pharynx, the pharyngeal phase is initiated.  The main 
functions of the pharyngeal phase are to protect the airway while transporting bolus material 
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through the pharynx.  In preparation for bolus transit through the pharynx, several airway 
protective acts are set in motion instantaneously with initiation of the oral phase. The 
arytenoid cartilages adduct and angle anteriorly, to compress the laryngeal vestibule, followed 
by near vocal fold closure (Groher & Crary, 2010).  Respiration is inhibited, generally after 
slight expiration to increase pressure in the trachea. Base of tongue retraction, during the oral 
phase, results in elevation and anterior movement of the hyolaryngeal complex and epiglottic 
retroflexion completing the steps for airway protection as the bolus passes through the 
pharynx.  The pharynx widens to allow bolus passage as a result of pharyngeal constrictor 
relaxation.  Bolus material is propelled through the pharynx by a combination of base of 
tongue retraction with contact on the posterior pharyngeal wall and contraction of the 
pharyngeal constrictors (Dodds, 1990).  Relaxation of the pharyngeal esophageal segment is 
achieved through anterior movement of the hyoid, creating a forward pulling affect, in 
addition to sensory relaxation of the segment to allow appropriate bolus passage into the 
esophagus (Dodds, 1990) 
The esophageal phase begins as the head of the bolus passes through the 
cricopharyngeal segment and continues to travel inferiorly through the esophagus and 
eventually into the stomach.  Passage into the esophagus is dependent on relaxation of the 
cricopharyngeal segment which occurs as a result of hyolaryngeal elevation and anterior 
movement.  Normal transit time through the esophagus averages from 6-20 seconds 
depending on the composition of the bolus.  Liquids may actually travel through the 
esophagus and into the stomach in as little as 3 seconds(Groher & Crary, 2010).  
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Swallowing and Respiratory Function 
Respiratory function and swallowing function are intertwined.  Breathing and 
swallowing are physiologically connected to provide protection from aspiration (Hiss, 
Strauss, Treole, Stuart, & Boutilier, 2003; Martin-Harris et al., 2005; Martin, Logemann, 
Shaker, & Dodds, 1994).  Extensive research has been conducted in the area of breathing and 
swallowing dynamics to identify the impact of reduced subglottic pressure and the effect of 
respiratory support on breath phase patterns surrounding swallowing.  “Swallowing apnea is 
the cessation of respiration that occurs with swallowing” (Hiss, Strauss, Treole, Stuart, & 
Boutilier, 2004).  A period of apnea is crucial for every swallow, food, liquid or saliva, to 
close and protect the airway from aspiration, the entry of a foreign substance (food, liquid or 
saliva) into the trachea.  Apnea for swallowing in healthy individuals is generally initiated at 
the onset of the oral phase and ceases as the bolus passes through the pharyngeal esophageal 
segment.  A study by Martin-Harris et. al (2005) studied healthy controls to determine if 
differences in apnea duration and respiratory phases surrounding swallowing were dependent 
on subject age.  This study revealed that older subjects, 65 years of age or older, were more 
likely to extend the duration of apnea and vary the phase of breathing by either inhaling 
immediately before or after swallowing.  This inhalation pattern may increase the risk of 
aspiration (Martin-Harris et al., 2005).  Increased periods of apnea with earlier onset occur 
with increased bolus size (Hiss et al., 2004).   Aging also affects the onset of apnea related to 
swallowing.  Older healthy individuals are likely to initiate apnea prior to lingual retraction 
(Hiss et al., 2004) 
 Lung capacity and respiratory support are very important to facilitate safe swallowing 
(Martin et al., 1994).  The severity of dysphagia may be exacerbated by compromised lung 
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volumes.  As lung volume approaches residual lung volume bolus transit time and pharyngeal 
activation duration are prolonged and subglottic pressure is reduced which can increase the 
risk of aspiration (Gross, Atwood, Grayhack, & Shaiman, 2003).  
Dysphagia  
Dysphagia, impaired swallowing ability, is not a primary diagnosis, rather a symptom 
of underlying disease.  Dysphagia is associated with many medical conditions and affects 
more than 22% of people over the age of 50 (Howden, 2004).  That percentage increases up to 
60% in the elderly and neurologically impaired populations such as Parkinson’s, Multiple 
Sclerosis, stroke, and Amyotrophic Lateral Sclerosis.  (Howden, 2004).  As many as 87% of 
nursing home residents may suffer from dysphagia (Groher & Crary, 2010).  Disorders of the 
peripheral and central nervous system as well as cancer of the alimentary tract are likely to 
result in long term changes to swallowing function.  The most common causes of dysphagia 
are neurogenic disorders including stroke, Parkinson’s disease, Multiple Sclerosis and 
Amyotrophic Lateral Sclerosis (Groher & Crary, 2010).   
Dysphagia in ALS – Oral Pharyngeal Decline 
 The progression of bulbar ALS can cause dysphagia, even in the early stages of the 
disease (Kawai et al., 2003).  During the course of ALS, bulbar degeneration affects lingual 
elevation and coordination as well as the timeliness of laryngeal elevation resulting in 
aspiration and piecemeal deglutition (Kawai et al., 2003).  The most common patterns of oral 
motor impairment include decreased anterior lingual coordination and posterior oral holding.  
Swallowing safety is not affected by impaired anterior lingual coordination; however, 
posterior oral holding increases the risk of aspiration (Kawai et al., 2003).  
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Impaired base of tongue movement will also result in increased pharyngeal transit 
duration, oral and pharyngeal residue, which are risk factors for dehydration, weight loss and 
aspiration pneumonia (Holaas, DePippo, & Reding, 1996; Kawai et al., 2003; Robbins et al., 
1995).  Base of tongue function has been evaluated through various methods including 
pressure testing using oral manometry and diadochokinesis.  Lingual pressures were 
significantly reduced in subjects who complained of dysphagia compared to subjects who did 
not complain of swallowing difficulty (Nicosia et al., 2000; Yoshida et al., 2006).   
Reduced bolus size and piecemeal swallowing movements has been associated with 
individuals with all forms of ALS (Goeleven, Robberecht, Sonies, Carbonez, & Dejaeger, 
2006). These movements are most often attributed to impaired base of tongue retraction 
resulting from prolonged bolus propulsion in to the pharynx as well as increased pharyngeal 
residue, fatigue (ClavÉ et al., 2006).  It is common to witness a reduction in meal size with an 
increase in meal duration (Tanasescu et al., 2007).  Fatigue and muscle weakness resulting in 
a greater number of swallows per bolus often leads to reduced appetite and weight loss. 
Dysphagia in ALS - Effects of Respiratory Compromise 
 In addition to decline in oral motor coordination and strength, individuals with ALS 
commonly experience a decline in swallowing function as a result of disease progression 
associated with respiratory decline.  The effect of decline in respiratory function on 
swallowing ability, as it relates to ALS, introduces several obstacles including reduced glottic 
abduction potentially resulting in upper airway obstruction, reduced diaphragmatic 
innervation, reduced coordination of apnea and swallowing timing as well as general fatigue 
(Hadjikoutis & Wiles, 2001).  This relationship was examined more closely in a study by 
Strand, Miller, Yorkston and Hillel (1996) that examined the correlation between the ALS 
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severity scale score for speech and swallowing (Yorkston et al., 1995) with clinical or 
objective swallowing assessments and with FVC scores.  There was a strong relationship 
between decline in speech, swallowing and respiratory function (Strand et al., 1996).  Decline 
in FVC can indicate impairments in other areas.  For example, when FVC was less than 1.5 
liters, fatigue was frequently reported.  Impairment in cough and secretion management were 
reported when FVC was less than one liter (Hillel, 1999; Yorkston et al., 1995).  Respiratory 
decline results in an increased likelihood of feeding tube placement (Bradley et al., 2001).  
Feeding tubes were placed frequently after forced vital capacity declined below 50% of the 
predicted value (Bradley et al., 2001; Sarfaty, 2013).  Respiratory function may be preserved, 
yet swallowing function may be severely impaired to the point that a feeding tube is required 
if oral motor function is severely affected.   
Dysphagia Assessment Tools 
 Dysphagia is a major cause of morbidity and mortality in hospitalized patients.  The 
identification of dysphagia and aspiration has to become increasingly important in order to 
improve; patient health and safety and reduce length of hospitalization (Langmore et al., 
1998).  The two most common objective assessment tools to date are the modified barium 
swallow study (MBSS) and the fiberoptic endoscopic evaluation of swallowing (FEES).  The 
MBSS has been the gold standard in the identification of impairment throughout the upper 
aerodigestive tract for decades (Langmore & Logemann, 1991).  There is an appropriate place 
for each assessment tool in the medical settings.  Both interventions have their advantages and 
disadvantages.  Advantages to MBSS evaluations include unobstructed view of all phases of 
swallowing, given adequate positioning, proper weight constraints, and the patient’s ability to 
sit upright and sit still (Langmore & Logemann, 1991; Spinelli, Easterling, & Shaker, 2002).   
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 An objective assessment examining the overall application of the MBSS was 
beneficial in identifying its many functions.  In addition to the evaluation of aspiration, the 
MBSS is used to modify diet recommendations, generate referrals for further assessment to 
Otolaryngologists or Gastroenterologists and Dietitians, and assess swallowing strategies and 
techniques to maintain safe oral intake (Martin-Harris, Logemann, McMahon, Schleicher, & 
Sandidge, 2000).  Martin-Harris et al. (2000) examined MBSS results of 608 patients with 
various medical diagnoses of which, only ten percent were determined to have normal 
swallowing function.  The remaining ninety percent benefited in various ways from the 
MBSS.  In another study that evaluated swallowing function through MBSS, pharyngeal 
residue was found to be a predictive marker for aspiration (Eisenhuber et al., 2002).  
Laryngeal penetration and/or aspiration were significantly more common in the presence of 
pharyngeal residue then in its absence, 93% to 33% respectively (Eisenhuber et al., 2002).   
 On the other hand, the FEES provides visualization of pharyngeal and laryngeal 
anatomy and physiology for speech and swallowing (Hafner, Neuhuber, Hirtenfelder, 
Schmedler, & Eckel, 2008; Langmore & Logemann, 1991).  FEES can be completed in the 
patient’s room and repeated without the adverse effects of radiation exposure.  A study by 
Hafner et al. (2008) provided excellent results for assessment of nearly one thousand patients 
using FEES in the intensive care setting.  Medically fragile patient’s swallowing function was 
assessed; aspiration and pharyngeal dysphagia was also assessed at bedside.  FEES 
examination allows for flexible and frequent assessment of swallowing function in addition to 
evaluation of pharyngeal and laryngeal sensation in high risk aspiration patients.   
 According to Aviv et al. (2001), disadvantages to the FEES examination include mild 
discomfort as a result of passage of the nasendoscope through the inferior nasal meatus and 
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through the nasopharynx to rest in the region of the oral pharynx during bolus trials.  The 
most remarkable disadvantage of the FEES examination is the brief obstructed view of the 
larynx, at the height of the swallow, due to posterior pharyngeal wall contraction in 
coordination with base of tongue retraction and epiglottic inversion.  The laryngeal vestibule, 
true vocal folds and trachea are able to be visualized prior to and immediately after the 
swallow.   There potential complications of the endoscopic evaluation include epistaxis, nose 
bleed, a vasovagal syncope or loss of consciousness and reflex syncope resulting in temporary 
decreased cardiac function due to stimulation of the vagus nerve.  
Self-Reported Severity of Dysphagia 
   While objective assessment measures such as the MBSS and the FEES are the most 
objective and complete method of swallowing evaluation, individual awareness and 
complaints of swallowing difficulty frequently are the source of the dysphagia evaluation 
consult referral.  Dysphagia can result in anxiety and panic during meal times causing 
individuals to avoid social situations during meals, resulting in isolated meal behaviors 
(Elmståhl, Bülow, Ekberg, Petersson, & Tegner, 1999; Gustafsson & Tibbling, 1991).  
Dysphagia was also reported to reduce perceived quality of life (Ekberg, Hamdy, Woisard, 
Wuttge–Hannig, & Ortega, 2002).   There area several patient self-reported outcome based 
tools available.   Most of them are disease specific such as the MD Anderson Dysphagia 
Inventory (Chen et al., 2001) for patients with head and neck cancer, and the health-related 
quality of life instrument (Carrau et al., 2004) to examine the effects of laryngopharyngeal 
reflux.  A few outcomes based patient reported dysphagia inventories do exist.  Two of the 
most common are the SWAL-QOL (McHorney et al., 2002) and the Dysphagia Handicap 
Index (DHI) (Silbergleit et al., 2012).  Both patient report tools examine the physical, 
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emotional and functional components of swallowing.  The DHI is composed of 25 questions 
whereas the SWAL-QOL is a 44 question assessment (McHorney et al., 2000).  Test-retest 
reliability was the same for both tools with a Pearson’s correlation coefficient of 0.83 overall.   
Dysarthria in ALS 
 Impairments in speech, dysarthria, are a result of abnormalities in muscle function and 
structures that affect voice quality, rate of speech, articulatory precision, intelligibility, pitch, 
volume, phrase length, velopharyngeal function and weakness of articulators (Ball et al., 
2001).  Dworkin and Aronson (1986) found that dysarthria was attributed to decreased lingual 
strength and range of motion, as well as changes in tongue size, shape and position.  The type 
of dysarthria associated with ALS is generally classified as a mixed spastic-flaccid type of 
speech impairment (Yorkston, 2007; Yorkston et al., 1995).  Speech impairments include: 
slowed rate, increase effort to enunciate words, decreased intelligibility, and imprecise 
articulation (Carrow et al., 1974; Chen, 2005; Duffy, 1995; Hillel, 1999).   Voice impairments 
include: hypernasality, voice quality may sound breathy, harsh, hoarse or strained (Hillel, 
1999).  Oral motor impairments in the ALS population include: weakness of the tongue, 
palate and facial muscles, and fasciculations of the tongue at rest (Chen, 2005; Hillel, 1999).  
Appearance of dysarthria characteristics from the time of symptom onset is variable 
dependent on the initial symptom onset type and individual rate of disease progression.   
 Throughout the years, dysarthria has been evaluated through a variety of methods 
including the assessment of intelligibility, rate of speech and diadochokinesis.  Assessment 
tool selection is up to the discretion of the Speech-Language Pathologist, Neurologist or other 
specialist evaluating speech production.  Formal tests for intelligibility and dysarthria include 
the Assessment of Intelligibility of Dysarthric Speech (AIDS) (Yorkston & Beukelman, 
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1981b), Frenchay Dysarthria Assessment (Enderby, 1983) and Sentence Intelligibility Test 
(Yorkston, Beukelman, & Tice, 1991) among others.  Each test has varying degrees of 
completeness.  For example, the Assessment of Intelligibility of Dysarthric Speakers is an 
evaluation of intelligibility of single words and sentences from five to 15 words in length.  
The Frenchay Dysarthria Assessment is the most complete assessment tool; however, special 
training is required for a Speech-Language Pathologist to administer the tool.  The Frenchay 
Dysarthria Assessment has 11 sections: reflex, respiration, lips, jaw, palate, laryngeal, tongue, 
intelligibility, rate, sensation, and associated factors.  Informal speech and voice assessment 
tools are frequently used in clinical settings.  Assessments include sustained phonation; 
diadochokinetic rate, conversational speech production, and examination of the oral 
mechanism..  
 Decline in rate of speech is an early indicator of bulbar involvement (Ball et al., 2001; 
Nishio & Niimi, 2006).  Normal rate of speech for healthy subjects is approximately 150 
words per minute; however, intelligibility was not a statistically significant predictor of true 
level of speech impairment in individuals with ALS (Ball et al., 2001).  Other non-statistically 
significant changes in speech ability include decreased velopharyngeal closure that results in 
hypernasality and in more severe cases, nasal emission, during conversation. There were 
statistically significant correlations between rate of speech decline, below 100 words per 
minute or less, and vocal quality change and rate of tongue movement in ALS (Ball et al., 
2001).  Statistical significance was also found between a decline in tongue strength and 
dysarthria in ALS (Dworkin et al., 1980).   
 Several studies have investigated factors contributing to decreased rate of speech in 
ALS including segmental timing (Tjaden & Turner, 2000), acoustic differences in content and 
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function words (Tjaden & Turner, 2000), phonetic contrast errors and laryngeal involvement 
(Riddel & McCauley, 1995), vowel space and temporal distinctiveness (Riddel & McCauley, 
1995; Tjaden & Turner, 1997, 2000).  Tjaden and Turner (2000) analyzed habitual and slow 
rate of speech in healthy control subjects and subjects with ALS.  Slow exaggerated speech 
rate was similar between groups; however, habitual rate was significantly decreased in the 
ALS population.  Interestingly, at the exaggerated rate of speech, ALS subjects produced 
inconsistently lengthened vowels more than consonants (Tjaden & Turner, 1997, 2000).  
Exaggerated speech characteristics differed from healthy controls even though the rate of 
speech was very similar.  In addition, subjects with ALS produced more centralized vowel 
sounds (Tjaden & Turner, 2000) that were likely a result of decreased  lingual strength and 
range of movement (Dworkin et al., 1980).   
Intelligibility 
 Previous research has determined that intelligibility measures were not effective for 
early identification of bulbar symptoms (Ball et al., 2001; Nishio & Niimi, 2006). In fact, 
intelligibility tended to remain relatively normal until the middle stages of disease 
progression.  Decline in intelligibility is preserved despite a reduction in articulatory 
precision, rate of speech and slowed diadochokinesis (Nishio & Niimi, 2006; Yorkston & 
Beukelman, 1981a).  Each intelligibility measure has a floor and ceiling effect and is only 
appropriate to changes in speech within a specific range (Yorkston & Beukelman, 1981a).  
The severity of dysarthria dictates the type and complexity of task necessary to accurately 
assess intelligibility.  Speech intelligibility in single words or sentences may remain relatively 
normal despite significant impairments in articulatory agility and rate of production (Yorkston 
& Beukelman, 1981a). 
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Rate of Speech 
As rate of speech declines there are definite ranges where all other variables become 
impaired.  A study by Ball et al. (2001) revealed that strength of volitional cough and lingual 
movements were the first to become impaired at approximately 150 words per minute (wpm).  
At approximately 125wpm voice quality was significantly affected.  There was rapid decline 
in speech intelligibility, velopharyngeal closure and the communication effectiveness index at 
100wpm (Ball et al., 2001; Yorkston & Beukelman, 1981a; Yorkston & Beukelman, 1978). 
 Researchers hypothesized that vowel spacing is crucial for speech intelligibility, due 
to the consistent findings regarding vowel space and duration (Turner, Tjaden, & Weismer, 
1995).  In addition to vowel duration, Riddel and McCauley (1995) also assessed phonetic 
contrast errors.  Significant findings included delayed initiation of voice onset, and imprecise 
articulation that resulted in difficulty distinguishing fricatives from affricates specifically 
alveolar phonemes from palatal fricatives.  
 While rate of speech can be directly measured, it must be combined with an 
intelligibility rating as well. In healthy adults, rate of speech can be affected by many factors.  
Language and linguistic factors including reading level, comfort reading aloud, syntactic 
structure, lexical selection, eye sight and length of utterance with longer utterance 
characteristically producing a more rapid rate of speech (Yuan, Liberman, & Cieri, 2006).  
Other factors known to affect rate of speech include demographic, cultural, physiological, 
psychological differences and natural aging (Amerman & Parnell, 1992; Verhoeven, De 
Pauw, & Kloots, 2004; Yuan et al., 2006).  Diadochokinesis (DDK) is an effective method of 
assessing basic motor speech capabilities for various levels of impairment (Darley, Aronson, 
& Brown, 1975; Duffy, 1995; Kent, Kent, & Rosenbek, 1987; Wang, Kent, Duffy, Thomas, 
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& Weismer, 2004; Ziegler, 2002).  DDK is sensitive to mild, even subtle neuromuscular 
impairments often overlooked in conversational tasks (Fletcher, 1972; Gadesmann & Miller, 
2008; Nishio & Niimi, 2006; Ziegler, 2002) and in structured reading tasks (Nishio & Niimi, 
2006). 
Diadochokinesis 
 Diadochokinesis is composed of two tasks: alternating motion rates (AMRs) and 
sequential motion rates (SMRs).  AMRs include rapid repetition of monosyllabic targets such 
as /pʌ/, /tʌ/ or /kʌ/ while SMRs include repetition of a multi-syllable target such as /pʌtʌkʌ/. 
Each sound production assesses a different articulation point.  Labial movements are assessed 
with /pʌ/, tongue tip movement is assessed with /tʌ/, and movement of the dorsum of the 
tongue is assessed with /kʌ/ (Kikutani et al., 2009).  AMRs are often affected before rate of 
speech is impaired (Nishio & Niimi, 2006).  There is minimal linguistic burden, simple 
syntactic structure in this task which allows subjects of most levels of cognitive functioning to 
complete the assessment (Wang, Kent, Duffy, & Thomas, 2005).  Diadochokinesis utilizes the 
simplest form, consonant-vowel, of speech and language sequence for the AMR portion of the 
assessment (Wang et al., 2005) and only a slightly more difficult 3 syllable combination for 
the SMR portion.  The simplicity of this task allows assessment of even severely dysarthric 
subjects who are unable to produce multiple word utterances (Duffy, 1995).  Correct 
production of DDK requires intact, balanced, rapid movement of the oral structures as well as 
adequate oral muscle integrity.  Any impairment in coordination or muscle strength will result 
in a slowed rate of production and/or imprecise articulation (Dworkin et al., 1980; Fletcher, 
1972).  In addition, inter-rater and intra-rater judgments are good for rate precision with inter-
rater agreement only varying by plus or minus one syllable (Gadesmann & Miller, 2008).  
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Order of presentation of stimuli does not significantly affect performance (Fletcher, 1972; 
Pierce, Cotton, & Perry, 2013) 
 Previous research has examined DDK in many ways from measuring the length of 
time it took for twenty productions of a target AMR (Fletcher, 1972), to measuring the 
number of productions in a set amount of time usually between 4 and 10 seconds (Dworkin et 
al., 1980; Gadesmann & Miller, 2008; Kikutani et al., 2009; Louzada, Beraldinelle, Berretin-
Felix, & Brasolotto, 2011; Neel & Palmer, 2012; Nishio & Niimi, 2006; Ozawa, Shiromoto, 
Ishizaki, & Watamori, 2001; Padovani, Gielow, & Behlau, 2009; Pierce et al., 2013; Portnoy 
& Aronson, 1982; Wang et al., 2004).  The average number of productions per second is 
approximately 6 to 6.5 productions of each AMR per second and approximately 1.3 
productions of SMR per second.  
 Subjects with ALS produce abnormalities in diadochokinesis due to lingual weakness 
that results in slower AMR and SMR productions (Dworkin et al., 1980).  Rate of production 
of AMR and SMR was significantly reduced in one study during repeated trials as a result of 
lingual fatigue (Dworkin et al., 1980). Subjects with ALS and dysarthria were found to have 
significantly slowed rate of DDK, approximately 66% of the rate of ALS subjects without 
dysarthria (Mulligan et al., 1994).  Significantly slowed DDK rates have been found in stroke, 
ALS, myasthenia gravis and head trauma when compared to control subject groups (Nishio & 
Niimi, 2006; Portnoy & Aronson, 1982; Strong et al., 1999; Wang et al., 2004).  Subjects with 
spastic dysarthria tend to exhibit a DDK pattern with a slow rate of production and normal 
rhythm (Portnoy & Aronson, 1982).   
Predictive Measures 
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 The impending decline of respiratory function combined with deterioration in function 
of lingual, pharyngeal and laryngeal musculature throughout the course of ALS, create a 
critical role for the Speech-Language Pathologist (SLP) in the continued assessment and 
treatment of speech and swallowing function throughout the disease progression.  It is 
imperative to accurately evaluate the swallowing function of each patient with ALS to reduce 
their risk of aspiration and minimize any controllable pulmonary infection when possible.  
The role of the SLP, when working with patients with ALS, requires not only accurate 
assessment of current level of speech and swallowing function, but also the ability to predict 
the rate of decline of function that is likely in the near future.  Prediction of rate of decline is 
important to determine the appropriate time to discuss diet consistency modification, nutrition 
supplementation and alternative methods of nutrition including long term feeding tube 
placement.  Patients frequently require professional intervention when it is necessary to 
modify liquid consistency or discuss feeding tube placement.  To date, the fundamental data 
necessary, on which a predictive model may be based, does not exist.  
 Predictive measures have been adopted in health care with the goal of prevention of 
adverse conditions or medical problems.  Predictive measures have been implemented to 
predict certain disorders, recurrent medical problems or even frailty.  Predictive measures 
have been developed to determine frailty of older adults through simple questionnaires to 
assist in identifying people at higher risk for medical problems (Dayhoff, Suhrheinrich, 
Wigglesworth, Topp, & Moore, 1998).  Previously, (Arena, Humphrey, & Peberdy, 2003) 
created an algorithm to predict future hospitalizations in patients with congestive heart failure 
through the assessment of pulmonary function tests.  Prediction of function exercise capacity 
in patients with Multiple Sclerosis was determined by examining walking distance in six 
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minutes (Savci et al., 2005).  A previous study (Gerdhem, Ringsberg, Åkesson, & Obrant, 
2005), found that function tests were not as accurate in predicting future falls as was a history 
of previous falls, conditions affecting the balance, tendency to fall, intake of psychoactive 
medication, inability to stand on one leg, of increased age.  Prediction tools are very useful for 
patient safety in addition to aiding healthcare professionals in planning and providing 
appropriate levels of care and medical recommendations.   
 The ability to predict the severity of dysphagia in people with ALS would be a very 
useful tool to assist in planning for feeding tube placement, and reducing hospitalizations for 
aspiration pneumonia and possible associated breathing issues.  The most notable benefit from 
prediction of dysphagia severity in ALS through clinical measures is that clinical assessments 
could be provided in many clinical or private practice settings, especially in geographic 
locations were large hospitals or advanced medical care is not readily accessible.  
The Goal of this Study 
 The progressive decline and impairment of even basic functions have been well 
studied in ALS.  Previous research has investigated the effects of ALS on speech, swallowing 
and respiratory function.  Limited research has been completed examining the relationship 
between decline in speech, swallowing and respiratory function in ALS (Strand et al., 1996) 
and individual self-assessment of dysphagia severity (Silbergleit et al., 2012).  Predictive 
measures are more abundant in healthcare and have proved beneficial in predicting length of 
survival based on FVC scores, future hospitalizations in congestive heart failure patients and 
exercise capacity in multiple sclerosis patients to name a few.   There is an absence of 
foundational evidence on which to base any predictive measures regarding the severity of 
dysphagia in ALS.  The goal of this investigation is to determine if the severity of dysphagia 
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in ALS can be predicted through common clinical tasks including DDK, FVC, number of 
swallows per bolus and patient dysphagia ratings on the DHI.  
Research Questions  
In order to better understand the correlation between speech and swallowing functions 
and the severity of dysphagia in individuals with ALS with bulbar involvement,  the following 
research questions were examined in this study: 1) Do individuals diagnosed with ALS with 
bulbar involvement perform significantly different on clinical measures (DDK, FVC, DHI, 
and tired level ) and on objective swallowing measures (PAS, pharyngeal residue and number 
of swallows per bolus) when compared to a control group? 2) Are there significant 
correlations between clinical measures and objective swallowing measures which would 
support the theory that swallowing function could be predicted in individuals with ALS? 3) In 
the ALS group, is there a significant correlation between type of symptom onset, duration of 
disease, and body mass index with the clinical assessment measures and objective swallowing 
measures? 
Working Hypotheses 
Hypotheses for this dissertation are summarized as follows.   
Research Hypothesis #1  
H0: There will not be a significant difference in performance on DDK, FVC, PAS 
pharyngeal residue, DHI, or number of swallows between the ALS group in 
comparison to the control group.    
H1: There will be a significant difference in performance on DDK, FVC, PAS 
pharyngeal residue, DHI, and number of swallows per bolus trial between the ALS 
group in comparison to the control group.    
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It is expected that the ALS group will demonstrate impairments in all assessment areas 
resulting in rejection of the null hypothesis.   
Research Hypothesis #2 
H0: There will not be significant correlations between DDK with PAS and pharyngeal 
residue scale results. 
H1: There will be significant correlations between DDK with PAS and pharyngeal 
residue scale results. 
It is expected that subjects who present with greater impairments in DDK will have 
more severe impairments on both swallowing function measures as a result of weakness and 
reduced oral motor movements resulting in rejection of the null hypothesis.   
Research Hypothesis # 3 
H0: There will not be significant correlations between number of swallows per bolus 
with PAS, pharyngeal residue scale, DDK and FVC results. 
H1: There will be significant correlations between number of swallows per bolus with 
PAS, pharyngeal residue scale, DDK and FVC results. 
It is expected that there will be a relationship between number of swallows and PAS, 
pharyngeal residue scale, DDK, and FVC performance resulting in rejection of the null 
hypothesis.   
Research Hypothesis # 4 
H0: There will not be significant correlations between FVC with PAS and pharyngeal 
residue scale results. 
H1: There will be significant correlations between FVC with PAS and pharyngeal 
residue scale results. 
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It is expected that subjects who present with impaired FVC will exhibit more 
significant impairments on both swallowing function measures resulting in rejection of the 
null hypothesis.   
Research Hypothesis # 5 
H0: There will not be significant correlations between DHI with PAS, pharyngeal 
residue scale, DDK and FVC results. 
H1: There will be significant correlations between DHI with PAS, pharyngeal residue 
scale, DDK and FVC results. 
It is expected that the scores on a patient reported outcomes tool for swallowing 
function will be positively related to impairments on both swallowing measures resulting in 
rejection of the null hypothesis.   
Research Hypothesis #6 
H0: There will not be a significant correlation, in the ALS group, between duration of 
disease, type of symptom onset, ALS-FRSR score or body mass index with 
performance on DDK, FVC, PAS, pharyngeal residue scale, number of swallows per 
bolus, or DHI.   
H1: There will be a significant correlation, in the ALS group, between duration of 
disease, type of symptom onset, ALS-FRSR score or body mass index with 
performance on DDK, FVC, PAS, pharyngeal residue scale, number of swallows per 
bolus, or DHI.   
Based on previous research it is likely that ALS-FRSR, symptom duration and type of 
onset will be significantly correlated to clinical and objective swallowing measures 
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resulting in rejection of the null hypothesis.  It is questionable if there will be a 
significant correlation with BMI.   
Research Hypothesis # 7 
H0: There will not be significant interactions of DDK and FVC with PAS and 
pharyngeal residue scale results. 
H1: There will be significant associations of DDK and FVC with PAS and pharyngeal 
residue scale results. 
It is expected that the combination of impairment in both FVC and DDK will result in 
abnormal results on the swallowing function measures.  Impairments in diadochokinesis will 
likely have the greatest effect on overall swallowing function and result in more severe ratings 
on the PAS and pharyngeal residue scale.  Impairment in FVC will affect swallowing function 
but not to the same degree as impaired DDK resulting in rejection of the null hypothesis.  
Expected Outcomes 
 Based upon previous research, it is expected that performance on clinical assessment 
measures will significantly correlate with severity of dysphagia documented during the FEES 
assessment through PAS, pharyngeal residue and number of swallows per bolus.   Previous 
studies have identified that impairment in oral motor movements and respiratory function 
increase the risk of dysphagia and aspiration in individuals with ALS.  This study may 
provide foundational data for a protocol to predict the severity of dysphagia in patients with 
ALS. 
 It is also expected that the ALS group will be significantly more impaired on all 
measures in comparison with the control group.  It is expected that certain historical data 
(duration of symptoms, type of onset, ALS-FRSR and potentially BMI) will significantly 
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correlate with impairments in DDK, FVC, PAS, pharyngeal residue, number of swallows per 
bolus or the DHI.   
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CHAPTER 3 
METHODS 
Subject Characteristics and Selection  
A total of 33 participants (18 subjects with ALS and 15 controls) were included in this 
study.  All participants with ALS had an El Escorial World Federation of Neurology (Brooks, 
1994) criteria  diagnosis of probable or definite ALS, as determined by a Neurologist, and 
presence of oral motor or speech symptoms consistent with bulbar dysfunction, as determined 
by a Speech-Language Pathologist.  Bulbar dysfunction was defined as impairments in oral 
motor, speech/voice or swallowing function (Carrow et al., 1974; Chen, 2005; Hillel, 1999).   
Subject recruitment was conducted from October 2012 thru May 2014 in the Harry J. 
Hoenselaar ALS Multidisciplinary Clinic in the Neurology Department at Henry Ford 
Hospital, Detroit, Michigan.  Subjects were recruited during a regularly scheduled clinic visit.  
All subjects were between 40 and 85 years of age.  Inclusion and exclusion criteria were 
developed in an effort to obtain speech, swallowing and respiratory deficits solely attributed 
to ALS.  All subjects and controls spoke Standard American English as their first language, 
and did not have a previous history of neurological or speech disorders.  Tobacco use was 
documented and subjects with current use or history of use were included.  Subjects were 
excluded if they had a documented history of emphysema, chronic obstructive pulmonary 
disease or other remarkable respiratory impairment unassociated with ALS. Individuals with 
any history of head and neck cancer or radiation or surgical intervention to the oral 
pharyngeal region were also excluded.  
Patient subjects were divided into three groups based upon respiratory function 
(normal, mildly impaired, and moderately impaired).  Respiratory function was determine by 
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performance on forced vital capacity assessment where groups were defined as: 1) normal 
function as determined by FVC performance of greater than 80% predicted capacity; 2) 
mildly impaired as determined by FVC performance between 65-79% predicted capacity and 
3) moderately impaired as determined by FVC performance between 50-64% predicted 
capacity (Schmidt et al., 2006).  Group A consisted of 9 subjects (4 males and 5 females) 
diagnosed with ALS and presented with oral motor or speech abnormalities and normal 
respiratory function (greater than 80% predicted). Group B was composed of 4 subjects (4 
females) diagnosed with ALS and presented with oral motor or speech abnormalities and mild 
respiratory impairment (between 65-79% predicted). Group C included 5 subjects (2 males 
and 3 females) diagnosed with ALS and presented with oral motor or speech abnormalities 
and moderate respiratory impairment.   
There were 148 ALS patients screened over 339 clinic visits.  Of these, 87 (59%) were 
male and 61 (41%) female. Forty patients met the inclusion criteria on at least one visit and 18 
(45%) were enrolled.  Of the 22 patients who refused enrollment, 15 stated they were too tired 
and 9 declined to due the necessity of having a nasopharyngeal scoping procedure as part of 
the swallowing examination.  Of the 108 patients excluded, the most common reasons were 
presence or history of another neurologic condition (n=28, 26%) including stroke, seizure or a 
dementing process, total nutritional dependence by feeding tube (n=21, 19%) and FVC below 
50% predicted (n=21, 19%).   
The ALS participant group was composed of 6 males and 12 females with an age 
range of 54-82 years of age, with a mean age of 67.9 years. The age range for male 
participants was 55-78 years of age, with a mean age of 68.7 years. The age range of female 
participants was 54-82 years of age, with a mean age of 67.6 years.   
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The control group was composed of 4 males and 11 females with an age distribution 
similar to that of the ALS subject group. The age range for all control subjects was 58-84 
years of age, with a mean age of 65.4 years. The age range for male controls was 59-69 years 
of age, with a mean age of 64.3 years. The age range of female controls was 58-84 years of 
age, with a mean age of 65.8 years.   
All participant data were coded for privacy.  Participants in the ALS group were coded 
with ALS, a number and then a gender indicator.  Control group participants were coded with 
CON, a number and a gender indicator.  
Testing Procedures and Instrumentation 
In this study, standardized clinical assessment batteries and self-report questionnaires 
were used to evaluate the speech, respiratory and swallowing function of the all participants in 
the ALS and control groups.  Assessment measurements included: 1) Oral motor and speech 
examination for symptoms consistent with bulbar dysfunction; 2) Questionnaire for inclusion 
and tiredness scale; 3) Dysphagia Handicap Index (DHI) (Silbergleit et al., 2012); 4) Forced 
Vital Capacity; 5) Diadochokinesis; 6) Swallowing function assessment with Fiberoptic 
Endoscopic Evaluation of Swallowing (FEES) (Langmore, Schatz, & Olsen, 1988) with 
impairment ratings using the Penetration-Aspiration Scale (Rosenbek et al., 1996) and a 
pharyngeal residue scale (Kelly et al., 2008); and 7) Documentation of the number of 
independent swallows generated for each bolus trial.  Additional information was collected 
for all subjects with ALS including: Amyotrophic Lateral Sclerosis-Functional Rating Scale-
Revised (ALS-FRSR) (Appendix A), date of diagnosis, and height and weight on the date of 
study participation (Appendix B), reported onset date, area of weakness complaint (bulbar, 
axial or mixed) and ALS-FRSR scores (Appendix C).  All assessments were completed 
38 
 
during one clinic visit. Instrumentation was calibrated by the principle investigator or a 
member of the research team.  A testing effect was not a concern since each subject was only 
assessed one time.   
Oral Motor Examination 
 Oral motor assessments included an evaluation of labial appearance, retraction, 
protrusion and seal; lingual appearance and range of motion; palatal appearance and elevation.   
Questionnaire:  
 All subjects were asked a series of questions to verify their appropriateness for this 
study (Appendix D).  The questionnaire included standard questions to identify possible 
impairments in speech, swallowing and/or breathing which could be attributed to a disorder 
other than ALS.  In addition to inclusion/exclusionary questions, age and tobacco use was 
also documented.  A history of tobacco use was reported for three females in both the ALS 
and control groups and two male in both ALS and control groups.   
Dysphagia Handicap Index 
   The Dysphagia Handicap Index is a patient reported outcomes tool that assesses the 
handicapping effects of dysphagia and allows subjects to rank their own swallowing ability in 
a series of 25 questions that cover physical, emotional and functional aspects of swallowing 
(Appendix E).  There were nine questions for both the function and physical sections and 
seven questions for the emotional section.  One of the emotional questions was excluded as a 
result of a typographical error.  The statement read “I feel depressed because I can’t eat when 
I want” instead of “I feel depressed because I can’t eat what I want.”  Subjects were asked to 
respond to each question regarding their swallowing difficulty as occurring always (4 points), 
sometimes (2 points), or never (0 points).  In addition, each subject provided a self-reported 
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severity of dysphagia on a 7-point scale with 1 being normal and 7 being a severe problem.  
Results were recorded based on categorical aspects of swallowing (physical, emotional and 
functional), overall score and self-reported severity of dysphagia (Appendix F).    
Tired Rating 
All subjects were asked to rate how tired they were on a 7-point scale from 1 (normal 
baseline) to 7 (severely tired) at the time of this study (Appendix G). This information was 
obtained to determine if general fatigue or level of tiredness contributed to swallowing 
function.   
Forced Vital Capacity (FVC) 
Forced vital capacity (FVC) is a measurement of maximal inhalation to total lung 
capacity, followed by immediate forced rapid exhalation for as long as possible, then 
completed with immediate maximal inhalation back to total lung capacity (Gold, 2000). FVC 
measurement is calculated in terms of percent predicted capacity based upon standardized 
data for gender, age, height and weight. The median percent predicted value based on gender, 
height, weight and age is considered 100% (Stanojevic et al., 2008).  As a result, it is possible 
for a person to have an FVC of greater than 100% predicted.   
FVC measurements were collected using a handheld SpiroPro+ from Jaeger with 
mouth piece.  A nasal closure was assured with a nasal occlusive device.  The SpiroPro+ 
Version V2.32 04.05.2006 had a calibration of 0.99%.  Subjects were instructed to place the 
mouth piece between the lips and teeth and to “close lips firmly around the mouthpiece 
creating a seal; slowly inhale to take a full deep breath and then forcefully exhale as hard, fast 
and long as possible.”  During exhalation, encouragement was provided by the examiner to 
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“blow hard” and “keep going”.   FVC measurement was performed one time per subject and 
recorded first manually and then transferred to an Excel Spreadsheet (Appendix G).  
Diadochokinesis 
Each subject performed one trial of each of the diadochokinetic tasks /pʌ/, /tʌ/, /kʌ/ 
and /pʌtʌkʌ/ in the same order following the examiners instructions and demonstration.   
The subjects were instructed to “take a deep breath and say the syllable /pʌ/ as quickly 
and evenly as possible for approximately 7 seconds, until requested to stop” by the 
investigator.  Then the examiner demonstrated the task, taking a deep breath and repeating 
/pʌpʌpʌ…/.  The examiner repeated these instructions for each additional syllable target, /tʌ/, 
/kʌ/ and /pʌtʌkʌ/. All productions were monitored and redirection was provided as 
necessary. The consonant-vowel combinations were selected due to their frequent use in 
clinical speech assessments for the evaluation of three major articulatory organs: lung, tongue 
tip and tongue dorsum, in addition to relatively low cognitive burden.     
Recording 
All diadochokinesis speech productions were digitally recorded using an Olympus 
WS-300M digital voice recorder and a Shure headset microphone placed 5 centimeters from 
the subjects mouth (Svec & Granqvist, 2010).   The recording of all speech productions for 
each subject was transferred from the Olympus WS-300M digital recorder to a computer with 
Praat software for speech analysis.  Praat software displayed a speech waveform for every 
speech production as well as a time stamp.  During the Praat assessment, a 5 second voice 
production segment was analyzed.  Data analysis was initiated after approximately one second 
of speech production for each task.  Speech productions were calculated for total productions 
during continuous production of five seconds.  The total number of speech productions over a 
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5 second period was then averaged to determine average productions per second (Appendix 
H).   
Fiberoptic Endoscopic Evaluation of Swallowing (FEES) 
 The basic FEES protocol as outlined in Langmore, Schatz & Olsen (1988) was used as 
a guideline for placement of nasendoscope with the subject sitting comfortably upright in a 
chair.  A flexible nasendoscope was passed through the most patent nostril as determined by 
patient report and visual observation by the primary investigator.  This procedure was 
performed without administration of topical anesthetics or vasoconstrictor application to the 
nasal passage to eliminate the potential for adverse anesthetic reactions (Aviv, Kaplan, & 
Langmore, 2001). FEES equipment consisted of a 3.6 millimeter diameter flexible fiberoptic 
rhinolaryngoscope (Olympus, ENF-P3P4), light source (Olympus CLK-4), camera (ELMO), 
an ACER color monitor and hard drive.  All data for subjects and controls was recorded on 
the system hard drive and backed up on DVD.  The FEES assessment provided visualization 
of the oral-pharyngeal and pharyngeal phases of swallowing except for a brief period when 
base of tongue retraction and inversion of the epiglottis obstructed the view of the larynx at 
the height of the swallow.  Liquid bolus amounts were measured using a 60mL syringe.  The 
desired amount was placed in a 6 ounce Styrofoam cup.  All thin liquid and pudding boluses 
were dyed blue with food coloring for improved visualization and given in the following 
order: 1) 10mL thin liquid bolus by straw, 2) 30mL thin liquid bolus by straw, 3) 3 ounce thin 
liquid bolus by straw, 4) 5mL puree bolus (leveled teaspoon), 5) 5mL puree bolus (leveled 
teaspoon), and 6) one inch by one inch piece of graham cracker.  The monitor was shielded 
from the subject.  No visual or verbal feedback was provided during the assessment.  
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Bolus trials were provided in the same order for all participants.  Participants were 
handed the premeasured amount of liquid in 6 ounce Styrofoam cup with a straw.  The 
instructions were to drink all the liquid in the cup and swallow as many times as necessary.  
All participants swallowed the entire measured amount for each trial, except for one female 
ALS subject she frank aspiration resulted in early termination (after 46mL) of the 3 ounce thin 
liquid trial.   
Swallowing Measures 
After a subject completed the FEES, the swallow evaluation was reviewed in real-time 
and slow motion to collect the following data for each trial: counting the initial swallow and 
number of successive swallows per bolus trial, and rating swallowing function with the 
Penetration-Aspiration Scale (PAS) (Rosenbek et al., 1996), and the Pharyngeal Residue 
Scale (Kelly et al., 2008).  The PAS is an 8-point ordinal scale of swallowing severity 
dependent on the depth of events of laryngeal airway penetration and tracheal aspiration as 
well as patient reaction to those events (Appendix I).   PAS analysis occurred throughout all 
swallows for each bolus.  The most severe rating, at any point during each trial was 
documented for that trial.  The pharyngeal residue scale (Kelly et al., 2008) was also utilized 
for each bolus trial.  Approximately 10 seconds after all oral pharyngeal movements ceased, 
the subject was asked, “Are you done swallowing?” At that time the pharyngeal residue was 
rated on a 5 point ordinal scale (Appendix I).      
All data were recorded on the FEES Rater Sheet (Appendix I) and then transferred to 
the Electronic Data Sheets.  All data was organized by group and task in the following order:  
1)  PAS ratings: female ALS group, male ALS group, and control group (Appendix J); 2) 
Pharyngeal residue ratings: female ALS group, male ALS group, and control group 
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(Appendix K); and 3) Number of swallows per bolus: female ALS group, male ALS group, 
and control group (Appendix L). 
Data Processing and Statistical Analysis Procedures 
When comparing the ALS patients to the control subjects, chi-squared tests were used 
for the categorical variables.  For the continuous variables, a two sample t-test was used for 
age and Wilcoxon two sample tests were used for FVC and the DHI, DDK and FEES 
measurements.  For assessing associations among the FVC, DHI, DDK and FEES 
measurements, Spearman’s correlation coefficients were used.  These nonparametric methods 
of Wilcoxon tests and Spearman’s correlations were done because the variables did not 
always follow a normal distribution or were measured on an ordinal scale.  Similar tests were 
used when assessing the association of ALS characteristics with the FVC, DHI, DDK and 
FEES measurements.  All testing was done at the 0.05 level.  Statistical analyses were 
performed using SAS version 9.4 (SAS, 2014).  Agreement between readers for the FEES 
measurements was assessed using kappa statistics for the ordinal responses of aspiration and 
residue and intraclass correlation coefficients for number of swallows.   
Interrater Reliability 
Preliminary interrater reliability was established between two experienced Speech-
Language Pathologists who ranked the swallowing function of 15 individual (91 individual 
swallows) FEES examinations selected randomly from a clinical database.  The SLPs 
independently rated each swallow and compared severity rankings on the PAS and residue 
scales.  Cohen’s Kappa analysis for interpreter reliability revealed very good to excellent 
agreement between the two raters with kappa values of 0.75 for PAS and 0.72 for pharyngeal 
residue scale.  
44 
 
Interrater reliability was conducted all recorded swallow trials for this study.  Each of 
the two Speech-Language Pathologists, the Primary Investigator and one other SLP trained in 
the FEES procedure, individually ranked the swallowing function of all 32 participants (169 
unique swallowing trials).  Swallowing rankings included the number of swallows per bolus 
trial, a Penetration-Aspiration Scale rating for each bolus trial, and a residue severity rating 
for each bolus trial.   
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CHAPTER 4 
RESULTS 
The primary purpose of this investigation was to examine potential correlations 
between commonly utilized clinical measures to assess speech and respiratory function with 
swallowing ability in individuals with ALS.  ALS group performance was compared to 
performance of a control group of similar age and gender composition.  
Interrater Reliability Rating 
 All FEES measurements were rated independently by two reviewers.  Their results 
were assessed for agreement.  All individuals of the ALS group and control group were 
included in the following analyses.  For the measurements of PAS and pharyngeal residue, 
regular Kappa statistics and weighted Kappa statistics were computed, along with their 95% 
confidence intervals.  Regular Kappa statistics do not distinguish between different levels of 
agreement where as weighted Kappa statistics account for disagreement between adjacent 
levels in a different weight compared to discordances of more than one level.  Due to the 
ordinal nature of the measurements, weighted kappa statistics were utilized for interpretation 
of the analysis.  For the measurement of number of swallows, the intra-class correlations 
coefficients (ICC) were computed, along with their 95% confidence intervals.  Landis and 
Koch (1977) provided interpretation for levels of agreement using these statistics.  Proposed 
values of agreement were as follows:  <0 as poor, 0 to .2 as slight, 0.21 to 0.4 as fair, 0.41 to 
0.6 as moderate, 0.61 to 0.8 as substantial and >0.8 as almost perfect agreement.   
Measures of agreement for PAS and residue were determined for six different bolus trials per 
individual (Table 1).  Levels of agreement for the PAS ranged from moderate to almost 
perfect for the weighted Kappa analysis.  The range of agreement for the pharyngeal residue 
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measure varied from substantial to almost perfect for the weighted Kappa results.     The level 
of agreement was almost perfect for measurement of the number of swallows (Table 2).   
Comparison of ALS and Control Group Performance 
Performance on all tasks was assessed for significance between individuals in the ALS 
group and the control group.  Various analyses were utilized to determine significance 
including two sample t-test, chi-square test and Wilcoxon two sample test.  The Wilcoxon two 
sample test was selected, over the two sample t-test to compare scores between the ALS and 
control group because of unequal variability between the groups and/or measurements using 
an ordinal scale. 
Demographics and FVC 
 Analysis of the demographic composition did not reveal significant differences in age, 
gender or history of tobacco use. Significant differences were present with FVC %, a 
continuous measure (p=<0.001), and FVC categories (p=0.004).  FVC performance for all 
control group participants was above the 80% predicted threshold for the within normal limits 
(WNL) category, while ALS participant performance was dispersed throughout all three 
categories, WNL, mild and moderate (Table 3). 
DHI and Tired Rating 
Performance on the DHI and tired rating measures were assessed with Wilcoxon two 
sample tests.  Significant differences were present between ALS subjects and controls on all 
measures of the DHI (Physical, Functional, Emotional, Overall rating and Self-reported 
Severity of Dysphagia) as well as self-reported tired rating at the time of the study (Table 4). 
The lowest level of significance on these measures was p=0.018. ALS subjects consistently 
reported higher ratings in all categories of the DHI and on the tired rating.    
47 
 
DDK, Number of Swallows, PAS and Pharyngeal Residue 
Individuals in the control group produced significantly more target repetitions per 
second than ALS subjects across all variables (p=0.001 or p=<0.001) (Table 5).  Controls 
achieved 2 more productions of /pʌ/, /tʌ/ and /kʌ/ per second in comparison to subjects with 
ALS.   The repetition rate for /pʌtʌkʌ/ was also significantly reduced in the ALS group at a 
rate of 1.3 repetitions per second in comparison to 2 repetitions per second in the control 
group. 
Significant differences were present between the ALS group and the control group for 
number of swallows for both the thin liquid 30mL (p=0.009) and thin liquid 3 ounce (p= 
0.002) boluses. No significant differences were present for number of swallows with thin 
liquid 10mL, puree or solid bolus trials (Table 6).  There was a significant difference for PAS 
measure ratings for all consistencies and trials with the exception of thin liquid 10mL (Table 
7).   
Significant differences were discovered in severity of pharyngeal residue after both the 
initial swallow and after the final swallow of various consistencies (Tables 8 and 9). 
Significantly increased pharyngeal residue severity, after the initial swallow, was present in 
the ALS group with thin liquid 30mL, thin liquid 3 ounces and puree #2 boluses. The control 
group severity was most often rated as coated, whereas the ALS group was frequently rated as 
mild with a few in the moderate range. Individuals in the ALS group had significantly higher, 
more severe, pharyngeal residue scale ratings after the final swallow for puree and solid 
boluses. There was not a significant difference in pharyngeal residue ratings after the final 
swallow for thin liquid bolus trials despite increased pharyngeal residue severity ratings for 
ALS subjects.  
48 
 
 ALS Group Correlations for Speech, Respiration and Swallowing Measures  
Correlations between DDK and FVC with Swallowing Measures  
 Within the ALS group, correlations between speech, respiration and swallowing 
measures were assessed.  Correlations between PAS severity ratings for all 6 bolus trials with 
the four DDK measures and FVC were examined (Table 10).  Significant negative 
correlations between PAS and /kʌ/ per second with thin liquid 10mL (r = - 0.504, p = 0.046), 
and between PAS and /pʌtʌkʌ/ per second for thin liquid 10mL (r = - 0.556, p = .025).  There 
were also significant negative correlations between PAS ratings for thin liquid 3oz and FVC 
(r = - 0.540, p = 0.046).   The ratings of swallowing impairment increased as FVC 
performance and DDK productions per second decreased.   
 Pharyngeal residue severity ratings for all 6 bolus trials were examined for significant 
correlations at two discrete periods (after the initial swallow and after the final swallow) 
during each trial with the four DDK measures and FVC performance (Table 11). Significant 
negative correlations were found between pharyngeal residue ratings for the second puree 
5mL bolus and solid bolus with DDK production /kʌ/ per second.  A significant negative 
correlation was also present with pharyngeal residue rating for thin liquid 10mL and DDK 
production of /pʌtʌkʌ/ per second (r = - 0.560, p = 0.024).  The volume of pharyngeal residue 
increased as DDK production decreased.  There were no significant correlations between FVC 
performance with either period of pharyngeal residue severity analysis.  There were no 
significant correlations between pharyngeal residue after the first swallow of a bolus and 
DDK (Table 12) 
Correlations between Number of Swallows with Swallowing Measures, DDK and FVC 
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 Number of swallows per bolus was also analyzed for potential correlations with the 
PAS, the pharyngeal residue scale, DDK, FVC and DHI (Tables 13, 14 and 15).  Significant 
positive correlations were determined between the number of swallows per bolus and the 
severity of PAS rating and pharyngeal residue severity rating after the final swallow with thin 
liquid 10mL bolus trials (Table 14).  The severity of the PAS rating for puree bolus #1 and 
solid bolus were also positively associated with number of swallows per bolus trial.  No 
significant correlations were revealed between DDK and FVC with number of swallows per 
bolus trial (Table 13).   
Correlations between the DHI with Swallowing Measures, DDK and FVC 
 Significant correlations were present between the DHI with the PAS, the pharyngeal 
residue scale, DDK and FVC.  Significant positive correlations were found between the PAS 
rating for thin liquid 30mL and the Functional, Emotional and Dysphagia Self-rating 
subscales of the DHI. Significant positive correlations were present between the PAS severity 
rating for thin liquid 3 ounce bolus trial and all of the DHI scales except the physical subscale.  
Levels of significance for both 30mL and 3 ounce thin liquid boluses were between p = 0.001 
and p = 0.039 (Table 16).  
Significant positive correlations were present for all DHI scales with pharyngeal residue 
severity (after the final swallow) for at least one bolus trial (Table 17).  The puree bolus trial 
number two had a significant positive correlation with the Physical and Overall scales of the 
DHI.  Pharyngeal residue severity for thin liquid 10mL has a significant positive correlation 
with the Functional, Overall, and Dysphagia Self-Rating scales of the DHI.  There was a 
significant positive correlation between the Emotional, Overall and Dysphagia Self-Rating 
scales of the DHI and pharyngeal residue severity, after the final swallow, with solid boluses.  
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Pharyngeal residue rating severity for 30mL was also significantly positively correlated with 
Functional scale severity on the DHI.   
No significant correlations were present with DHI and pharyngeal residue after the initial 
swallow with any bolus trial (Table 18).  Significant negative correlations existed between the 
Functional scale of the DHI and the FVC percentage (r = -0.517, p = 0.028), and between the 
Emotion scale of the DHI and the Ka/second DDK measure (r = -0.502, p = 0.034) (Table 
19). 
Analysis of ALS Aspiration/Non-Aspiration Groups with Clinical Assessments and 
Swallowing Measures.  
 
 Swallowing ability was assessed categorically within the ALS group to evaluate for 
significant correlations between aspirators and non-aspirators.  This analysis combined PAS 
ratings 1-5 (no aspiration) and 6-8 (aspiration) (Tables 20-22).  Significant correlations were 
found between aspiration and non-aspiration groups with the thin liquid 10mL trial (Table 20) 
and ka/second, p = 0.024.  The non-aspiration group produced twice as many targets per 
second on average as the aspiration group.   
Significant correlations were present between aspirators and non-aspirators with the thin 
liquid 30mL bolus (Table 21) and the Functional DHI scale (p = 0.049), Emotional (p=0.04) 
and Self-Rating of Swallowing (p = 0.029).  Functional DHI scores on average were 2.87 
times greater for the aspiration group (14.75) than the non-aspiration group (5.14). For the 
mean Emotional DHI score, the aspiration group was 5.42 times higher than the non-
aspiration group. Self-Reported Severity of Dysphagia scores were 2.59 times greater (i.e., 
indicating more severe impairments in swallowing ability) for the aspiration group (4.06) in 
comparison to the no aspiration group (1.57).  Significant differences were also present 
between PAS severity rating of thin liquid 3 ounces trials (Table 22) with the following DHI 
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severity scales: Functional (p = 0.030), Emotional (p = 0.016), Overall (0.034) and Self-
Rating of Swallowing (p = 0.043).  On average, the aspiration group reported a severity level 
that was more than twice as much compared to the non-aspiration group.  PAS categories 
were not assessed with puree #1, puree #2 or solid boluses due to the limited number of 
aspiration events.  
Analysis of Duration of Disease, Onset, ALS-FRSR and BMI with Clinical and 
Swallowing Measures in the ALS Group 
 
 During the course of the study, several additional factors were identified for analysis.  
These factors included: type of ALS symptom onset, duration of ALS disease at time of study 
completion, body mass index (BMI) at the time of study completion and total ALS-FRSR 
score.   These factors were analyzed to determine if any correlations existed with the primary 
assessment measures (FVC, PAS, pharyngeal residue, DDK and DHI).   
 There were no significant correlations between FVC categories (WNL, Mild, 
Moderate impairment) and DHI measures, DDK performance, PAS severity, pharyngeal 
residue severity or number of swallows per bolus (Table 23-27).  Analysis between type of 
onset (bulbar, axial and mixed) and DHI scores revealed significant correlations with the 
Physical and the Self-Reported Severity of Dysphagia Rating (Table 28).  In both DHI 
measures the bulbar onset group reported the most severe ratings, the mixed onset group 
second most severe and the axial onset group with the least impairments. The bulbar onset 
group scored more than twice as high (more severe) as the other two groups. Significant 
differences were present between type of onset and PAS severity with thin liquid 10mL 
(Table 29) and with pharyngeal residue severity with thin liquid 30mL (Table 30).  The bulbar 
onset group demonstrated the greatest impairments on both the PAS and pharyngeal residue 
scales.  Eighty percent of the bulbar onset group, 13% of the axial group and 0% of the mixed 
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group received the most severe PAS rating score for thin liquid 10mL.  There were no 
significant correlations between type of onset and DDK or FVC (Table 31).   
Seventeen of the ALS participants had duration of symptoms less than four years, 
while one patient has had symptoms for over 15 years.  Analyses for duration of ALS 
symptoms were done for all ALS participants, as well as only those with duration within the 
last four years.  Significant positive correlations between duration of ALS symptoms 
(including all participants) with PAS score for puree #2 (r = 0.517, p = 0.040) and with 
number of swallows for thin liquid 3oz and puree #1 (Tables 32 and 33) were noted.  No 
significant associations were found between duration of ALS symptoms (all participants) and 
DDK, FVC, DHI or pharyngeal residue measures (Tables 34-36).  Significant positive 
correlation was present between duration of ALS symptoms (within 4 years) and number of 
swallows for thin liquid 3oz and puree#1 (Table 37).  No significant correlations were present 
between duration of ALS symptoms (within 4 years) and DDK, FVC, DHI, pharyngeal 
residue or PAS ratings (Tables 38-41).  
A significant positive correlation was present between total ALS-FRSR score and 
number of swallows for thin liquid 10mL and solid boluses (r = 0.569, 0.574 and p = 0.021, 
0.016 respectively) (Table 42).  There were no significant correlations between total ALS-
FRSR and DDK, FVC, DHI, PAS or pharyngeal residue (Tables 43-46).  
Analyses were completed to examine the correlation between body mass index (BMI) 
rating of normal or overweight/obese and with FVC, DDK, DHI, PAS severity, pharyngeal 
residue severity and number of swallows per bolus.  There was a significant difference in 
pharyngeal residue of thin liquid 30mL between the normal or overweight/obese BMI groups 
(Table 47).  Eighty-eight percent of the ALS participants in the overweight/obese BMI 
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category had mild residue compared to only 29% of the subjects with normal BMI category.    
There were no significant correlations between BMI and DDK, FVC, DHI or PAS measures 
(Tables 48-51).   
 
 
 
 
 
 
 
 
 
 
Table 1: Measurements of Interrater Agreement for PAS and Pharyngeal Residue 
 
 
Bolus 
PAS Residue 
Kappa 
w/ 95%CI 
Weighted Kappa 
w/ 95%CI 
Kappa 
w/ 95%CI 
Weighted Kappa 
w/ 95%CI 
Thin liquid 10ml 0.54 (0.34,0.74) 0.72 (0.56, 0.89) 0.83 (0.64, 1.00) 0.85 (0.70, 1.00) 
Thin liquid 30ml 0.67 (0.48, 0.86) 0.81 (0.68, 0.95) 0.70 (0.45, 0.94) 0.73 (0.50, 0.96) 
Thin liquid 3oz 0.54 (0.33, 0.75) 0.77 (0.65, 0.90) 0.72 (0.50, 0.94) 0.76 (0.56, 0.96) 
     
Puree 1 0.70 (0.48, 0.93) 0.83 (0.67, 0.98) 0.63 (0.37, 0.89) 0.69 (0.47, 0.92) 
Puree 2 0.65 (0.44, 0.87) 0.86 (0.74, 0.98) 0.72 (0.51, 0.94) 0.77 (0.59, 0.95) 
Solid 0.44 (0.20, 0.67) 0.58 (0.30, 0.85) 0.59 (0.38, 0.81) 0.74 (0.59, 0.88) 
Table 2: Measurements of Interrater Agreement for Number of Swallows 
Bolus ICC w/ 95% CI 
Thin liquid 10ml 0.98 (0.96, 0.99) 
Thin liquid 30ml 0.98 (0.96, 0.99) 
Thin liquid 3oz 0.81 (0.65, 0.90) 
  
Puree 1 0.89 (0.79, 0.94) 
Puree 2 0.95 (0.90, 0.97) 
Solid 0.91 (0.83, 0.95) 
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Table 3: Demographic and FVC for ALS and Control subjects 
Variable Response 
ALS patients 
(N= 18) 
Controls 
(N= 15) p-value 
Age  Mean ± S.D 
Median (Range) 
67.9 ± 8.7 
66 (54 to 82) 
65.5 ± 8.2 
63 (58 to 84) 
0.409a 
Gender F 12 (67%) 11 (73%) 0.678b 
M 6 (33%) 4 (27%) 
Tobacco  
History 
N 13 (72%) 10 (67%) 0.730b 
Y 5 (28%) 5 (33%) 
FVC, % Mean ± S.D 
Median (Range) 
76.2 ± 16.7 
79 (51 to 107) 
110.7 ± 16.8 
112 (87 to 150) 
<.001a 
FVC categories WNL 9 (50%) 15 (100%) 0.004c 
Mild 4 (22%) 0 (0%) 
Moderate 5 (28%) 0 (0%) 
a -- p-value from two sample t-test.  
b -- p-value from chi-square test. 
c – p-value from Wilcoxon two sample test. 
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Table 4: DHI response and tired rating for ALS and Control subjects 
Variable 
 ALS patients 
(N= 18) 
Controls 
(N= 15) p-valuea 
Physical  Mean ± S.D 
Median (Range)
9.9 ± 6.5 
6 (2 to 22) 
3.9 ± 2.7 
4 (0 t 10) 
0.004 
Functional  Mean ± S.D 
Median (Range)
11.2 ± 9.6 
8 (0 to 30) 
0.1 ± 0.5 
0.2 0 (0 to 2) 
<.001 
Emotional  Mean ± S.D 
Median (Range)
4.9 ±5.8 
2 (0 to 16) 
0 
All 0’s 
0.001 
Overall  Mean ± S.D 
Median (Range)
26.0 ± 19.8 
18 (6 to 68) 
4.0 ± 3.0 
4 (0 to 12) 
<.001 
Self-report  
swallowing difficulty 
Mean ± S.D 
Median (Range)
3.0 ± 1.9 
2.5 (1 to 6) 
1.3 ± 0.6 
1 ( 1 to 3) 
0.006 
Tired Rating Mean ± S.D 
Median (Range)
3.2 ± 2.0 
3.5 (1 to 7) 
1.5 ± 0.7 
1 (1 to 3) 
0.018 
a – p-value from Wilcoxon two sample test. 
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Table 5: DDK information for ALS and control subjects 
Variable 
 ALS patients 
(N= 18) 
Controls 
(N= 15) p-valuea 
pʌ /sec Mean ± S.D 
Median (Range)
3.6 ± 1.6 
3.3 (1.4 to 6.4) 
5.7 ± 0.6 
5.6 (4.6 to 6.8) 
<.001 
tʌ/sec Mean ± S.D 
Median (Range)
3.2 ± 1.6 
3.1 (1 to 6.4) 
5.3 ± 0.7 
5.2 (4.4 to 6.8) 
0.001 
kʌ/ sec Mean ± S.D 
Median (Range)
2.8 ± 1.3 
2.7 (1 to 5.8) 
5.1 ± 0.7 
5.3 (4.2 to 6) 
<.001 
pʌtʌkʌ/sec Mean ± S.D 
Median (Range)
1.3 ± 0.6 
1.2 (0.4 to 2.066) 
2.0 ± 0.3 
2 (1.6 to 2.6) 
0.001 
a – p-value from Wilcoxon two sample test. 
 
Table 6: Number of swallows for ALS and control subjects 
Bolus Response 
ALS patients 
(N= 18) 
Controls 
(N= 15) p-valuea 
Thin liquid 10mL Mean ± S.D 
Median (Range) 
5.8 ± 5.2 
4 (2 to 22) 
3.4 ± 1.5 
3 (2 to 7) 
0.104 
Thin liquid 30 mL Mean ± S.D 
Median (Range) 
7.1 ± 4.9 
6 (1 to 22) 
3.9 ± 1.2 
4 (2 to 6) 
0.009 
Thin liquid 3 oz Mean ± S.D 
Median (Range) 
11.5 ± 4.6 
10 (6 to 23) 
6.3 ± 3.0 
5 (4 to 13) 
0.002 
Puree 5mL #1 Mean ± S.D 
Median (Range) 
3.4 ± 1.9 
3 (1 to 8) 
2.9 ± 1.0 
3 (2 to 5) 
0.829 
Puree 5mL #2 Mean ± S.D 
Median (Range) 
3.4 ± 2.2 
3 (1 to 10) 
2.9 ± 1.1 
3 (2 to 5) 
0.798 
Solid Mean ± S.D 
Median (Range) 
3.9 ± 2.1 
4 (1 to 9) 
3.1 ± 1.2 
3 (1 to 5) 
0.248 
a – p-value from Wilcoxon two sample test. 
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Table 7: Penetration Aspiration Scale for ALS and control subjects 
Bolus Response 
ALS 
patients 
(N= 18) 
Controls 
(N= 15) 
p-
valuea 
Thin 
Liquid 
10 mL 
Does not enter airway 5 (31%) 8 (53%) 0.158 
Enters airway, above VF, ejected from airway 2 (13%) 2 (13%) 
Enters airway, above VF, not ejected from airway 2 (13%) 0 (0%) 
Enters airway, contacts VF, ejected from airway 1 (6%) 0 (0%) 
Enters airway, contacts VF, not ejected from airway 1 (6%) 5 (33%) 
Enters airway, below VF, no effort made to eject 5 (31%) 0 (0%) 
Thin 
Liquid 
30 mL 
Does not enter airway 3 (20%) 10 (67%) 0.005 
Enters airway, above VF, ejected from airway 2 (13%) 1 (7%) 
Enters airway, above VF, not ejected from airway 1 (7%) 1 (7%) 
Enters airway, contacts VF, ejected from airway 0 (0%) 1 (7%) 
Enters airway, contacts VF, not ejected from airway 1 (7%) 2 (13%) 
Enters airway, below VF, not ejected from trachea 
despite effort 
1 (7%) 0 (0%) 
Enters airway, below VF, no effort made to eject 7 (47%) 0 (0%) 
Thin 
Liquid 
3 oz 
Does not enter airway 1 (7%) 9 (60%) 0.003 
Enters airway, above VF, ejected from airway 3 (21%) 3 (20%) 
Enters airway, contacts VF, not ejected from airway 3 (21%) 0 (0%) 
Enters airway, below VF, ejected into larynx or out 
of airway 
0 (0%) 2 (3%) 
Enters airway, below VF, not ejected from trachea 
despite effort 
1 (7%) 1 (7%) 
Enters airway, below VF, no effort made to eject 6 (43%) 0 (0%) 
Puree 
5mL 
#1 
Does not enter airway 8 (50%) 14 (93%) 0.014 
Enters airway, above VF, ejected from airway 1 (6%) 0 (0%) 
Enters airway, above VF, not ejected from airway 4 (25%) 1 (7%) 
Enters airway, contacts VF, not ejected from airway 2 (13%) 0 (0%) 
Enters airway, below VF, no effort made to eject 1 (6%) 0 (0%) 
Puree Does not enter airway 7 (44%) 12 (80%) 0.026 
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Table 7: Penetration Aspiration Scale for ALS and control subjects 
Bolus Response 
ALS 
patients 
(N= 18) 
Controls 
(N= 15) 
p-
valuea 
5mL 
#2 
Enters airway, above VF, ejected from airway 0 (0%) 1 (7%) 
Enters airway, above VF, not ejected from airway 5 (31%) 2 (13%) 
Enters airway, contacts VF, not ejected from airway 1 (6%) 0 (0%) 
Enters airway, below VF, no effort made to eject 3 (19%) 0 (0%) 
Solid Does not enter airway 7 (44%) 11 (73%) 0.037 
Enters airway, above VF, ejected from airway 2 (13%) 4 (27%) 
Enters airway, above VF, not ejected from airway 2 (13%) 0 (0%) 
Enters airway, contacts VF, not ejected from airway 4 (25%) 0 (0%) 
Enters airway, below VF, no effort made to eject 1 (6%) 0 (0%) 
a – p-value from Wilcoxon two sample test. 
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Table 9: Pharyngeal Residue Scale after the Final Swallow  
for ALS and Control subjects 
Table 8: Comparing Pharyngeal Residue after the Initial Swallow for 
ALS and Control subjects 
Variable Response 
ALS patients 
(N= 18) 
Controls 
(N= 15) p-valuea 
Thin liquid 10ml None 1 (6%) 2 (13%) 0.911 
Coating 6 (38%) 3 (20%) 
Mild 8 (50%) 10 (67%) 
Severe 1 (6%) 0 (0%) 
Thin liquid 30ml Coating 3 (19%) 10 (67%) 0.004 
Mild 10 (63%) 5 (33%) 
Moderate 3 (19%) 0 (0%) 
Thin liquid 3oz None 0 (0%) 1 (7%) 0.010 
Coating 3 (19%) 9 (60%) 
Mild 12 (75%) 5 (33%) 
Moderate 1 (6%) 0 (0%) 
Puree 1 None 0 (0%) 1 (7%) 0.826 
Coating 6 (35%) 4 (27%) 
Mild 10 (59%) 10 (67%) 
Moderate 1 (6%) 0 (0%) 
Puree 2 Coating 1 (6%) 5 (33%) 0.038 
Mild 13 (81%) 10 (67%) 
Moderate 2 (13%) 0 (0%) 
Solid None 5 (29%) 6 (40%) 0.287 
Coating 3 (18%) 4 (27%) 
Mild 6 (35%) 4 (27%) 
Moderate 1 (6%) 1 (7%) 
Severe 2 (12%) 0 (0%) 
aP-value from Wilcoxon two sample test. 
60 
 
Variable Response 
ALS patients 
(N= 18) 
Controls 
(N= 15) p-valuea 
Thin liquid, 10mL None 0 (0%) 2 (13%) 0.09 
Coating 5 (31%) 7 (47%) 
Mild 11 (69%) 6 (40%) 
Thin liquid, 30 mL None 0 (0%) 2 (13%) 0.054 
Coating 6 (40%) 9 (60%) 
Mild 9 (60%) 4 (27%) 
Thin liquid, 3 oz None 0 (0%) 3 (20%) 0.061 
Coating 8 (53%) 9 (60%) 
Mild 7 (47%) 3 (20%) 
Puree, 5mL #1 None 0 (0%) 2 (13%) 0.015 
Coating 3 (18%) 7 (47%) 
Mild 13 (76%) 6 (40%) 
Moderate 1 (6%) 0 (0%) 
Puree, 5mL #2 None 0 (0%) 1 (7%) 0.006 
Coating 3 (18%) 9 (60%) 
Mild 12 (71%) 5 (33%) 
Moderate 2 (12%) 0 (0%) 
Solid  None 1 (6%) 9 (60%) 0.002 
Coating 4 (24%) 3 (20%) 
Mild 10 (59%) 3 (20%) 
Moderate 2 (12%) 0 (0%) 
a – p-value from Wilcoxon two sample test. 
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Table 10: Associations for PAS with DDK and FVC  
DDK Bolus N 
Spearman’s 
Correlation 
Coefficient  p-value 
pʌ/sec Thin liquid 10mL 16 -0.267 0.317 
Thin liquid 30 mL 15 -0.023 0.936 
Thin liquid 3 oz 14 -0.307 0.286 
Puree 5mL #1 16 0.088 0.747 
Puree 5 mL #2 16 -0.189 0.484 
Solid 16 0.036 0.895 
tʌ/ sec Thin liquid 10mL 16 -0.251 0.348 
Thin liquid 30 mL 15 -0.102 0.717 
Thin liquid 3 oz 14 -0.366 0.198 
Puree 5mL #1 16 0.209 0.437 
Puree 5 mL #2 16 -0.091 0.737 
Solid 16 0.174 0.519 
kʌ/sec Thin liquid 10mL 16 -0.504 0.046 
Thin liquid 30 mL 15 -0.261 0.348 
Thin liquid 3 oz 14 -0.509 0.063 
Puree 5mL #1 16 0.124 0.646 
Puree 5 mL #2 16 -0.087 0.750 
Solid 16 -0.032 0.907 
pʌtʌkʌ/sec Thin liquid 10mL 16 -0.556 0.025 
Thin liquid 30 mL 15 -0.092 0.746 
Thin liquid 3 oz 14 -0.236 0.417 
Puree 5mL #1 16 0.199 0.460 
Puree 5 mL #2 16 0.125 0.646 
Solid 16 0.084 0.756 
FVC Thin liquid 10mL 16 -0.366 0.164 
Thin liquid 30 mL 15 -0.314 0.255 
Thin liquid 3 oz 14 -0.540 0.046 
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Table 10: Associations for PAS with DDK and FVC  
DDK Bolus N 
Spearman’s 
Correlation 
Coefficient  p-value 
Puree 5mL #1 16 0.024 0.930 
Puree 5 mL #2 16 -0.295 0.268 
Solid 16 -0.340 0.198 
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Table 11: Associations for Pharyngeal Residue Scale (after final swallow)  with 
DDK and FVC  
DDK Bolus N 
Spearman’s Correlation 
CoeffieientCoefficient p-value 
pʌ/sec Thin liquid 10mL 16 -0.308 0.245 
Thin liquid 30 mL 15 0.174 0.535 
Thin liquid 3 oz 15 0.232 0.405 
Puree 5mL #1 17 0.385 0.127 
Puree 5 mL #2 17 -0.441 0.076 
Solid 17 -0.211 0.416 
tʌ/sec Thin liquid 10mL 16 -0.278 0.296 
Thin liquid 30 mL 15 0.158 0.574 
Thin liquid 3 oz 15 0.186 0.507 
Puree 5mL #1 17 0.424 0.089 
Puree 5 mL #2 17 -0.455 0.067 
Solid 17 -0.258 0.317 
kʌ/sec Thin liquid 10mL 16 -0.397 0.128 
Thin liquid 30 mL 15 -0.079 0.779 
Thin liquid 3 oz 15 0.171 0.542 
Puree 5mL #1 17 0.317 0.215 
Puree 5 mL #2 17 -0.512 0.036 
Solid 17 -0.484 0.049 
pʌtʌkʌ/sec Thin liquid 10mL 16 -0.560 0.024 
Thin liquid 30 mL 15 -0.159 0.572 
Thin liquid 3 oz 15 0.109 0.698 
Puree 5mL #1 17 0.296 0.248 
Puree 5 mL #2 17 -0.350 0.169 
Solid 17 -0.293 0.253 
FVC Thin liquid 10mL 16 -0.337 0.202 
Thin liquid 30 mL 15 -0.095 0.737 
Thin liquid 3 oz 15 -0.449 0.093 
Puree 5mL #1 17 0.344 0.176 
Puree 5 mL #2 17 0.060 0.818 
Solid 17 -0.139 0.594 
64 
 
Table 12: Associations of Pharyngeal Residue Scale (after first swallow) with  
 DDK and FVC with residue after first swallow 
 
DDK Bolus N 
Spearman’s 
Correlation 
Coefficient p-value 
pʌ/sec Thin liquid 10ml 16 -0.020 0.943 
Thin liquid 30ml 16 0.067 0.806 
Thin liquid 3oz 16 0.147 0.587 
Puree 1 17 0.170 0.515 
Puree 2 16 0.069 0.798 
Solid 17 -0.077 0.770 
tʌ/sec Thin liquid 10ml 16 0.060 0.825 
Thin liquid 30ml 16 0.067 0.806 
Thin liquid 3oz 16 0.145 0.592 
Puree 1 17 0.182 0.485 
Puree 2 16 0.179 0.508 
Solid 17 -0.047 0.857 
kʌ/sec Thin liquid 10ml 16 -0.205 0.446 
Thin liquid 30ml 16 -0.134 0.622 
Thin liquid 3oz 16 -0.098 0.717 
Puree 1 17 0.136 0.603 
Puree 2 16 -0.108 0.692 
Solid 17 -0.209 0.421 
pʌtʌkʌ/sec Thin liquid 10ml 16 -0.263 0.326 
Thin liquid 30ml 16 -0.067 0.806 
Thin liquid 3oz 16 -0.068 0.801 
Puree 1 17 0.303 0.237 
Puree 2 16 0.053 0.844 
Solid 17 -0.226 0.383 
FVC, % Thin liquid 10ml 16 -0.242 0.367 
Thin liquid 30ml 16 -0.399 0.126 
Thin liquid 3oz 16 0.049 0.858 
Puree 1 17 0.415 0.097 
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Table 12: Associations of Pharyngeal Residue Scale (after first swallow) with  
 DDK and FVC with residue after first swallow 
 
DDK Bolus N 
Spearman’s 
Correlation 
Coefficient p-value 
Puree 2 16 -0.128 0.638 
Solid 17 -0.033 0.901 
 
Table 13: Associations for DDK and FVC with number of swallows 
Swallows Bolus N 
Spearman’s Correlation 
Coefficient p-value 
Thin liquid 10ml pʌ/sec 16 0.039 0.886 
tʌ/sec 16 0.040 0.884 
kʌ/sec 16 -0.194 0.471 
pʌtʌkʌ/sec 16 -0.276 0.300 
FVC, % 16 -0.029 0.917 
Thin liquid 30ml pʌ/sec 15 0.316 0.252 
tʌ/sec 15 0.311 0.259 
kʌ/sec 15 0.000 1.000 
pʌtʌkʌ/sec 15 0.015 0.959 
FVC, % 15 0.097 0.730 
Thin liquid 3oz pʌ/sec 15 -0.178 0.526 
tʌ/sec 15 -0.163 0.563 
kʌ/sec 15 -0.312 0.257 
pʌtʌkʌ/sec 15 -0.190 0.497 
FVC, % 15 -0.139 0.622 
Puree 5 mL #1 pʌ/sec 17 0.215 0.407 
tʌ/sec 17 0.323 0.206 
kʌ/sec 17 0.240 0.353 
pʌtʌkʌ/sec 17 0.161 0.537 
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Table 13: Associations for DDK and FVC with number of swallows 
Swallows Bolus N 
Spearman’s Correlation 
Coefficient p-value 
FVC, % 17 -0.265 0.305 
Puree 5 mL #2 pʌ/sec 17 -0.018 0.945 
tʌ/sec 17 0.101 0.701 
kʌ/sec 17 0.008 0.977 
pʌtʌkʌ//sec 17 0.017 0.949 
FVC, % 17 -0.156 0.551 
Solid pʌ/sec 17 0.257 0.320 
tʌ/sec 17 0.330 0.196 
kʌ/sec 17 0.095 0.717 
pʌtʌkʌ/sec 17 -0.024 0.928 
FVC, % 17 -0.264 0.305 
 
Table 14: Association of PAS and residue with number of swallows 
Swallows N 
PAS Residue 
Spearman’s  
Correlation 
Coefficient  p-value 
Spearman’s  
Correlation 
Coefficient p-value 
Thin liquid 10ml 16 0.689 0.003 0.522 0.038 
Thin liquid 30ml 15 0.188 0.503 0.460 0.084 
Thin liquid 3oz 14 0.329 0.251 0.158 0.574 
Puree 5 mL #1 16 0.532 0.034 0.100 0.704 
Puree 5 mL #2 16 0.440 0.088 0.034 0.896 
Solid 16 0.631 0.009 -0.077 0.768 
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Table 15: Associations of DHI with Number of Swallows 
Swallows DHI N 
Spearman’s 
Correlation 
Coefficient p-value 
Thin liquid 10ml Physical 16 0.316 0.233 
Functional 16 0.435 0.092 
Emotional 16 0.205 0.446 
Overall 16 0.464 0.070 
Self-rating swallowing 16 0.293 0.271 
Tired Rating 16 -0.231 0.389 
Thin liquid 30ml Physical 15 0.269 0.331 
Functional 15 0.183 0.514 
Emotional 15 0.005 0.987 
Overall 15 0.194 0.488 
Self-rating swallowing 15 0.118 0.675 
Tired Rating 15 -0.344 0.209 
Thin liquid 3oz Physical 15 0.368 0.177 
Functional 15 0.364 0.182 
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Table 15: Associations of DHI with Number of Swallows 
Swallows DHI N 
Spearman’s 
Correlation 
Coefficient p-value 
Emotional 15 0.113 0.689 
Overall 15 0.266 0.338 
Self-rating swallowing 15 0.150 0.593 
Tired Rating 15 -0.185 0.508 
Puree #1 Physical 17 0.140 0.592 
Functional 17 0.235 0.365 
Emotional 17 0.095 0.717 
Overall 17 0.186 0.475 
Self-rating swallowing 17 -0.080 0.761 
Tired Rating 17 -0.143 0.583 
Puree #2 Physical 17 0.225 0.386 
Functional 17 0.123 0.639 
Emotional 17 -0.097 0.710 
Overall 17 0.112 0.668 
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Table 15: Associations of DHI with Number of Swallows 
Swallows DHI N 
Spearman’s 
Correlation 
Coefficient p-value 
Self-rating swallowing 17 -0.137 0.599 
Tired Rating 17 -0.446 0.073 
Solid Physical 17 0.166 0.524 
Functional 17 0.242 0.349 
Emotional 17 -0.041 0.876 
Overall 17 0.174 0.505 
Self-rating swallowing 17 0.030 0.908 
Tired Rating 17 -0.356 0.161 
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Table 16: Associations for Penetration-Aspiration Scale (PAS) with DHI 
DHI Bolus N 
Spearman’s Correlation 
Coefficient p-value 
Physical Thin liquid 10mL 16 0.099 0.714 
Thin liquid 30 mL 15 0.059 0.835 
Thin liquid 3 oz 14 0.347 0.224 
Puree 5mL #1 16 -0.122 0.652 
Puree 5mL #2 16 -0.043 0.875 
Solid 16 0.002 0.993 
Functional Thin liquid 10mL 16 0.446 0.083 
Thin liquid 30 mL 15 0.545 0.035 
Thin liquid 3 oz 14 0.653 0.011 
Puree 5mL #1 16 -0.102 0.707 
Puree 5mL #2 16 0.049 0.858 
Solid 16 0.286 0.283 
Emotional Thin liquid 10mL 16 0.256 0.339 
Thin liquid 30 mL 15 0.538 0.039 
Thin liquid 3 oz 14 0.771 0.001 
Puree 5mL #1 16 -0.079 0.770 
Puree 5mL #2 16 0.306 0.250 
Solid 16 0.328 0.215 
Overall Thin liquid 10mL 16 0.399 0.126 
Thin liquid 30 mL 15 0.410 0.129 
Thin liquid 3 oz 14 0.679 0.008 
Puree 5mL #1 16 -0.154 0.568 
Puree 5mL #2 16 0.066 0.808 
Solid 16 0.250 0.351 
Self-rating swallowing Thin liquid 10mL 16 0.435 0.092 
Thin liquid 30 mL 15 0.558 0.031 
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Table 16: Associations for Penetration-Aspiration Scale (PAS) with DHI 
DHI Bolus N 
Spearman’s Correlation 
Coefficient p-value 
Thin liquid 3 oz 14 0.601 0.023 
Puree 5mL #1 16 -0.391 0.135 
Puree 5mL #2 16 -0.061 0.823 
Solid 16 -0.027 0.921 
 
 
Table 17: Associations for Pharyngeal Residue Scale (after final swallow) with DHI 
DHI Bolus N 
Spearman’s Correlation 
Coefficient p-value 
Physical Thin liquid 10mL 16 0.163 0.545 
Thin liquid 30 mL 15 0.321 0.244 
Thin liquid 3 oz 15 0.266 0.337 
Puree 5mL #1 17 0.322 0.208 
Puree 5mL #2 17 0.554 0.021 
Solid 17 0.366 0.149 
Functional Thin liquid 10mL 16 0.529 0.035 
Thin liquid 30 mL 15 0.174 0.534 
Thin liquid 3 oz 15 0.450 0.092 
Puree 5mL #1 17 0.012 0.965 
Puree 5mL #2 17 0.246 0.341 
Solid 17 0.438 0.079 
Emotional Thin liquid 10mL 16 0.374 0.154 
Thin liquid 30 mL 15 0.049 0.864 
Thin liquid 3 oz 15 0.225 0.420 
Puree 5mL #1 17 0.003 0.990 
Puree 5mL #2 17 0.437 0.080 
Solid 17 0.668 0.003 
Overall Thin liquid 10mL 16 0.528 0.036 
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Table 17: Associations for Pharyngeal Residue Scale (after final swallow) with DHI 
DHI Bolus N 
Spearman’s Correlation 
Coefficient p-value 
Thin liquid 30 mL 15 0.237 0.395 
Thin liquid 3 oz 15 0.341 0.213 
Puree 5mL #1 17 0.206 0.429 
Puree 5mL #2 17 0.513 0.035 
Solid 17 0.583 0.014 
Self-rating swallowing Thin liquid 10mL 16 0.507 0.045 
Thin liquid 30 mL 15 0.274 0.323 
Thin liquid 3 oz 15 0.476 0.073 
Puree 5mL #1 17 0.040 0.878 
Puree 5mL #2 17 0.436 0.080 
Solid 17 0.491 0.046 
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Table 18: Associations of Pharyngeal Residue (after first swallow) with DHI  
DHI Bolus N 
Spearman’s 
Correlation 
Coefficient 
p-
value 
Physical Thin liquid 10ml 16 0.040 0.882 
Thin liquid 30ml 16 0.045 0.869 
Thin liquid 3oz 16 0.241 0.370 
Puree 1 17 0.407 0.105 
Puree 2 16 0.343 0.193 
Solid 17 0.322 0.207 
Functional Thin liquid 10ml 16 0.369 0.159 
Thin liquid 30ml 16 0.523 0.038 
Thin liquid 3oz 16 0.243 0.364 
Puree 1 17 0.023 0.931 
Puree 2 16 0.362 0.169 
Solid 17 0.334 0.190 
Emotional Thin liquid 10ml 16 0.220 0.413 
Thin liquid 30ml 16 0.407 0.117 
Thin liquid 3oz 16 0.016 0.953 
Puree 1 17 0.081 0.757 
Puree 2 16 0.349 0.185 
Solid 17 0.036 0.891 
Overall Thin liquid 10ml 16 0.339 0.200 
Thin liquid 30ml 16 0.333 0.207 
Thin liquid 3oz 16 0.201 0.454 
Puree 1 17 0.170 0.515 
Puree 2 16 0.345 0.191 
Solid 17 0.393 0.119 
Self-reported Severity of Self-reported Thin liquid 10ml 16 0.278 0.296 
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Table 18: Associations of Pharyngeal Residue (after first swallow) with DHI  
DHI Bolus N 
Spearman’s 
Correlation 
Coefficient 
p-
value 
Severity of Dysphagia Thin liquid 30ml 16 0.474 0.063 
Thin liquid 3oz 16 0.126 0.642 
Puree 1 17 0.033 0.900 
 
 
Table 19: Associations for DDK and FVC with DHI (n=17 for all) 
DHI Bolus 
Spearman’s Correlation 
Coefficient p-value 
Physical pʌ/sec -0.124 0.624 
tʌ/sec -0.202 0.422 
kʌ/sec -0.302 0.223 
pʌtʌkʌ/sec -0.059 0.816 
FVC, % 0.035 0.891 
Functional pʌ/sec -0.191 0.447 
tʌ/sec -0.183 0.466 
kʌ/sec -0.304 0.219 
pʌtʌkʌ/sec -0.287 0.247 
FVC, % -0.517 0.028 
Emotional pʌ/sec -0.404 0.096 
tʌ/ /sec -0.408 0.092 
kʌ/sec -0.502 0.034 
pʌtʌkʌ/sec -0.365 0.136 
FVC, % -0.412 0.090 
Overall pʌ/sec -0.272 0.275 
tʌ/sec -0.2685 0.252 
kʌ/sec -0.378 0.122 
75 
 
Table 19: Associations for DDK and FVC with DHI (n=17 for all) 
DHI Bolus 
Spearman’s Correlation 
Coefficient p-value 
pʌtʌkʌ/sec -0.297 0.232 
FVC, % -0.364 0.137 
Self-rating swallowing pʌ/sec -0.238 0.342 
tʌ/sec -0.297 0.231 
kʌ/sec -0.372 0.129 
pʌtʌkʌ/sec -0.306 0.218 
FVC, % -0.465 0.052 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
76 
 
 
Table 20: PAS (Asp/no Asp) of Thin liquid 10mL with DHI, DDK and FVC  
Variable 
No Aspiration 
(N= 11) 
Aspiration 
(N= 5) p-valuea 
DHI    
Physical 7.27 ± 5.08 14.00 ± 5.83 0.116 
Functional 8.18 ± 7.24 18.80 ± 11.01 0.108 
Emotional 4.18 ± 5.40 8.40 ± 6.54 0.153 
Overall 19.64 ± 16.19 41.20 ± 21.57 0.073 
Self-rating of swallowing 2.36 ± 1.80 4.50 ± 1.12 0.061 
Tired rating 3.36 ± 2.06 2.60 ± 1.14 0.426 
DDK and FVC    
pʌ/sec 3.75 ± 1.51 2.64 ± 1.38 0.211 
tʌ/ sec 3.38 ± 1.62 2.33 ± 1.34 0.211 
kʌ/sec 3.22 ± 1.33 1.64 ± 0.61 0.024 
pʌtʌkʌ/sec 1.33 ± 0.47 0.79 ± 0.42 0.058 
FVC, % 80.27 ± 16.79 67.60 ± 17.94 0.231 
aP-values from Wilcoxon two sample tests 
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Table 21: PAS (Asp/no Asp) of Thin liquid 30mL with DHI, DDK and FVC  
Variable 
No Aspiration 
(N= 7) 
Aspiration 
(N= 8) p-valuea 
DHI     
Physical 6.86 ± 4.74 10.50 ± 6.39 0.282 
Functional 5.14 ± 4.30 14.75 ± 9.07 0.049 
Emotional 1.43 ± 2.23 7.75 ± 5.70 0.040 
Overall 13.43 ± 6.60 33.00 ± 20.28 0.076 
Self-rating of swallowing 1.57 ± 0.79 4.06 ± 1.78 0.029 
Tired rating 3.43 ± 2.07 2.88 ± 1.81 0.859 
DDK and FVC    
pʌ/sec 3.83 ± 1.82 3.28 ± 1.15 0.570 
tʌ/sec 3.72 ± 1.84 2.70 ± 1.15 0.341 
kʌ/sec 3.49 ± 1.61 2.28 ± 0.70 0.152 
pʌtʌkʌ/sec 1.35 ± 0.50 1.08 ± 0.47 0.428 
FVC, % 82.57 ± 18.46 73.50 ± 16.13 0.341 
aP-values from Wilcoxon two sample tests 
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Table 22: PAS (Asp/no Asp) of Thin liquid 3oz with DHI, DDK and FVC  
Variable 
No Aspiration 
(N= 7) 
Aspiration 
(N= 7) p-valuea 
DHI    
Physical 6.86 ± 4.74 11.43 ± 6.29 0.177 
Functional 4.57 ± 4.43 16.29 ± 8.44 0.030 
Emotional 1.14 ± 2.23 8.86 ± 5.15 0.016 
Overall 12.57 ± 6.90 36.57 ± 19.00 0.034 
Self-rating of swallowing 1.57 ± 0.79 4.00 ± 1.91 0.043 
Tired rating 3.00 ± 2.24 3.57 ± 1.51 0.405 
DDK and FVC    
pʌ/sec 3.94 ± 1.69 3.37 ± 1.21 0.574 
tʌ/sec 3.87 ± 1.66 2.77 ± 1.20 0.386 
kʌ/sec 3.57 ± 1.52 2.31 ± 0.69 0.181 
pʌtʌkʌ/sec 1.35 ± 0.50 1.18 ± 0.41 0.659 
FVC, % 86.57 ± 17.80 72.71 ± 11.80 0.096 
aP-values from Wilcoxon two sample tests 
 
Table 23: Association of FVC categories with DHI 
Variable Response 
WNL 
(N=9) 
Mild 
(N=4) 
Moderate 
(N=5) 
 
p-valuea 
Physical Mean (SD) 11.33 (7.00) 5.00 (1.15) 11.20 (7.01) 0.257 
Functional Mean (SD) 9.78 (9.82) 5.50 (3.79) 18.40 (9.32) 0.088 
Emotional Mean (SD) 3.11 (4.91) 3.50 (3.00) 9.20 (7.56) 0.245 
Overall Mean (SD) 24.2 (19.40) 14.00 (5.66) 38.80 (23.18) 0.250 
Self-rating for 
swallowing 
Mean (SD) 2.89 (1.96) 1.50 (0.58) 4.50 (1.50) 0.065 
  
Tired rating Mean (SD) 3.00 (1.58) 4.75 (2.87) 2.40 (1.67) 0.338 
a P-value from Kruskal-Wallis test. 
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Table 24: Association of FVC categories with DDK 
Variable Response 
WNL 
(N=9) 
Mild 
(N=4) 
Moderate 
(N=5) 
 
p-
valuea 
pʌ/sec Mean (SD) 3.80 (1.64) 3.70 (1.60) 3.20 (1.63) 0.727 
tʌ/sec Mean (SD) 3.47 (1.66) 3.30 (1.48) 2.76 (1.73) 0.737 
kʌ/sec Mean (SD) 3.09 (1.34) 2.70 (0.60) 2.40 (1.74) 0.486 
pʌtʌkʌ/sec Mean (SD) 1.36 (0.57) 1.42 (0.35) 0.91 (0.57) 0.179 
a P-value from Kruskal-Wallis test.  
Table 25: Association of FVC categories with Number of swallows 
Bolus Response 
WNL 
(N=9) 
Mild 
(N=4) 
Moderate 
(N=5) 
 
p-valuea 
Thin liquid10ml Mean (SD) 5.75 (3.73) 3.00 (1.00) 7.40 (8.26) 0.284 
Thin liquid 30ml Mean (SD) 8.13 (5.84) 4.33 (3.06) 7.25 (4.19) 0.551 
Thin liquid 3oz Mean (SD) 11.78 (5.36) 12.00 (5.29) 10.00 (1.73) 0.971 
Puree 1 Mean (SD) 2.67 (1.00) 3.33 (0.58) 4.60 (3.13) 0.500 
Puree 2 Mean (SD) 2.89 (1.27) 4.00 (2.00) 4.00 (3.46) 0.678 
Solid Mean (SD) 3.44 (1.59) 3.33 (0.58) 5.20 (3.19) 0.528 
      
a P-value from Kruskal-Wallis test. 
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Table 26: Association of FVC categories with PAS 
Variable Response 
WNL 
(N=9) 
Mild 
(N=4) 
Moderate 
(N=5) 
 
p-
valuea
  
Thin 
liquid  
10ml 
Does not enter airway 3 (38%) 1 (33%) 1 (20%)  
0.286 
Enters airway, above VF, ejected from airway 1 (13%) 1 (33%) 0 (0%)  
Enters airway, above VF, not ejected from  
airway 
1 (13%) 1 (33%) 0 (0%)  
Enters airway, contacts VF, ejected from airway 0 (0%) 0 (0%) 1 (20%)  
Enters airway, contacts VF, not ejected from 
airway 
1 (13%) 0 (0%) 0 (0%)  
Enters airway, below VF, no effort made to eject 2 (25%) 0 (0%) 3 (60%)  
  
Thin  
liquid  
30ml 
Does not enter airway 2 (25%) 1 (33%) 0 (0%)  
0.498 
Enters airway, above VF, ejected from airway 1 (13%) 0 (0%) 1 (25%)  
Enters airway, above VF, not ejected from 
airway 
1 (13%) 0 (0%) 0 (0%)  
Enters airway, contacts VF, not ejected from 
airway 
0 (0%) 1 (33%) 0 (0%)  
Enters airway, below VF, not ejected from 
trachea despite effort 
1 (13%) 0 (0%) 0 (0%)  
Enters airway, below VF, no effort made to eject 3 (38%) 1 (33%) 3 (75%)  
  
Thin  
liquid  
3oz 
Does not enter airway 1 (13%) 0 (0%) 0 (0%)  
0.380 
Enters airway, above VF, ejected from airway 2 (25%) 0 (0%) 1 (33%)  
Enters airway, contacts VF, not ejected from 
airway 
2 (25%) 1 (33%) 0 (0%)  
Enters airway, below VF, not ejected from 
trachea despite effort 
1 (13%) 0 (0%) 0 (0%)  
Enters airway, below VF, no effort made to eject 2 (25%) 2 (67%) 2 (67%)  
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Table 26: Association of FVC categories with PAS 
Variable Response 
WNL 
(N=9) 
Mild 
(N=4) 
Moderate 
(N=5) 
 
p-
valuea
Puree 1 Does not enter airway 4 (50%) 1 (33%) 3 (60%)  
0.506 
Enters airway, above VF, ejected from airway 0 (0%) 0 (0%) 1 (20%)  
Enters airway, above VF, not ejected from 
airway 
4 (50%) 0 (0%) 0 (0%)  
Enters airway, contacts VF, not ejected from 
airway 
0 (0%) 2 (67%) 0 (0%)  
Enters airway, below VF, no effort made to eject 0 (0%) 0 (0%) 1 (20%)  
  
Puree 2 Does not enter airway 5 (63%) 0 (0%) 2 (40%)  
0.059 
Enters airway, above VF, not ejected from 
airway 
3 (38%) 1 (33%) 1 (20%)  
Enters airway, contacts VF, not ejected from 
airway 
0 (0%) 0 (0%) 1 (20%)  
Enters airway, below VF, no effort made to eject 0 (0%) 2 (67%) 1 (20%)  
  
Solid Does not enter airway 5 (63%) 0 (0%) 2 (40%)   
0.052 
Enters airway, above VF, ejected from airway 1 (13%) 0 (0%) 1 (20%)  
Enters airway, above VF, not ejected from 
airway 
2 (25%) 0 (0%) 0 (0%)  
Enters airway, contacts VF, not ejected from 
airway 
0 (0%) 3 
(100%) 
1 (20%)  
Enters airway, below VF, no effort made to eject 0 (0%) 0 (0%) 1 (20%)  
 
 
    
a P-value from Kruskal-Wallis test. 
 
82 
 
 
Table 27: Association of FVC categories with Pharyngeal Residue 
Variable Response 
WNL 
(N=9) 
Mild 
(N=4) 
Moderate 
(N=5) 
 
p-valuea 
  
Thin liquid10ml Coating 3 (38%) 1 (33%) 1 (20%) 0.811 
 Mild 5 (63%) 2 (67%) 4 (80%)  
  
Thin liquid 30ml Coating 3 (38%) 2 (67%) 1 (25%) 0.549 
 Mild 5 (63%) 1 (33%) 3 (75%)  
  
Thin liquid 30oz Coating 6 (67%) 2 (7%) 0 (0%) 0.135 
 Mild 3 (33%) 1 (33%) 3 (100%)  
  
Puree 1 Coating 1 (11%) 1 (33%) 1 (20%) 0.540 
 Mild 7 (78%) 2 (67%) 4 (80%)  
 Moderate 1 (11%) 0 (0%) 0 (0%)  
  
Puree 2 Coating 1 (11%) 1 (33%) 1 (20%) 0.641 
 Mild 7 (78%) 2 (67%) 3 (60%)  
 Moderate 1 (11%) 0 (0%) 1 (20%)  
  
Solid None 1 (11%) 0 (0%) 0 (0%) 0.735 
 Coating 2 (22%) 1 (33%) 1 (20%)  
 Mild 5 (56%) 2 (67%) 3 (60%)  
 Moderate 1 (11%) 0 (0%) 1 (20%)  
      
a P-value from Kruskal-Wallis test. 
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Table 28: Association of type of onset with DHI  
Variable Response 
bulbar 
(N=6) 
axial 
(N=9) 
Mixed 
(N=3) 
p-valuea 
  
Physical Mean (SD) 16.33 (6.38) 6.22 (3.67) 8.00 (3.46) 0.030
  
Functional Mean (SD) 18.67 (9.85) 7.33 (7.75) 8.00 (7.21) 0.095
  
Emotional Mean (SD) 8.00 (7.38) 2.67 (3.32) 5.33 (7.57) 0.298
  
Overall Mean (SD) 43.00 (20.50) 16.22 (12.55) 21.33 (18.15) 0.054
  
Self-rating 
swallowing 
Mean (SD) 4.92 (1.11) 2.00 (1.22) 2.33 (2.31) 0.011
  
Tired Rating Mean (SD) 2.50 (1.52) 3.67 (2.35) 3.33 (2.08) 0.597
aP-values from Kruskal-Wallis test. 
 
 
 Table 29: Association of type of onset with PAS  
Bolus Response 
bulbar 
(N=6) 
axial 
(N=9) 
Mixed 
(N=3) 
p-valuea 
  
Thin 
liquid 
10 mL 
Does no enter airway 1 (20%) 1 (13%) 3 (100%) 0.032
Above VF, ejected 0 (0%) 2 (25%) 0 (0%) 
Above VF, not ejected 0 (0%) 2 (25%) 0 (0%) 
Contacts VF, ejected 0 (0%) 1 (13%) 0 (0%) 
Contacts VF, not ejected 0 (0%) 1 (13%) 0 (0%) 
Below VF, no effort 4 (80%) 1 (13%) 0 (0%) 
  
Thin 
liquid 
30mL 
Does no enter airway 1 (25%) 1 (13%) 1 (33%) 0.885
Above VF, ejected 0 (0%) 2 (25%) 0 (0%) 
Above VF, not ejected 0 (0%) 1 (13%) 0 (0%) 
Contacts VF, not ejected 0 (0%) 1 (13%) 0 (0%) 
Below VF, not ejected with effort 1 (25%) 0 (0%) 0 (0%) 
Below VF, no effort 2 (50%) 3 (38%) 2 (67%) 
  
Thin Does no enter airway 0 (0%) 1 (13%) 0 (0%) 0.408
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 Table 29: Association of type of onset with PAS  
Bolus Response 
bulbar 
(N=6) 
axial 
(N=9) 
Mixed 
(N=3) 
p-valuea 
liquid 
3 oz 
Above VF, ejected 0 (0%) 3 (38%) 0 (0%) 
Contacts VF, not ejected 1 (33%) 1 (13%) 1 (33%) 
Below VF, not ejected with effort 1 (33%) 0 (0%) 0 (0%) 
Below VF, no effort 1 (33%) 3 (38%) 2 (67%) 
  
Puree 
5mL 
#1 
Does no enter airway 4 (80%) 2 (25%) 2 (67%) 0.468
Above VF, ejected 0 (0%) 1 (13%) 0 (0%) 
Above VF, not ejected 0 (0%) 4 (50%) 0 (0%) 
Contacts VF, not ejected 0 (0%) 1 (13%) 1 (33%) 
Below VF, no effort 1 (20%) 0 (0%) 0 (0%) 
  
Puree 
5mL 
#2 
Does no enter airway 3 (60%) 3 (38%) 1 (33%) 0.602
Above VF, not ejected 1 (20%) 4 (50%) 0 (0%) 
Contacts VF, not ejected 0 (0%) 0 (0%) 1 (33%) 
Below VF, no effort 1 (20%) 1 (13%) 1 (33%) 
  
Solid  Does no enter airway 3 (60%) 2 (25%) 2 (67%) 0.808
 Above VF, ejected 0 (0%) 2 (25%) 0 (0%) 
 Above VF, not ejected 0 (0%) 2 (25%) 0 (0%) 
 Contacts VF, not ejected 1 (20%) 2 (25%) 1 (33%) 
 Below VF, no effort 1 (20%) 0 (0%) 0 (0%) 
aP-values from Kruskal-Wallis test. 
 
85 
 
 
Table 30: Association of type of onset with Pharyngeal Residue  
Bolus Response 
bulbar 
(N=6) 
axial 
(N=9) 
mixed 
(N=3) 
p-valuea 
  
Thin liquid 10 mL Coating 0 (0%) 3 (38%) 2 (67%) 0.141
 Mild 5 (100%) 5 (63%) 1 (33%) 
  
Thin liquid 30 mL Coating 0 (0%) 3 (38%) 3 (100%) 0.034
 Mild 4 (100%) 5 (63%) 0 (0%) 
  
Thin liquid 3 oz Coating 1 (25%) 5 (63%) 2 (67%) 0.436
 Mild 3 (75%) 3 (38%) 1 (33%) 
  
Puree 5mL #1 Coating 1 (17%) 1 (13%) 1 (33%) 0.639
 Mild 4 (67%) 7 (88%) 2 (67%) 
 Moderate 1 (17%) 0 (0%) 0 (0%) 
  
Puree 5mL #2 Coating 0 (0%) 2 (25%) 1 (33%) 0.100
 Mild 4 (67%) 6 (75%) 2 (67%) 
 Moderate 2 (33%) 0 (0%) 0 (0%) 
  
Solid  None 0 (0%) 1 (13%) 0 (0%) 0.661
 Coating 1 (17%) 2 (25%) 1 (33%) 
 Mild 4 (67%) 4 (50%) 2 (67%) 
 Moderate 1 (17%) 1 (13%) 0 (0%) 
aP-values from Kruskal-Wallis test. 
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Table 31: Association of type of onset with DDK and FVC 
Variable Response 
bulbar 
(N=6) 
axial 
(N=9) 
mixed 
(N=3) 
p-valuea 
  
pʌ/sec Mean (SD) 2.80 (1.34) 4.38 (1.50) 2.93 (1.33) 0.125
  
tʌ/sec Mean (SD) 2.44 (1.22) 4.07 (1.61) 2.33 (0.90) 0.086
  
kʌ/sec Mean (SD) 2.07 (1.13) 3.44 (1.35) 2.40 (0.60) 0.085
  
pʌtʌkʌ/sec Mean (SD) 0.97 (0.62) 1.43 (0.50) 1.27 (0.46) 0.195
  
FVC Mean (SD) 69.83 (16.92) 81.11 (16.20) 74.33 (19.30) 0.399
aP-values from Kruskal-Wallis test. 
 
 
Table 32: Associations for Duration of symptoms  
(all participants) with PAS  
Bolus N 
Spearman’s Correlation 
Coefficient p-value 
Thin liquid 10ml 16 0.000 1.000 
Thin liquid 30ml 15 -0.011 0.968 
Thin liquid 3oz 14 0.284 0.325 
Puree #1 16 0.374 0.153 
Puree #2 16 0.517 0.040 
Solid 16 0.246 0.357 
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Table 33: Associations for Duration of symptoms (all participants)  
with number of swallows 
Bolus N 
Spearman’s Correlation 
Coefficient p-value 
Thin liquid 10ml 16 -0.112 0.679 
Thin liquid 30ml 15 -0.115 0.683 
Thin liquid 3oz 15 0.654 0.008 
Puree #1 17 0.560 0.019 
Puree #2 17 0.482 0.050 
Solid 17 0.066 0.802 
 
Table 34 Associations for Duration of symptoms (all participants) 
with DDK and FVC          
N=18 
DDK 
Spearman’s Correlation 
Coefficient p-value 
pʌ/sec -0.184 0.464 
tʌ/sec -0.109 0.668 
kʌ/sec -0.137 0.587 
pʌtʌkʌ/sec -0.110 0.664 
FVC -0.382 0.117 
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Table 35: Associations for Duration of symptoms  
(all participants)  with DHI 
N=18 
DHI 
Spearman’s Correlation 
Coefficient p-value 
Physical 0.184 0.466 
Functional 0.387 0.113 
Emotional 0.249 0.319 
Overall 0.296 0.233 
Self-rating swallowing 0.227 0.365 
 
Table 36: Associations for Duration of symptoms (all participants)  
with Pharyngeal Residue 
Bolus N 
Spearman’s Correlation 
Coefficient p-value 
Thin liquid 10ml 16 0.190 0.481 
Thin liquid 30ml 15 0.189 0.500 
Thin liquid 3oz 15 0.186 0.508 
Puree #1 17 -0.377 0.136 
Puree #2 17 -0.067 0.798 
Solid 17 -0.042 0.874 
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Table 37: Associations for Duration of symptoms (onset within 4 yrs) 
 with number of swallows 
Bolus N 
Spearman’s Correlation 
Coefficient 
 p-value 
Thin liquid 10ml 15 0.049 0.862 
Thin liquid 30ml 14 0.091 0.757 
Thin liquid 3oz 14 0.577 0.031 
Puree #1 16 0.515 0.041 
Puree #2 16 0.383 0.144 
Solid 16 0.060 0.827 
 
Table 38: Associations for Duration of symptoms (onset within 4 yrs) 
with DDK and FVC 
N=17 
DDK 
Spearman’s Correlation 
Coefficient  p-value 
pʌ/sec -0.058 0.826 
tʌ/sec 0.012 0.963 
kʌ/sec -0.079 0.763 
pʌtʌkʌ/sec -0.090 0.731 
FVC -0.369 0.145 
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Table 39: Associations for Duration of symptoms  
(onset within 4 yrs) with DHI 
N=17 
DHI 
Spearman’s Correlation 
Coefficient  p-value 
Physical 0.245 0.344 
Functional 0.477 0.053 
Emotional 0.283 0.271 
Overall 0.381 0.131 
Self-rating swallowing 0.382 0.130 
 
Table 40: Associations for Duration of symptoms (onset within 4 yrs) 
with Pharyngeal Residue 
Bolus N 
Spearman’s Correlation 
Coefficient  p-value 
Thin liquid 10ml 15 0.419 0.120 
Thin liquid 30ml 14 0.388 0.170 
Thin liquid 3oz 14 0.337 0.239 
Puree #1 16 -0.231 0.389 
Puree #2 16 0.136 0.617 
Solid 16 0.093 0.731 
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Table 42: Associations for Total ALS FRSR with number of swallows 
Bolus N 
Spearman’s Correlation 
Coefficient  p-value 
Thin liquid 10ml 16 0.569 0.021 
Thin liquid 30ml 15 0.330 0.230 
Thin liquid 3oz 15 0.308 0.263 
Puree #1 17 0.067 0.798 
Puree #2 17 0.396 0.115 
Solid 17 0.574 0.016 
 
Table 43: Associations for Total ALS FRSR with DDK and FVC 
N=18 
DDK 
Spearman’s Correlation 
Coefficient  p-value 
Pʌ/sec 0.087 0.731 
tʌ/sec 0.138 0.586 
kʌ/sec -0.022 0.931 
pʌtʌkʌ/sec -0.096 0.704 
FVC -0.099 0.696 
Table 41: Associations for Duration of symptoms  
(onset within 4 yrs) with PAS 
Bolus N 
Spearman’s Correlation 
Coefficient  p-value 
Thin liquid 10ml 15 0.156 0.578 
Thin liquid 30ml 14 0.188 0.519 
Thin liquid 3oz 13 0.183 0.550 
Puree #1 15 0.251 0.368 
Puree #2 15 0.421 0.118 
Solid 15 0.136 0.628 
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Table 44: Associations for Total ALS FRSR with DHI 
N=18 
DHI 
Spearman’s Correlation 
Coefficient  p-value 
Physical 0.366 0.135 
Functional 0.371 0.129 
Emotional -0.031 0.903 
Overall 0.314 0.204 
Self-rating swallowing 0.301 0.225 
 
Table 45: Associations for Total ALS FRSR with PAS 
Bolus N 
Spearman’s Correlation 
Coefficient  p-value 
Thin liquid 10ml 16 0.427 0.099 
Thin liquid 30ml 15 -0.184 0.512 
Thin liquid 3oz 14 -0.119 0.685 
Puree #1 16 0.009 0.974 
Puree #2 16 -0.430 0.097 
Solid 16 0.126 0.642 
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Table 46: Associations for Total ALS FRSR with Pharyngeal Residue 
Bolus N 
Spearman’s Correlation 
Coefficient  p-value 
Thin liquid 10ml 16 0.337 0.202 
Thin liquid 30ml 15 0.331 0.228 
Thin liquid 3oz 15 0.232 0.405 
Puree #1 17 0.479 0.052 
Puree #2 17 0.031 0.907 
Solid 17 -0.143 0.584 
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Table 47: Association of BMI with Pharyngeal Residue 
Variable Response 
Normal 
(N=9) 
Overweight/ 
Obese 
(N=9) 
 
p-valuea 
  
Thin liquid10ml Coating 3 (38%) 2 (25%) 0.654 
 Mild 5 (63%) 6 (75%)  
  
Thin liquid 30ml Coating 5 (71%) 1 (13%) 0.047 
 Mild 2 (29%) 7 (88%)  
  
Thin liquid 30oz Coating 5 (63%) 3 (43%) 0.514 
 Mild 3 (38%) 4 (57%)  
  
Puree 1 Coating 2 (22%) 1 (13%) 0.411 
 Mild 7 (78%) 6 (75%)  
 Moderate 0 (0%) 1 (13%)  
  
Puree 2 Coating 2 (22%) 1 (13%) 0.723 
 Mild 6 (67%) 6 (75%)  
 Moderate 1 (11%) 1 (13%)  
  
Solid None 1 (11%) 0 (0%) 0.708 
 Coating 2 (22%) 2 (25%)  
 Mild 5 (56%) 5 (63%)  
 Moderate 1 (11%) 1 (13%)  
     
aP-value from Wilcoxon two sample test. 
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Table 48: BMI and  DDK and FVC 
Variable Response 
Normal 
(N=9) 
Overweight/ 
Obese 
(N=9) 
 
p-valuea 
  
pʌ/sec Mean (SD) 3.58 (1.71) 3.64 (1.49) 0.827 
  
Tʌ/sec Mean (SD) 3.13 (1.77) 3.34 (1.45) 0.827 
  
kʌ/sec Mean (SD) 2.84 (1.42) 2.78 (1.27) 0.930 
  
pʌtʌkʌ/sec Mean (SD) 1.32 (0.61) 1.18 (0.51) 0.487 
  
FVC, % Mean (SD) 76.22 (12.88) 76.22 (20.67) 0.965 
     
aP-value from Wilcoxon two sample test. 
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Table 49: Association of BMI with DHI 
Variable Response 
Normal 
(N=9) 
Overweight/ 
Obese 
(N=9) 
 
p-valuea 
  
Physical Mean (SD) 11.56 (7.40) 8.22 (5.33) 0.382 
  
Functional Mean (SD) 15.56 (9.15) 6.89 (8.37) 0.073 
  
Emotional Mean (SD) 7.11 (6.25) 2.67 (4.69) 0.109 
  
Overall Mean (SD) 34.22 (20.48) 17.78 (16.23) 0.102 
  
Self-rating for 
swallowing 
Mean (SD) 3.67 (1.87) 2.39 (1.80) 0.207 
  
Tired rating Mean (SD) 4.11 (1.62) 2.33 (2.06) 0.056 
     
aP-value from Wilcoxon two sample test. 
 
 
Table 50: Association of BMI with PAS 
Variable Response 
Normal 
(N=9) 
Overweight/ 
Obese 
(N=9) 
 
p-
valuea 
 
   
Thin liquid 
10ml 
Does not enter airway 3 
(38%) 
2 (25%) 0.632  
 Enters airway, above VF, ejected from airway 1 
(13%) 
1 (13%)   
 Enters airway, above VF, not ejected from 
airway 
1 
(13%) 
1 (13%)   
 Enters airway, contacts VF, ejected from airway 0 (0%) 1 (13%)   
 Enters airway, contacts VF, not ejected from 
airway 
1 
(13%) 
0 (0%)   
 Enters airway, below VF, no effort made to eject 2 
(25%) 
3 (38%)   
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Table 50: Association of BMI with PAS 
Variable Response 
Normal 
(N=9) 
Overweight/ 
Obese 
(N=9) 
 
p-
valuea 
 
   
Thin liquid 
30ml 
Does not enter airway 1 
(14%) 
2 (25%) 0.763  
 Enters airway, above VF, ejected from airway 0 (0%) 2 (25%)   
 Enters airway, above VF, not ejected from 
airway 
1 
(14%) 
0 (0%)   
 Enters airway, contacts VF, not ejected from 
airway 
1 
(14%) 
0 (0%)   
 Enters airway, below VF, not ejected from 
trachea despite effort 
1 
(14%) 
0 (0%)   
 Enters airway, below VF, no effort made to eject 3 
(43%) 
4 (50%)   
   
Thin liquid 
3oz 
Does not enter airway 0 (0%) 1 (14%) 0.202  
 Enters airway, above VF, ejected from airway 1 
(14%) 
2 (29%)   
 Enters airway, contacts VF, not ejected from 
airway 
1 
(14%) 
2 (29%)   
 Enters airway, below VF, not ejected from 
trachea despite effort 
1 
(14%) 
0 (0%)   
 Enters airway, below VF, no effort made to eject 4 
(57%) 
2 (29%)   
   
Puree 1 Does not enter airway 4 
(50%) 
4 (50%) 0.738  
 Enters airway, above VF, ejected from airway 0 (0%) 1 (13%)   
 Enters airway, above VF, not ejected from 
airway 
2 
(25%) 
2 (25%)   
 Enters airway, contacts VF, not ejected from 
airway 
1 
(13%) 
1 (13%)   
 Enters airway, below VF, no effort made to eject 1 
(13%) 
0 (0%)   
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Table 50: Association of BMI with PAS 
Variable Response 
Normal 
(N=9) 
Overweight/ 
Obese 
(N=9) 
 
p-
valuea 
 
Puree 2 Does not enter airway 3 
(38%) 
4 (50%) 0.478  
 Enters airway, above VF, not ejected from 
airway 
2 
(25%) 
3 (38%)   
 Enters airway, contacts VF, not ejected from 
airway 
1 
(13%) 
0 (0%)   
 Enters airway, below VF, no effort made to eject 2 
(25%) 
1 (13%)   
   
Solid Does not enter airway 3 
(38%) 
4 (50%) 0.551  
 Enters airway, above VF, ejected from airway 1 
(13%) 
1 (13%)   
 Enters airway, above VF, not ejected from 
airway 
1 
(13%) 
1 (13%)   
 Enters airway, contacts VF, not ejected from 
airway 
2 
(25%) 
2 (25%)   
 Enters airway, below VF, no effort made to eject 1 
(13%) 
0 (0%)   
aP-value from Wilcoxon two sample test.  
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Table 51: Association of BMI with Number of swallows 
Variable Response 
Normal 
(N=9) 
Overweight/ 
Obese 
(N=9) 
 
p-valuea 
  
Thin liquid10ml Mean (SD) 7.13 (7.14) 4.38 (1.77) 0.874 
  
Thin liquid 30ml Mean (SD) 6.86 (6.96) 7.38 (2.67) 0.220 
  
Thin liquid 3oz Mean (SD) 12.25 (5.92) 10.57 (2.70) 0.953 
  
Puree 1 Mean (SD) 3.44 (1.94) 3.25 (2.05) 0.557 
  
Puree 2 Mean (SD) 3.78 (2.86) 3.00 (0.93) >0.99 
  
Solid Mean (SD) 3.78 (2.39) 4.13 (1.96) 0.773 
     
aP-value from Wilcoxon two sample test. 
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CHAPTER 5 
DISCUSSION 
The primary objective of this study was to determine if there was a correlation 
between speech, respiratory and swallowing functions in individuals with ALS with bulbar 
involvement. This study examined three research questions.  In the investigation of the first 
research question, do individuals diagnosed with ALS with bulbar involvement perform 
significantly different on clinical measures (DDK, FVC, DHI, and tired level) and on 
objective swallowing measures (PAS, pharyngeal residue and number of swallows per bolus) 
when compared to a control group?   Between-group differences were evaluated for ALS and 
control groups, performance on measures of speech, swallowing and respiratory function were 
compared between individuals with ALS with bulbar impairment and a control group of 
similar age.  In this study, significant differences were found in the performance between the 
ALS group and the control group on all clinical measures for speech production, respiratory 
function and patient reported outcomes for swallowing function.  ALS group performance 
was consistent with decline in muscle strength and degeneration of motor neurons resulting in 
impairments of FVC and a 40% reduction in rate of DDK production (p = 0.001) for all 
targets, compared to the control group.  Reduced rate of DDK production is strongly 
suggestive of articulatory impairment, specifically reduced rate of lingual movement.  
Diadochokinetic tasks are frequently utilized for identification of early speech changes in 
neurogenic diseases (Enderby, 1983; Gadesmann & Miller, 2008; Kent et al., 1987; Nishio & 
Niimi, 2006).  The results from the control group are consistent with previous normative 
DDK literature.(Nishio & Niimi, 2006; Portnoy & Aronson, 1982; Ptacek, Sander, Maloney, 
& Jackson, 1966; Wang et al., 2004)  As expected, the ALS group showed significant 
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impairments in FVC and speech productions, compared to the control group.  This finding is 
consistent with previous research by Lechtzin et al. (2002).    They found that forced vital 
capacity is likely to decline by 3.5% per month as a result of ALS.  
In the investigation of the second research question, are there significant correlations 
between clinical measures and objective swallowing measures which would support the 
theory that swallowing function could be predicted in individuals with ALS? This study 
examined the correlations between clinical measures and objective swallowing measures.  
One of the focuses of this study was to investigate if the hypothesis that swallowing function 
can be predicted in individuals with ALS by clinical measures, such as DDK, FVC, DHI and 
tired level would be supported.  In motor speech research, DDK is a common method to 
assess articulatory precision and agility (Nishio & Niimi, 2006; Portnoy & Aronson, 1982).  It 
is commonly accepted that alterations in speech production in ALS are associated with 
decreased range, rate and strength of the tongue and oral pharyngeal musculature (Mulligan et 
al., 1994) and that decreased lingual coordination and impaired base of tongue movement 
increases the risk of pharyngeal residue and aspiration (Kawai et al., 2003).  This study 
investigated the ability of DDK tasks to assess lingual movements that may predict 
swallowing impairments in ALS subjects.  The results of this study supported the hypothesis 
that testing /kʌ/ is important because of the finding of a negative correlation between reduced 
/kʌ/ productions per second and severity of dysphagia.  Individuals with ALS who aspirated 
10mL liquid boluses produced, on average, half the number of /kʌ/ repetitions per second as 
the ALS non-aspiration subjects.  This may indicate that highly timed movements are more 
important in the management of small bolus volumes.  The idea of the importance of highly 
coordinated movements for safe swallowing of small volumes is further supported by the 
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significant negative correlation between /pʌtʌkʌ/ productions per second and pharyngeal 
residue and aspiration ratings in the ALS group. Rate of /kʌ/ productions per second was also 
negatively correlated with severity of residue with the second puree and solid bolus trials 
within the ALS group.  Base of tongue movements for formation of velar sounds such as /kʌ/ 
during speech production as well as bolus propulsion through the pharynx during swallowing, 
require similar posterior lingual movements.  The negative correlation between pharyngeal 
residue with rate of /kʌ/ productions supports the hypothesis that impairment in production of 
velar sounds can indicate impairments in base of tongue movements affecting swallowing 
function. Anterior lingual movements are important in bolus manipulation and initiation of 
transport to the posterior oral cavity; however, posterior lingual movement, responsible for 
production of /kʌ/, is important for bolus holding and propulsion through the pharynx.  
Impairment in base of tongue movement is more likely to result in aspiration and pharyngeal 
residue (Kawai et al., 2003; Takahiro Ono, 2007).   
ALS subjects with more impaired respiratory function demonstrated increased risk of 
aspiration with large, 3 ounce, liquid trials. Increased PAS scores for a larger bolus may be a 
result of dis-coordination of the swallow apnea period.  The onset of swallow apnea occurs 
earlier in the oral phase with larger boluses (Hiss et al., 2004). This earlier onset of swallow 
apnea may place increased stress on the respiratory system due to lack of respiratory reserve 
resulting in early opening of the larynx after swallowing or alteration of the exhale-swallow-
exhale typical motor pattern (Gross et al., 2003).  The FVC assessment is part of the gold 
standard assessment for determining progression of ALS.  It is often necessary to anticipate 
feeding tube placement for supplemental and eventually total nutrition, as FVC approaches 
50% predicted function (Miller, 1999).  For this reason, ALS patients with an FVC below 
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50% were excluded from this study.   This study showed that the ALS group declined in both 
speech rate production and respiratory function which is consistent with previous research. 
This study also showed that the significant correlation between DDK with risk of aspiration 
and pharyngeal residue is supportive of the hypothesis to predict swallowing impairments 
through DDK and FVC assessment in individuals with ALS.  
Compared to the control group, the ALS group exhibited impairments in swallowing 
function characterized by greater pharyngeal residue with food versus liquids and increased 
aspiration risk with all bolus trials, except the 10mL liquid trial.  The thin liquid 10mL bolus 
trial is representative of a small sip.  An average liquid bolus size taken by an adult over the 
age of 55 is 11 to 17mL for a female and 20 to 23mL for a male (Ertekin, 2000; Hughes & 
Wiles, 1996).  Multiple investigations have documented the decline in bolus size as a function 
of decline in swallowing ability (Ertekin, 2000; Kawai et al., 2003).  This may explain why 
there was not a significant difference in PAS for the 10mL liquid trial.  PAS scores were 
greater for larger thin liquid bolus trials, 30mL and 3 ounces, and for puree and solid boluses 
in the ALS group as a result of this group’s inability to manage larger volumes of liquid and 
food.  In this study, a higher rate of aspiration occurred during the second puree bolus 
compared to the first puree bolus, 19% and 6% respectively, in the ALS group.  Additionally, 
the ALS group demonstrated significant correlations in pharyngeal residue only for the 
second puree bolus compared to DDK and the DHI.   It is also possible that fatigue played a 
role in the significant finding of increased pharyngeal residue and aspiration with larger liquid 
boluses and during the second puree bolus in comparison to the first puree bolus.  ALS 
subjects swallowed between 15 and 50 times during the four boluses preceding the second 
puree bolus.  In comparison, subjects in the control group swallowed on average between 10-
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25 times during the initial four boluses.  The need for frequent and repetitive swallows to 
manage boluses could be fatiguing which would explain the correlation with the final two 
bolus trials in this study.  In addition, texture and order of presentation may have also 
contributed to increased residue on these two trials.  All liquid trials were completed at the 
beginning of the study so subjects were provided with three food boluses sequentially.  
 The severity of swallowing impairment demonstrated by increased ratings on the PAS 
and pharyngeal residue tool likely affected the ratings on the DHI for the ALS group.  ALS 
subjects reported higher scores for all categories of the DHI and severity of dysphagia 
potentially indicating awareness of decline in swallowing function compared to the control 
group.   The concept of awareness of swallowing difficulty in the ALS group was supported 
by a significant difference on all sections of the DHI (Physical, Functional, Emotional, 
Overall and Self-reported Severity of Dysphagia).  These significant differences in DHI 
scores indicate that the participants in the ALS group are aware of their swallowing 
impairments and that these impairments affect their quality life.  For example, reported 
physical impairments included symptoms such as coughing when eating or drinking.  
Emotional stressors included concerns of anxiety, depression and fear of eating in public.  
Functional modifications of oral intake were also reported, including small bites and sips, 
modification of diet, and smaller meal portions.   
The significant group differences between ALS, as compared to the control group, 
vividly describe the challenges associated with progressive dysphagia.  Physical deterioration 
in swallowing function is associated with declining oral pharyngeal muscle strength and 
fatigue which consequently results in increased risk for laryngeal penetration and aspiration as 
well as increased pharyngeal residue.  These physical impairments are likely to cause 
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necessary functional modifications to oral intake in the form of eliminating challenging foods, 
smaller bolus size and smaller portions.  Meal times may be prolonged as a result of fatigue 
and reduced respiratory support affecting rate of oral intake due to the need for additional 
time to recover from obligatory periods of swallowing apnea.  The emotional stress and 
anxiety due to concerns of swallowing difficulty could alter the perception of eating from an 
enjoyable, social experience to an activity completed in isolation.   
Awareness of decline in swallowing function and implementation of compensatory 
strategies may contribute to significant differences in the number of swallows per bolus for 
larger, 30mL and 3 ounce, thin liquid volumes in the ALS group as compared to the control 
group.  It is possible that the ALS subjects intentionally partitioned larger bolus amounts into 
several swallows of smaller volumes to compensate for lingual weakness and decreased bolus 
control in an attempt to avoid an aspiration event.  The theory of the ALS subjects utilizing 
multiple swallows as a compensatory strategy is further supported by the absence of 
significant differences of pharyngeal residue after the final swallow of liquid boluses.  Even 
though the ALS group demonstrated significantly increased pharyngeal residue with food 
boluses, there was not a significant difference in the number of swallows compared to the 
control group.  These findings may suggest that an intact motor response to sensory feedback 
could initially lead to a greater number of swallows to reduce bolus retention.  However, as 
muscle fatigue progresses during a meal, motor responses may be too impaired to generate a 
swallow despite appropriate sensation, or there may be reduced sensory function which results 
in fewer swallows.  Alternately, it is entirely possible that there may be an increased demand 
in motor movement and sensory-motor coordination in order to prevent aspiration events with 
thin liquids, more so than to reduce pharyngeal residue with solid foods.  This hypothesis 
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requires further study.  Piecemeal deglutition is common in the swallowing impaired 
population (Ertekin, 2000; Hiss et al., 2004; Kawai et al., 2003).  Within the ALS group, high 
correlations between DHI scores with higher PAS ratings for large thin liquid volumes and 
greater pharyngeal residue scores with puree and solid boluses support the hypothesis that the 
DHI may be beneficial in predicting swallowing decline in individuals with ALS.  
Surprisingly, number of swallows was not significantly correlated with DDK production, 
pharyngeal residue or FVC performance. It was expected that the /kʌ/ production of DDK 
would be associated with number of swallows.  DHI scores for emotion were highly 
correlated with DDK /kʌ/ production indicating that the swallowing problems associated with 
base of tongue impairments result in feeling of anger, depression, stress and lack of 
enjoyment of eating.  FVC performance was correlated with the DHI functional scale ratings 
likely indicating that ALS subjects with respiratory impairments implement compensatory 
strategies to alter foods or methods of intake in order to accommodate for longer periods of 
apnea. 
When examining PAS ratings for the ALS group, a large percentage demonstrated 
silent aspiration across bolus consistencies in this study.  In the ALS group, 30% of all bolus 
trials were aspirated.  Of the total number of aspiration events, only 8% were followed by an 
attempt to protect the airway (cough or throat clear).  Silent aspiration occurred in 31%, 47% 
and 43% of thin liquid boluses of 10mL, 30mL and 3 ounces respectively.  The frequency of 
silent aspiration was greatest with liquids, but also occurred in puree #2 trials.  This finding is 
concerning because by definition, ALS is strictly a motor disease without sensory 
deterioration.   If laryngeal and tracheal sensations are not impaired as a result of ALS, an 
alternative possibility is that the laryngeal and tracheal sensory receptors no longer perceive 
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the bolus material as foreign due to a history of prolonged duration of aspiration events.   In 
previous ALS research, silent aspiration rates are generally between 0% (Chen et al., 1992; 
Leder, Novella, & Patwa, 2004; Ruoppolo et al., 2013) and 15% (Briani et al., 1998).  In the 
study by Leder, Novella and Patwa (2004), aspiration was documented in 17% of subjects.  In 
a study by Ruoppolo et al. (2013), no aspiration occurred during the assessment of 
swallowing function, despite a diagnosis of impaired cough reflex during laryngeal sensitivity 
testing in 20% of the ALS subjects tested.  It is noteworthy that the current study used larger 
bolus volumes (30mL and 3 ounces) whereas previous research evaluated swallowing 
function with 3-20mL bolus trials of thin liquid, nectar thick liquid and puree consistencies 
(Briani et al., 1998; Leder et al., 2004; Ruoppolo et al., 2013).  It is possible that aspiration, 
especially silent aspiration, has been under diagnosed in ALS as a result of assessments with 
limited bolus size.   
Laryngeal penetration with vocal fold contact or aspiration occurred within a few 
subjects in the control group.  In the control group, laryngeal penetration contacting the vocal 
folds, without aspiration occurred during the smaller thin liquid bolus trials of 10mL and 
30mL.  During the 3 ounce thin liquid trial, 20% of the control group aspirated followed by an 
immediate attempt to clear the material from the trachea with a cough.  Control subjects who 
aspirated were 59, 65 and 84 years of age and female.  The findings of this study were 
consistent with previous research from Daggett (2007) and Butler et al. (2009).  Natural 
changes in swallowing function of the healthy aging population resulted in occasional 
episodes of laryngeal penetration and aspiration (Butler, 2009; Daggett, 2007; Todd, 2013).  
Decline in swallowing function in healthy adults has been attributed to prolonged oral 
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pharyngeal phase duration and a delay in bolus transit and delayed airway protection 
(Daggett, 2007) 
The third research question examined the correlations between patient history and the 
development of the disease, individual and disease course information including symptom 
onset, duration of symptoms, BMI and ALS-FRSR scores.  All of these analyses showed 
significant correlations with clinical assessments and objective swallowing ratings.   Subjects 
with bulbar onset were found to have the greatest impairment in swallowing function with 
80% of participants with bulbar onset silently aspirating the 10mL liquid bolus and 
demonstrated pharyngeal residue of thin liquid 30mL boluses.  Swallowing function was 
distributed across the 8 levels of the PAS rating for axial and mixed type of onset.  This data 
supports the findings that individuals with bulbar onset ALS have a more significant decline 
in swallowing function than non-bulbar onset individuals (Ruoppolo et al., 2013).   
The duration of ALS symptoms was significantly positively correlated to the number 
of swallows for the liquid 3 ounce and first puree bolus trial as well as aspiration risk (PAS)  
for the second puree bolus.  These correlations are likely due to changes in timing of muscle 
movements to contain and propel bolus material safely and efficiently through the pharynx.  
Onset type was also significantly correlated to DHI ratings for the physical category and the 
Self-Reported Severity of Dysphagia.  Bulbar onset ALS individuals appear to experience 
more symptoms of dysphagia including coughing, choking, and weight loss than non-bulbar 
patients with ALS.  The finding of swallowing decline as a result of bulbar onset and 
prolonged duration of symptoms is consistent with deterioration of the corticobulbar tract.  
Subsequently, the decline in the corticobulbar tract certainly affects the functions of cranial 
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nerves essential for appropriate swallowing movements such as the trigeminal, facial, 
glossopharyngeal, vagus and hypoglossal nerves.  
Findings associated with BMI and ALS-FRSR was limited.  Body mass index was not 
significantly associated with any other measure or bolus trial with the exception of pharyngeal 
residue with a thin liquid 30mL bolus. It was expected that low BMI would be positively  
correlated with decline in swallowing function due to the known association between 
decreased BMI and reduced caloric intake (Clavelou, Blanquet, Peyrol, Ouchchane, & 
Gerbaud, 2013).  However, ALS-FRSR scores were significantly positively correlated with 
the number of swallows required for thin liquid 10mL and solid boluses only.  This positive 
correlation suggests that ALS subjects with more severe swallowing impairments will 
swallow fewer times per bolus.   This finding may also support the theory that muscle fatigue 
will override sensory feedback which dictates the frequency of swallows per bolus.  This 
study integrated the number of swallows per bolus measure to assess effort required for bolus 
propulsion.  This measure also appears to be an indicator of fatigue.   
In this study, the ALS-FRSR scores were not significantly correlated with PAS or 
pharyngeal residue scales.  This finding directly contradicts previous research by Ruoppolo 
(2013), which found that the risk for dysphagia increased by 9% for every point variation 
from normal function on the ALS-FRS scale. Inconsistencies in findings between the two 
studies may be a result of a different version of the ALS-FRS used.  In the current study the 
ALS-FRSR was used compared to the ALS-FRS in the Ruoppolo (2013) study.   In the 
current study, most subjects with ALS were rated as having either normal or mildly impaired 
function on most sections of the ALS-FRSR which may have accounted for the differences in 
findings.  In the study by Ruoppolo (2013), individuals with ALS were examined in an 
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attempt to establish clinical indicators of dysphagia though evaluation of demographic data 
including duration of disease, type of onset (bulbar or axial), ALS-FRS score and completion 
of a clinical swallowing assessment and FEES examination.  The current study supplements 
the findings of Ruoppolo (2013) by adding findings of significant correlations between 
dysphagia with diadochokinesis, number of swallows and the Dysphagia Handicap Index.   
Overall, in this study, foundational data have been established for future investigation to 
determine if swallowing function in ALS patients could be predicted though common clinical 
assessments. 
Limitations of the Current Study  
In this study, enrollment included 18 subjects with ALS and 15 controls similar in age.   
While the enrollment criteria ensured that participating members would most likely only 
present with impairments secondary to the ALS disease process, it also resulted in challenges 
with subject recruitment.  A large number of the potential ALS subjects (108) were excluded 
due to the stringent exclusionary criteria. The small sample size prohibited assessment of 
potential interactions between PAS and pharyngeal residue ratings with combinations of 
DDK, FVC, number of swallows per bolus and DHI scores.   In addition, the small sample 
size reduced the power to detect some clinically meaningful findings.  Correlations between 
0.4 and 0.5 may provide useful information.  However, with a sample size of 18 the power to 
detect associations at this level is very low, between 10 to 53%, assuming alpha of 0.05 and 
two sided testing.   
Furthermore, subject recruitment was limited to the Harry J. Hoenselaar ALS clinic 
schedule.  Subject enrollment and study completion was convenient for ALS subjects since 
patients were already in clinic for an appointment; however, several patients declined 
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participation due to fatigue from a long clinic appointment.  Testing time and duration for 
ALS subjects were not controlled.  Thus, the study occurred anywhere from 30 minutes to 4 
hours into the appointment. The duration of the clinic appointment may have also contributed 
to the increased tiredness rating or other findings within the study in the ALS group in 
comparison to the control group.   
There were several measures that were approaching but did not achieve significance in 
this study, for example differences in pharyngeal residue ratings with liquid boluses between 
the ALS group and the control group.  Additional studies with larger sample sizes may further 
verify results of this study.   
Summary:  
Early identification of dysphagia in individuals with ALS can facilitate appropriate 
planning and discussions regarding proper nutritional goals and a long term nutritional plan 
while reducing the risk of complications from aspiration pneumonia.  This study revealed 
statistical significance between objective swallowing measures of the PAS and pharyngeal 
residue rating with clinical assessments of the DHI, DDK, FVC and number of swallows per 
bolus, along with common disease assessment information, ALS-FRSR, type of onset, 
duration of disease and BMI.  The battery of clinical measures included in this study provides 
a foundational step toward the development of a predictive dysphagia assessment that could 
be conducted to determine the risk of dysphagia in an individual with ALS.   
Additional findings indicate that individuals with ALS demonstrated significant 
impairment of all clinical assessment and objective swallowing measures in comparison to 
healthy controls.  Unexpected but clinically relevant findings included a high rate of silent 
aspiration in the ALS group with all consistencies.  This important finding suggests that 
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dysphagia and aspiration may have been overlooked in the clinical setting.  Additionally there 
were findings of aspiration with cough in the control group during the 3 ounce liquid trial 
which is consistent with previous research (Butler, 2009; Daggett, 2007).  
Future research should focus on the incidence of silent aspiration in ALS patients as 
well as attempt to replicate the results of this study on a larger scale.  If silent aspiration is 
more prevalent than previously thought, implementation of periodic objective swallowing 
evaluations through MBSS or FEES will be beneficial.  In addition, future studies should 
include the examination of whether or not dysphagia occurs prior to the presence of bulbar 
impairment for all patients with ALS.  Based upon the results of this study, it may be 
beneficial to assess the relationship between number of swallows, DHI, FVC and DDK as 
predictive measures of dysphagia in other neurological populations.    
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APPENDIX A: ALSFRS-R The ALS Functional Rating Scale, Revised 
   
  
Total Score:   
  
I.  Comparisons are made with the patient's status prior to the onset of the disease, 
not with the status at the last visit 
  
II. Patient's response (on a 5-point scale is recorded in relation to the question  
     "How are you doing at (…)?" for each of the 12 functions listed.  
   
 1. Speech 
  
[ ] 4 Normal speech processes 
  
[ ] 3 Detectable speech disturbance 
  
[ ] 2 Intelligible with repeating 
  
[ ] 1 Speech combined with non-vocal communication 
  
[ ] 0 Loss of useful speech 
   
 2. Salivation 
  
[ ] 4 Normal 
  
[ ] 3 Slight but definite excess of saliva in mouth; may have nighttime drooling 
  
[ ] 2 Moderately excessive saliva; may have minimal drooling 
  
[ ] 1 Marked excess of saliva with some drooling 
  
[ ] 0 Marked drooling; requires constant tissue or handkerchief 
   
 3. Swallowing 
  
[ ] 4 Normal eating habits 
  
[ ] 3 Early eating problems-occasional choking 
  
[ ] 2 Dietary consistency changes 
  
[ ] 1 Needs supplemental tube feeding 
  
[ ] 0 NPO (exclusively parenteral or enteral feeding) 
   
 4. Handwriting 
  
[ ] 4 Normal 
  
[ ] 3 Slow or sloppy; all words are legible 
  
[ ] 2 Not all words are legible 
  
[ ] 1 Able to grip pen but unable to write 
  
[ ] 0 Unable to grip pen 
   
 5a. Cutting Food and Handling Utensils (patients without gastrostomy) 
  
[ ] 4 Normal 
  
[ ] 3 Somewhat slow and clumsy, but no help needed 
  
[ ] 2 Can cut most foods, although clumsy and slow; some help needed 
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[ ] 1 Food must be cut by someone, but can still feed slowly 
  
[ ] 0 Needs to be fed 
   
 
5b. Cutting Food and Handling Utensils (alternate scale for patients with        
gastrostomy) 
  
[ ] 4 Normal 
  
[ ] 3 Clumsy but able to perform all manipulations 
  
[ ] 2 Some help needed with closures and fastners 
  
[ ] 1 Provides minimal assistance to caregiver 
  
[ ] 0 Unable to perform any aspect of task 
   
 6. Dressing and Hygiene 
  
[ ] 4 Normal function 
  
[ ] 3 Independent and complete self-care with effort or decreased efficiency 
  
[ ] 2 Intermittent assistance or substitute methods 
  
[ ] 1 Needs attendant for self-care 
  
[ ] 0 Total dependence 
   
 7. Turning in Bed and Adjusting Bed Clothes 
  
[ ] 4 Normal 
  
[ ] 3 Somewhat slow and clumsy but no help needed 
  
[ ] 2 Can turn alone or adjust sheets, but with great difficulty 
  
[ ] 1 Can initiate, but not turn or adjust sheets alone 
  
[ ] 0 Helpless 
   
 8. Walking 
  
[ ] 4 Normal 
  
[ ] 3 Early ambulation difficulties 
  
[ ] 2 Walks with assistance 
  
[ ] 1 Non-ambulatory, functional movement only. 
  
[ ] 0 No purposeful leg movement 
   
 9. Climbing Stairs 
  
[ ] 4 Normal 
  
[ ] 3 Slow 
  
[ ] 2 Mild unsteadiness or fatigue 
  
[ ] 1 Needs assistance 
  
[ ] 0 Cannot do 
   
 10. Dyspnea 
  
[ ] 4 None 
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[ ] 3 Occurs when walking 
  
[ ] 2 Occurs with one or more of the following: eating, bathing, dressing (ADL) 
  
[ ] 1 Occurs at rest, difficult breathing when either sitting or lying 
  
[ ] 0 Significant difficulty, considering using mechanical respiratory support 
  
 
 11. Orthopnea 
  
[ ] 4 None 
  
[ ] 3 Some difficult sleeping at night due to shortness of breath.  
        Does not routinely use more than two pillows 
  
[ ] 2 Needs extra pillow in order to sleep (more than two pillows) 
  
[ ] 1 Can only sleep sitting up 
  
[ ] 0 Unable to sleep 
   
 12. Respiratory Insufficiency 
  
[ ] 4 None 
  
[ ] 3 Intermittent use of BiPaP 
  
[ ] 2 Continuous use of BiPaP 
  
[ ] 1 Continuous use of BiPaP during the night and day 
  
[ ] 0 Invasive mechanical ventilation by intubation or tracheostomy  
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APPENDIX B: ALS Group - History of Disease, Weight and Height 
Subject     
ID # 
Symptom 
onset 
Date of 
Diagnosis 
Study 
Enrollment 
Date 
Weight 
 (kg) 
Height 
 (cm) 
Female:       
ALS_001F 1997 1997 10/22/2012 59 160 
ALS_002F 1/1/2010 12/14/2011 10/29/2012 45 152 
ALS_003F 3/1/2011 4/1/2011 10/29/2012 62 154 
ALS_004F 5/1/2011 6/1/2012 11/19/2012 80 160 
ALS_005F 12/1/2010 6/1/2012 12/3/2012 62 167 
ALS_006F 2/1/2011 7/6/2012 1/14/2013 93 167 
ALS_007F 1/1/2011 11/1/2012 1/14/2013 60 170 
ALS_008F 12/1/2011 10/15/2012 2/4/2013 83 161 
ALS_009F 5/1/2012 7/1/2013 8/26/2013 61 165 
ALS_010F 9/1/2012 6/4/2013 2/3/2014 45 152 
ALS_011F 8/15/2013 2/12/2014 3/17/2014 81 164 
ALS_012F 7/1/2013 3/24/2014 5/5/2014 79 168 
Male:             
ALS_001M 5/1/2011 3/18/2013 4/15/2013 77 178 
ALS_002M 1/1/2012 7/12/2012 4/29/2013 102 180 
ALS_003M 2/13/2013 3/28/2013 7/1/2013 62 170 
ALS_004M spring 2012 7/19/2013 7/22/2013 61 172 
ALS_005M 1/1/2012 6/29/2012 9/9/2013 100 170 
ALS_006M 11/1/2012 11/1/2013 12/16/2013 108 178 
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APPENDIX C: ALS Group - Region of Onset and ALS-FRS Revised Scores 
Subject     
ID # 
Onset ALS-FRSR Scores 
Bulbar, 
Axial or  
Mixed 
Speech 
 
Saliva 
 
Swallow 
 
Dyspnea 
 
Resp. 
 
Overall 
ALS-FRSr 
Score  
Female:         
ALS_001F Mixed 2 4 4 4 4 33 
ALS_002F Axial 3 4 3 2 4 34 
ALS_003F Axial 3 3 2 3 4 31 
ALS_004F Axial 4 4 4 2 4 31 
ALS_005F Bulbar 1 4 1 4 4 36 
ALS_006F Bulbar 2 2 3 3 3 31 
ALS_007F Bulbar 3 3 3 1 4 36 
ALS_008F Axial 4 4 4 4 4 21 
ALS_009F Axial 3 3 3 3 4 19 
ALS_010F Axial 2 4 3 4 4 26 
ALS_011F Bulbar 2 3 3 3 4 43 
ALS_012F Bulbar 3 4 2 4 4 45 
Male:               
ALS_001M Bulbar 3 3 3 4 4 45 
ALS_002M Axial 2 3 4 4 4 28 
ALS_003M Axial 4 4 4 4 4 37 
ALS_004M Mixed 3 2 3 3 4 25 
ALS_005M Axial 4 4 4 4 4 39 
ALS_006M Mixed 2 4 4 4 4 34 
- The ALS-FRSR is a patient reporting tool composed of 12 functions (Speech, Salivation, 
Swallowing,      Handwriting, Cutting Food and Handling Utensils, Dressing and 
Hygiene, Turning in Bed and       Adjusting Bed Clothes, Walking, Climbing Stairs, 
Dyspnea, Orthopnea and Respiratory insufficiency.  
- Rating for each function uses a 5 point scale: 4=normal function and 0=severe 
dysfunction. 
- Maximum Overall Score is 48 points 
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APPENDIX D:  Questionnaire for DDK and dysphagia assessment in ALS. 
 
  Y/N 
 
If any bold response is reported the subject does not meet criteria for this 
study.    
1 Do you have a history of tobacco use? Y N 
2 Do you currently use tobacco? Y N 
3 What is your current age?                           Birthdate?      
4 History of stroke or other neurologic event other than ALS? Y N 
5 History of speech difficulties unrelated to ALS?   Y N 
6 History of swallowing difficulties unrelated to ALS? Y N 
7 
History of respiratory disease unrelated to ALS (emphysema, COPD, Lung 
CA)? Y N 
8 History of head/neck cancer? Y N 
9 History of radiation or surgery to the head/neck? Y N 
10 Is English the first language you learned?  Y N 
11 Have you noticed changes in your speech? Y N 
12 Have you noticed changes in your swallowing? Y N 
    
13 
Compared to your baseline, on a scale from 1-7, how tired are you right 
now? 
  1 = normal   7 = severely tired 
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APPENDIX E: DYSPHAGIA HANDICAP INDEX (DHI)  
Silbergleit, A.K., Schultz, L., Jacobson, B., Beardsley, T. and Johnson, A. (Dysphagia, 2011)  
Please place a check in the box that describes your swallowing difficulty  
                                                                                              
NEVER   SOMETIMES   ALWAYS 
 
1P.      I cough when I drink liquids. 
   
 
2P.     I cough when I eat solid food. 
   
 
3P.     My mouth is dry. 
   
 
4P.   I need to drink fluids to wash food down.  
   
 
5P.   I’ve lost weight because of my swallowing problem. 
   
 
1F.   I avoid some foods because of my swallowing problem  
   
 
2F.   I have changed the way I swallow to make it easier to eat. 
   
 
1E.   I’m embarrassed to eat in public. 
   
 
3F.   It takes me longer to eat a meal that it used to. 
   
                                                                                                           
                  NEVER    SOMETIMES   ALWAYS 
 
4F.   I eat smaller meals more often due to my swallowing 
problem 
   
 
6P.   I have to swallow again before food will go down. 
   
 
2E.   I feel depressed because I can’t eat what I want.* 
   
 
3E.   I don’t enjoy eating as much as I used to. 
   
 
5F.   I don’t socialize as much due to my swallowing problem. 
   
 
6F.    I avoid eating because of my swallowing problem. 
   
 
7F.   I eat less because of my swallowing problem. 
   
 
4E.   I am nervous because of my swallowing problem. 
   
 
* This question was excluded from data analysis due to a typographical error.  The word 
“what” was accidentally replaced with the word “when”.   
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                                                                                               NEVER    SOMETIMES   ALWAYS 
 
5E.   I feel handicapped because of my swallowing problem. 
   
 
6E.   I get angry at myself because of my swallowing   
          problem. 
   
 
7P.   I choke when I take my medication. 
   
 
7E.   I’m afraid that I’ll choke and stop breathing because  
           of my swallowing problem. 
   
  
8F.   I must eat another way (e.g. feeding tube) because  
           of my swallowing problem. 
   
 
                                                                                                
            NEVER   SOMETIMES    ALWAYS 
 
Please circle the number that matches the severity of your swallowing difficulty 
(1 = no difficulty as all; 4 = somewhat of a problem; 7 = the worst problem you could have): 
   
1    2 3 4 5 6 7 
 
                                           normal                        moderate                        severe 
                                                                               problem                       problem 
 
 
 
 
 
 
 
9F.   I’ve changed my diet due to my swallowing 
problem. 
   
 
8P.   I feel a strangling sensation when I swallow. 
   
 
9P.   I cough up food after I swallow. 
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APPENDIX F: Demographic Information and Dysphagia Handicap Index (DHI) Scores 
Table F1: ALS Female Group - Demographic Information and Dysphagia Handicap 
Index (DHI) Ratings 
Subject     
ID # 
Age 
  
Tobacco Use DHI 
Past  Current Physical Functional Emotional  
Over 
-all   
Self-
Report 
ALS_001
F 58 N N 6 6 2 14 1 
ALS_002
F 75 N N 14 24 8 46 4 
ALS_003
F 79 N N 4 8 6 18 2 
ALS_004
F 67 N N 6 0 0 6 1 
ALS_005
F 62 N N 18 30 20 68 5 
ALS_006
F 65 N N 4 8 2 14 4.5 
ALS_007
F 69 N N 20 24 16 60 6 
ALS_008
F 64 Y N 10 0 0 10 1 
ALS_009
F 82 Y N 6 10 4 20 4 
ALS_010
F 63 N N 4 8 10 22 2 
ALS_011
F 73 N N 18 26 16 60 6 
ALS_012
F 54 Y N 16 6 2 24 3 
- The DHI is composed of 24 statements (one was excluded due to a typographical error) 
that require the patient to respond with Never (0 points), Sometimes (2 points) or 
Always (4 points) to each.  
- Statements are separated into 3 categories: Physical (9 statements with maximum 36 
possible points), Emotional (6 statements with maximum 24 possible points) and 
Functional (9 statements with maximum 36 possible points).   
- Additionally an Overall score and a Self Reported Severity of Dysphagia rating (7 
points scale where 1 is normal and 7 is severely impaired).  
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Table F2: ALS Male Group - Demographic Information and Dysphagia Handicap Index 
(DHI) Ratings 
Subject 
ID # 
Age 
Tobacco Use DHI 
 Past Current Physical Functional  Emotional  
Over 
-all 
Self-
Report 
ALS_001
M 60 Y N 22 18 0 40 5 
ALS_002
M 55 Y N 6 0 0 6 1 
ALS_003
M 78 N N 2 4 0 6 1 
ALS_004
M 77 N N 12 16 14 42 5 
ALS_005
M 77 N N 4 12 0 16 2 
ALS_006
M 65 N N 6 2 0 8 1 
- The DHI is composed of 24 statements (one was excluded due to a typographical error) 
that require the patient to respond with Never (0 points), Sometimes (2 points) or 
Always (4 points) to each.  
- Statements are separated into 3 categories: Physical (9 statements with maximum 36 
possible points), Emotional (6 statements with maximum 24 possible points) and 
Functional (9 statements with maximum 36 possible points).   
- Additionally an Overall score and a Self Reported Severity of Dysphagia rating (7 
points scale where 1 is normal and 7 is severely impaired). 
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Table F3: Control Group - Demographic Information and Dysphagia Handicap Index 
(DHI) Ratings 
Subject  
ID # 
Age Tobacco Use DHI 
Past Current Physical Functional  Emotional  
Over 
-all 
Self-
Report 
CON_001
F 60 N N 2 0 0 2 1 
CON_002
M 66 Y N 2 0 0 2 2 
CON_003
F 65 N N 2 0 0 2 1 
CON_004
F 61 N N 2 0 0 2 1 
CON_005
M 69 Y N 2 0 0 2 1 
CON_006
F 66 Y N 2 0 0 2 1 
CON_007
M 63 N N 0 0 0 0 1 
CON_008
F 59 N N 6 0 0 6 2 
CON_009
F 69 N N 4 0 0 4 1 
CON_010
F 62 Y N 6 0 0 6 3 
CON_011
F 84 N N 10 2 0 12 1 
CON_012
F 58 Y N 4 0 0 4 1 
CON_013
F 58 N N 4 0 0 4 1 
CON_014
M 59 N N 8 0 0 8 1 
CON_015
F 83 N N 4 0 0 4 1 
- The DHI is composed of 24 statements (one was excluded due to a typographical error) 
that require the patient to respond with Never (0 points), Sometimes (2 points) or 
Always (4 points) to each.  
- Statements are separated into 3 categories: Physical (9 statements with maximum 36 
possible points), Emotional (6 statements with maximum 24 possible points) and 
Functional (9 statements with maximum 36 possible points).   
- Additionally an Overall score and a Self Reported Severity of Dysphagia rating (7 
points scale where 1 is normal and 7 is severely impaired). 
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APPENDIX G: Tired Rating and Forced Vital Capacity Performance 
 
 
 
Table G1: ALS Female Group - Tired Rating and Forced Vital Capacity 
Performance 
Subject     
ID # 
Tired  
Rating 
 
Forced Vital Capacity 
Within  
Normal Limit  
(+80%) 
Mild Impairment 
(79-65%) 
Moderate 
Impairment 
 (64-50%) 
ALS_001F 4   68%   
ALS_002F 4 85%     
ALS_003F 1   71%   
ALS_004F 7   69%   
ALS_005F 3     55% 
ALS_006F 1     51% 
ALS_007F 5 84%     
ALS_008F 1 93%     
ALS_009F 4 84%     
ALS_010F 7   76%   
ALS_011F 2     58% 
ALS_012F 3 89%     
- Tired rating on a seven point scale where a normal = 1 and severely tired = 7.  
- FVC scores are documented as percent predicted performance based on height, 
weight, age and gender.   
- An FVC score of 100% predicted capacity is the median predicted value (based 
on height, weight, age and gender), as such it is possible to achieve a percent 
predicted FVC that is greater than 100%.   
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Table G2: ALS Male Group - Tired Rating and Forced Vital Capacity Performance 
Subject     
ID # 
Tired  
Rating 
 
Forced Vital Capacity 
Within Normal 
Limit  
(+80%) 
Mild 
Impairment (79-
65%) 
Moderate 
Impairment 
 (64-50%) 
ALS_001M 1 82%     
ALS_002M 4 107%     
ALS_003M 4 93%     
ALS_004M 5     59% 
ALS_005M 1     52% 
ALS_006M 1 96%   
- Tired rating on a seven point scale where a normal = 1 and severely tired = 7.  
- FVC scores are documented as percent predicted performance based on height, 
weight, age and gender.  
- An FVC score of 100% predicted capacity is the median predicted value (based on 
height, weight, age and gender), as such it is possible to achieve a percent 
predicted FVC that is greater than 100%.   
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Table G3: Control Group - Tired Rating and  Forced Vital Capacity Performance 
Subject        
ID # 
Tired  
Rating 
 
Forced Vital Capacity 
Within Normal 
Limit  
(+80%) 
Mild 
Impairment 
 (79-65%) 
Moderate Impairment 
 (64-50%) 
CON_001F 1 128%     
CON_002M 2 115%     
CON_003F 1 88%     
CON_004F 2 94%     
CON_005M 1 113%     
CON_006F 1 125%     
CON_007M 1 104%     
CON_008F 3 150%     
CON_009F 1 112%     
CON_010F 1 125%     
CON_011F 1 87%     
CON_012F 3 114%     
CON_013F 2 101%     
CON_014M 2 101%     
CON_015F 1 103%   
- Tired rating on a seven point scale where a normal = 1 and severely tired = 7.  
- FVC scores are documented as percent predicted performance based on height, 
weight, age and gender.  
- An FVC score of 100% predicted capacity is the median predicted value (based on 
height, weight, age and gender), as such it is possible to achieve a percent predicted 
FVC that is greater than 100%.   
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APPENDIX H: Diadochokinesis Results 
Table H1: ALS Female Group - Diadochokinesis Results 
Subject 
ID # 
Alternating Motion Rate (AMR) 
Sequential Motion 
Rate (SMR) 
/ pʌ/ / tʌ/ / kʌ/ / pʌtʌkʌ/ 
# in 
5sec /sec 
# in 
5sec /sec 
# in 
5sec /sec 
# in 
5sec /sec 
ALS_001F 9.00 1.80 7.00 1.40 9.00 1.80 5.00 1.00 
ALS_002F 24.00 4.80 22.00 4.40 13.00 2.60 7.00 1.40 
ALS_003F 21.00 4.20 18.00 3.60 15.00 3.00 7.00 1.40 
ALS_004F 28.00 5.60 25.00 5.00 15.00 3.00 9.30 1.86 
ALS_005F 7.00 1.40 6.00 1.20 5.00 1.00 2.00 0.40 
ALS_006F 9.00 1.80 6.00 1.20 7.00 1.40 2.00 0.40 
ALS_007F 17.00 3.40 15.00 3.00 14.00 2.80 6.00 1.20 
ALS_008F 27.00 5.40 24.00 4.80 21.00 4.20 10.00 2.00 
ALS_009F 9.00 1.80 5.00 1.00 8.00 1.60 2.66 0.53 
ALS_010F 16.00 3.20 16.00 3.20 15.00 3.00 7.00 1.40 
ALS_011F 16.00 3.20 14.00 2.80 7.00 1.40 4.66 0.93 
ALS_012F 10 2.00 10.33 2.07 9.00 1.80 4.00 0.80 
     -     /sec = Average number of productions per second; sec = seconds 
 
 
Table H2: ALS Male Group - Diadochokinesis Results 
Subject  
ID # 
Alternating Motion Rate  
(AMR) 
Sequential  
Motion Rate 
(SMR) 
/ pʌ/ / tʌ/ / kʌ/ / pʌtʌkʌ/ 
# in 
5sec /sec 
# in 
5sec /sec 
# in 
5sec /sec 
# in 
5sec /sec 
ALS_001M 25.00 5.00 22.00 4.40 20.00 4.00 10.33 2.07 
ALS_002M 14.00 2.80 14.00 2.80 13.00 2.60 6.00 1.20 
ALS_003M 32.00 6.40 32.00 6.40 29.00 5.80 10.33 2.07 
ALS_004M 22.00 4.40 16.00 3.20 15.00 3.00 9.00 1.80 
ALS_005M 26.00 5.20 27.00 5.40 26.00 5.20 5.00 1.00 
ALS_006M 13.00 2.60 12.00 2.40 12.00 2.40 5.00 1.00 
     -     /sec = Average number of productions per second; sec = seconds 
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Table H3: Control Group - Diadochokinesis Results 
Subject 
 ID # 
Alternating Motion Rate (AMR) 
Seq. Motion Rate 
(SMR) 
/ pʌ/ / tʌ/ / kʌ/ / pʌtʌkʌ/ 
# in 
5sec /sec 
# in 
5sec /sec 
# in 
5sec /sec 
# in 
5sec /sec 
CON_001F 34.00 6.80 34.00 6.80 30.00 6.00 13.00 2.60 
CON_002M 26.00 5.20 24.00 4.80 21.00 4.20 9.00 1.80 
CON_003F 28.00 5.60 28.00 5.60 27.00 5.40 9.00 1.80 
CON_004F 30.00 6.00 28.00 5.60 27.00 5.40 8.00 1.60 
CON_005M 32.00 6.40 29.00 5.80 29.00 5.80 11.33 2.27 
CON_006F 27.00 5.40 24.00 4.80 24.00 4.80 9.00 1.80 
CON_007M 24.00 4.80 22.00 4.40 21.00 4.20 10.00 2.00 
CON_008F 30.00 6.00 30.00 6.00 29.00 5.80 11.00 2.20 
CON_009F 28.5 5.70 24.00 4.80 23.00 4.60 9.00 1.80 
CON_010F 23.00 4.60 22.00 4.40 22.00 4.40 9.00 1.87 
CON_011F 27.00 5.40 23.00 4.60 21.00 4.20 9.00 1.80 
CON_012F 31.00 6.20 31.00 6.20 30.00 6.00 12.00 2.40 
CON_013F 28.00 5.60 29.00 5.80 29.00 5.80 11.00 2.20 
CON_014M 26.00 5.20 25.00 5.00 23.2 4.64 10.00 2.00 
CON_015F 29.00 5.80 26.00 5.20 26.5 5.30 10.00 2.00 
     -     /sec = Average number of productions per second; sec = seconds 
129 
 
APPENDIX I: FEES Rater Sheet with PAS and Pharyngeal Residue Scale Ratings 
  
Subject  ID   Date  
  
Investigator      
  
Bolus    
Number of 
Swallows   
PAS 
Rating   
Pharyngeal 
Residue 
Rating Comments  
10mL Thin Liquid 
by spoon 
          
30mL Thin Liquid  
by straw 
          
3 oz Thin Liquid  
by straw 
          
5mL Puree 
          
5mL Puree 
          
Cookie bite 
          
Penetration - Aspiration Scale 
Rating Definition       
1 material does not enter the airway   
2 
material enters the airway, remains above the vocal folds, and is ejected from the 
airway 
3 
material enters the airway, remains above the vocal folds, and is not ejected from the 
airway 
4 material enters the airway, contacts the vocal folds, and is ejected from the airway 
5 material enters the airway, contacts the vocal folds, and is not ejected from the airway 
6 
material enters the airway, passes below the vocal folds and is ejected into the larynx 
or out of the airway 
7 
material enters the airway, passes below the vocal folds, and is not ejected from the 
trachea despite effort 
8 material enters the airway, passes below the vocal folds, and no effort is made to eject 
Rosenbek, J. C., Robbins, J., Roecker, E. B., Coyle, J. L., & Wood, J. L. (1996). A penetration-
aspiration scale. Dysphagia, 11, 93 - 98.  
Pharyngeal Residue Scale 
Rating Definition   
0 None No coating/residue in pharynx 
1 Coating coating of pharyngeal mucosa, no pooling 
2 Mild mild pooling/residue 
3 Moderate moderate pooling/residue 
4 Severe severe pooling/residue 
Kelly, A. M., Macfarlane, K., Ghufoor, K., Drinnan, M. J., & Lew-Gor, S. (2008). Pharyngeal 
residue across the lifespan: a first look at what's normal. Clinical Otolaryngology, 
33(4), 348-351.  
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APPENDIX J: Penetration Aspiration Scale (PAS) Ratings 
Table J1: ALS Female Group - Penetration Aspiration Scale (PAS) Ratings 
Subject ID# 
FEES results 
Thin 
Liquid 
10mL 
Straw 
Thin 
Liquid 
30mL 
Straw 
Thin 
Liquid 3oz 
straw Puree (5mL) 
Puree 
(5mL) Solid 
ALS_001F Rater 1 1 1 8 5 8 5 Rater 2 1 1 8 5 8 5 
ALS_002F Rater 1 8 8 8 3 3 3 Rater 2 8 8 6 3 2 2 
ALS_003F Rater 1 3 8 8 5 8 5 Rater 2 5 5 5 8 8 3 
ALS_004F Terminated at Subject Request  No bolus trials 
ALS_005F Rater 1 8 n/a n/a 8 8 8 Rater 2 8 n/a n/a 8 8 8 
ALS_006F Rater 1 8 8 n/a 1 3 1 Rater 2 8 8 n/a 2 3 1 
ALS_007F Rater 1 1 7 7 1 1 1 Rater 2 1 7 7 1 1 1 
ALS_008F Rater 1 1 2 2 3 3 3 Rater 2 2 2 2 3 3 2 
ALS_009F Rater 1 5 8 8 1 1 1 Rater 2 8 4 8 1 1 4 
ALS_010F Rater 1 2 5 5 1 3 5 Rater 2 5 5 5 1 3 3 
ALS_011F Rater 1 8 8 8 1 1 5 Rater 2 5 5 5 2 2 2 
ALS_012F Rater 1 8 1 5 1 1 1 Rater 2 8 3 8 1 1 3 
- PAS ratings are based on an 8 point scale were one is the least severe and 8 is the most 
severe.  
- n/a = Not administered due to severity of impairment on smaller bolus trial. 
 
 
 
 
 
131 
 
Table J2: ALS Male Group - Penetration Aspiration Scale (PAS) Ratings 
Subject ID# 
FEES results 
Thin 
Liquid 
10mL 
Straw 
Thin 
Liquid  
30mL 
Straw 
Thin 
Liquid  
3oz straw Puree 
 (5mL) 
Puree 
 (5mL) Solid 
ALS_001M Rater 1  UTV UTV   UTV UTV  UTV UTV  Rater 2  UTV UTV   UTV  UTV  UTV UTV  
ALS_002M Rater 1 2 1 1 3 3 1 Rater 2 3 1 1 3 3 3 
ALS_003M Rater 1 3 3 2 3 1 2 Rater 2 1 1 1 3 1 1 
ALS_004M Rater 1 1 8 8 1 5 1 Rater 2 1 8 8 1 5 1 
ALS_005M Rater 1 4 2 2 2 1 2 Rater 2 2 2 2 2 2 2 
ALS_006M Rater 1 1 8 5 1 1 1 Rater 2 1 8 5 1 3 1 
- PAS ratings are based on an 8 point scale were one is the least severe and 8 is the most 
severe.  
- UTV = Unable to visualize 
 
 
132 
 
 
Table J3: Control Group - Penetration Aspiration Scale (PAS) Ratings 
Subject ID# 
FEES results 
Thin 
Liquid  
10mL 
Straw 
Thin 
Liquid 
 30mL 
Straw 
Thin 
Liquid  
3oz straw Puree  (5mL) 
Puree  
(5mL) Solid 
CON_001F Rater 1 1 1 1 1 1 2 Rater 2 1 1 1 1 1 2 
CON_002M Rater 1 1 1 1 1 3 1 Rater 2 1 1 1 1 3 1 
CON_003F Rater 1 5 5 6 1 1 1 Rater 2 5 5 8 3 UTV 1 
CON_004F Rater 1 2 2 2 1 1 1 Rater 2 2 UTV 2 2 1 1 
CON_005M Rater 1 5 3 2 1 1 1 Rater 2 2 2 2 1 2 2 
CON_006F Rater 1 1 1 1 1 1 1 Rater 2 1 1 1 1 1 1 
CON_007M Rater 1 1 1 1 3 3 2 Rater 2 1 1 1 3 3 1 
CON_008F Rater 1 1 1 6 1 1 1 Rater 2 1 1 7 1 1 1 
CON_009F Rater 1 1 1 1 1 1 2 Rater 2 1 1 1 1 2 2 
CON_010F Rater 1 1 1 1 1 1 1 Rater 2 1 1 1 2 1 1 
CON_011F Rater 1 5 5 7 1 1 1 Rater 2 5 5 8 1 1 1 
CON_012F Rater 1 1 1 1 1 1 2 Rater 2 1 1 1 1 1 2 
CON_013F Rater 1 2 1 1 1 1 1 Rater 2 2 1 1 1 1 1 
CON_014M Rater 1 5 4 2 1 2 1 Rater 2 5 5 5 1 2 1 
CON_015F Rater 1 5 1 1 1 1 1 Rater 2 2 1 2 1 2 1 
- PAS ratings are based on an 8 point scale were one is the least severe and 8 is the most 
severe.  
- UTV = Unable to visualize 
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APPENDIX K: Pharyngeal Residue Ratings 
Table K1: ALS Female Group - Pharyngeal Residue Ratings 
Subject ID# 
FEES results 
Thin 
Liquid 
10mL 
Straw 
Thin 
Liquid 
30mL 
Straw 
Thin 
Liquid 3oz 
straw Puree (5mL) 
Puree 
(5mL) Solid 
ALS_001F Rater 1 1 1 1 1 1 1 Rater 2 1 1 1 2 1 2 
ALS_002F Rater 1 2 2 1 2 2 3 Rater 2 3 2 2 3 3 3 
ALS_003F Rater 1 2 2 2 2 2 2 Rater 2 2 2 2 2 2 1 
ALS_004F Terminated at Subject Request No bolus trials administered 
ALS_005F Rater 1 2 n/a n/a 2 3 2 Rater 2 2 n/a n/a 2 3 3 
ALS_006F Rater 1 2 2 n/a 1 2 2 Rater 2 2 2 n/a 1 2 2 
ALS_007F Rater 1 2 2 2 2 2 2 Rater 2 2 2 2 2 2 2 
ALS_008F Rater 1 1 2 1 2 2 2 Rater 2 1 2 1 2 2 2 
ALS_009F Rater 1 2 1 1 1 2 2 Rater 2 2 2 2 1 1 3 
ALS_010F Rater 1 2 1 1 2 2 2 Rater 2 2 2 2 2 3 2 
ALS_011F Rater 1 2 2 2 2 2 3 Rater 2 3 2 2 2 3 4 
ALS_012F Rater 1 2 2 1 3 3 2 Rater 2 2 2 2 3 2 2 
- Pharyngeal residue ratings were based on a 5 point scale where 0 = no residues or 
coating and 4= severe residue 
- n/a = Not administered due to severity of impairment on smaller bolus trial. 
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Table K2: ALS Male Group - Pharyngeal Residue Ratings 
Subject ID# 
FEES results 
Thin 
Liquid 
10mL 
Straw 
Thin 
Liquid 
30mL 
Straw 
Thin 
Liquid 3oz 
straw Puree (5mL) 
Puree 
(5mL) Solid 
ALS_001M Rater 1 UTV UTV 2 2 2 1 Rater 2 UTV UTV 2 2 2 1 
ALS_002M Rater 1 1 2 2 2 2 1 Rater 2 1 2 2 2 2 2 
ALS_003M Rater 1 1 1 1 2 1 0 Rater 2 1 1 1 2 1 0 
ALS_004M Rater 1 1 1 2 2 2 2 Rater 2 1 1 2 2 2 1 
ALS_005M Rater 1 2 2 2 2 1 1 Rater 2 2 2 2 2 1 1 
ALS_006M Rater 1 2 1 1 2 2 2 Rater 2 2 1 1 2 2 2 
- Pharyngeal residue ratings were based on a 5 point scale where 0 = no residues or 
coating and 4= severe residue 
- UTV = Unable to visualize 
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Table K3: Control Group - Pharyngeal Residue Ratings 
Subject ID# 
FEES results 
Thin 
Liquid 
10mL 
Straw 
Thin 
Liquid 
30mL 
Straw 
Thin 
Liquid 3oz 
straw Puree (5mL) 
Puree 
(5mL) Solid 
CON_001F Rater 1 2 1 1 2 2 0 Rater 2 2 1 1 2 2 1 
CON_002M Rater 1 1 1 1 2 2 0 Rater 2 1 1 1 1 2 0 
CON_003F Rater 1 2 2 0 1 1 2 Rater 2 2 1 0 2 UTV 2 
CON_004F Rater 1 1 1 1 1 1 0 Rater 2 1 1 1 1 1 0 
CON_005M Rater 1 2 1 2 2 2 2 Rater 2 2 2 2 2 2 2 
CON_006F Rater 1 1 1 1 1 1 0 Rater 2 1 1 0 1 1 0 
CON_007M Rater 1 1 2 1 2 2 0 Rater 2 1 2 1 2 2 0 
CON_008F Rater 1 1 1 1 1 1 0 Rater 2 1 2 1 1 1 0 
CON_009F Rater 1 2 2 1 1 1 0 Rater 2 2 2 1 1 1 0 
CON_010F Rater 1 1 1 2 1 1 1 Rater 2 1 1 2 2 1 1 
CON_011F Rater 1 1 1 1 0 1 1 Rater 2 2 1 1 1 1 1 
CON_012F Rater 1 0 0 0 1 1 1 Rater 2 0 0 0 1 1 1 
CON_013F Rater 1 0 0 0 0 0 0 Rater 2 0 0 0 0 0 0 
CON_014M Rater 1 2 2 2 2 2 2 Rater 2 2 2 2 2 2 2 
CON_015F Rater 1 2 1 1 2 1 0 Rater 2 2 1 1 2 1 1 
- Pharyngeal residue ratings were based on a 5 point scale where 0 = no residues or 
coating and 4= severe residue 
- UTV = Unable to visualize 
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APPENDIX L: Number of Swallows per Bolus Trial 
Table L1: ALS Female Group - Number of Swallows per Bolus Trial 
Subject ID# 
FEES results 
Thin 
Liquid 
10mL 
Straw 
Thin 
Liquid 
30mL 
Straw 
Thin 
Liquid 3oz 
Straw Puree (5mL) 
Puree 
(5mL) Solid 
ALS_001F Rater 1 2 1 18 4 6 4 Rater 2 2 2 5 4 6 4 
ALS_002F Rater 1 14 22 23 4 4 4 Rater 2 13 22 21 3 5 4 
ALS_003F Rater 1 4 5 10 3 4 3 Rater 2 4 4 9 4 4 3 
ALS_004F 
 Terminated at Subject Request No bolus trials/No interrater necessary 
ALS_005F Rater 1 22 n/a n/a 8 10 9 Rater 2 20 n/a n/a 8 11 9 
ALS_006F Rater 1 3 6 n/a 2 2 3 Rater 2 3 6 n/a 2 2 4 
ALS_007F Rater 1 4 6 14 3 2 3 Rater 2 3 6 12 3 3 3 
ALS_008F Rater 1 4 9 8 4 3 6 Rater 2 6 6 8 4 3 5 
ALS_009F Rater 1 5 4 8 1 1 1 Rater 2 4 4 6 1 1 2 
ALS_010F Rater 1 3 7 8 3 2 3 Rater 2 3 7 9 2 2 3 
ALS_011F Rater 1 5 13 11 2 2 6 Rater 2 4 13 11 2 3 8 
ALS_012F Rater 1 8 6 8 2 3 4 Rater 2 8 5 6 2 3 3 
- The number of discrete swallows per bolus were counted during each trial 
- n/a = Not administered due to severity of impairment on smaller bolus trial. 
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Table L2: ALS Male Group - Number of Swallows per Bolus Trial 
Subject ID# 
FEES results 
Thin 
Liquid 
10mL 
Straw 
Thin 
Liquid 
30mL 
Straw 
Thin 
Liquid 3oz 
Straw Puree (5mL) 
Puree 
(5mL) Solid 
ALS_001M Rater 1 UTV  UTV 13 3 5 4 Rater 2  UTV  UTV 13 3 4 4 
ALS_002M Rater 1 2 5 10 2 2 2 Rater 2 2 5 10 2 2 2 
ALS_003M Rater 1 5 5 6 2 2 5 Rater 2 4 5 6 2 2 4 
ALS_004M Rater 1 2 3 8 3 2 1 Rater 2 2 3 8 3 3 1 
ALS_005M Rater 1 5 7 11 8 4 7 Rater 2 5 8 5 8 5 6 
ALS_006M Rater 1 4 8 16 3 4 2 Rater 2 5 8 15 3 4 2 
- The number of discrete swallows per bolus were counted during each trial 
- UTV = Unable to visualize 
 
138 
 
 
Table L3: Control Group - Number of Swallows per Bolus Trial 
Subject ID# 
FEES results 
Thin 
Liquid 
10mL 
Straw 
Thin 
Liquid 
30mL 
Straw 
Thin 
Liquid 3oz 
Straw Puree (5mL) 
Puree 
(5mL) Solid 
CON_001F Rater 1 2 5 7 3 2 3 Rater 2 2 5 7 3 2 3 
CON_002M Rater 1 3 4 4 2 2 2 Rater 2 3 4 4 2 2 2 
CON_003F Rater 1 3 5 13 3 3 4 Rater 2 3 5 8 3 2 3 
CON_004F Rater 1 2 4 4 2 3 1 Rater 2 2 2 3 2 2 1 
CON_005M Rater 1 3 4 7 3 3 3 Rater 2 3 4 7 2 3 2 
CON_006F Rater 1 5 6 8 4 4 5 Rater 2 4 4 7 4 3 4 
CON_007M Rater 1 2 3 4 3 3 3 Rater 2 2 3 4 2 3 3 
CON_008F Rater 1 3 4 11 4 5 5 Rater 2 3 4 8 4 5 3 
CON_009F Rater 1 3 4 4 3 2 3 Rater 2 3 2 3 2 2 3 
CON_010F Rater 1 6 6 4 2 2 3 Rater 2 6 6 4 3 2 3 
CON_011F Rater 1 3 3 10 5 5 5 Rater 2 3 3 7 2 5 4 
CON_012F Rater 1 7 3 5 4 4 3 Rater 2 5 3 4 3 3 2 
CON_013F Rater 1 3 2 6 2 2 2 Rater 2 3 2 4 2 2 2 
CON_014M Rater 1 4 3 4 2 2 2 Rater 2 4 3 4 2 2 2 
CON_015F Rater 1 2 3 4 2 2 2 Rater 2 2 3 3 2 2 2 
        -    The number of discrete swallows per bolus were counted during each trial 
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ABSTRACT 
EVALUATING THE RELATIONSHIP BETWEEN DIADOCHOKINESIS AND 
SEVERITY OF DYSPHAGIA AS IT RELATES TO FORCED VITAL CAPACITY IN 
INDIVIDUALS WITH AMYOTROPHIC LATERAL SCLEROSIS 
 
by 
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Co-Advisor: Dr. Li Hsieh 
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Major: Speech-Language Pathology 
Degree: Doctor of Philosophy 
Purpose:  To determine if the severity of dysphagia, as determined by Penetration Aspiration 
Scale (PAS) ratings and pharyngeal residue scale ratings in individuals with ALS, can be 
predicted through performance on diadochokinesis (DDK) and force vital capacity (FVC) 
measures.   
This study was designed to evaluate differences in performance of clinical measures 
and objective swallowing severity ratings between individuals with ALS and a Control group 
of similar age.  The goal of this study was to attempt to develop a clinical assessment battery 
that can predict swallowing impairment in ALS patients.  In addition, potential predictive 
relationships between dysphagia ratings and other commonly utilized measures in the 
evaluation and treatment of ALS including duration of disease, type of onset (axial, bulbar, 
mixed), current Amyotrophic Lateral Sclerosis Function Rating Score – Revised (ALS-FRS-
R) score, body mass index, and the Dysphagia Handicap Index (DHI) patient-reported 
outcome based dysphagia tool were also investigated.   
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Swallowing function was assessed with three thin liquid boluses of increased volume, 
two 5mL pudding boluses and one piece of graham cracker. Pharyngeal residue, PAS and 
number of swallows per bolus were rated by two independent investigators.   Between-group 
findings included significant impairment in function in the ALS group on all clinical measures 
and all swallowing severity ratings with the exception of the smallest liquid bolus trial, 
compared to the performance of the control group.  Within the ALS group, significant 
correlations were present to support the hypothesis that swallowing function can be predicted 
by various clinical measures including DDK, FVC the DHI and number of swallows per 
bolus.  Duration of disease and type of onset were significantly correlated with severity of 
dysphagia in ALS.   
In conclusion, clinical measures can be beneficial in predicting severity of dysphagia 
in individuals with ALS.  There is a significant correlation between DDK, FVC, DHI, number 
of swallows per bolus with decline in swallowing function in ALS.   
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